Oncology

KRAS ctDNA Predicts Outcomes After Neoadjuvant Therapy in PDAC: Annals of Surgery | July 2026

Introduction: Circulating tumor DNA (ctDNA) has emerged as a promising noninvasive biomarker for monitoring treatment response and residual disease in solid tumors. However, its prognostic value during neoadjuvant chemotherapy (NAC) for localized pancreatic ductal adenocarcinoma (PDAC) has not been well established. This study evaluated whether mutant KRAS ctDNA measured by digital droplet PCR (ddPCR) predicts survival in patients undergoing NAC and surgical resection. Why was this study needed? Reliable biomarkers are needed to assess response to neoadjuvant therapy in localized PDAC. Radiologic assessment alone often fails to accurately reflect tumor biology. The prognostic significance of serial KRAS ctDNA measurements during treatment remains unclear. ctDNA could help identify patients at high risk of recurrence after surgery. Results: Among 84 patients with localized PDAC receiving NAC, mutant KRAS ctDNA was detected in approximately half at diagnosis and in nearly 70% after NAC and after surgery. Around 18% of patients achieved complete ctDNA clearance during treatment, which was associated with significantly improved overall survival. In contrast, persistent detection of the KRAS G12V mutation after NAC and especially after surgical resection identified patients with substantially poorer survival outcomes. On multivariable analysis, postoperative detection of KRAS G12V was one of the strongest predictors of reduced overall survival, suggesting persistent molecular disease despite apparently curative treatment. Clinical Impact: Serial KRAS ctDNA monitoring may provide valuable prognostic information beyond conventional imaging and pathology. Clearance of ctDNA during neoadjuvant therapy identifies patients with favorable tumor biology, whereas persistent postoperative KRAS mutations may indicate minimal residual disease and identify candidates for intensified surveillance, additional systemic therapy, or enrollment in clinical trials. Bottom Line: Serial KRAS ctDNA monitoring during neoadjuvant treatment is a promising prognostic biomarker in localized PDAC, with postoperative persistence of KRAS G12V identifying patients at particularly high risk of poor survival.

Low-Dose Aspirin for Lynch Syndrome: Lancet | July 2026

Introduction: Aspirin is one of the few interventions proven to reduce colorectal and other Lynch syndrome–associated cancers. The earlier CaPP2 trial established 600 mg daily aspirin as an effective chemopreventive strategy, but concerns regarding long-term toxicity and bleeding have limited its widespread use. The CaPP3 trial evaluated whether lower aspirin doses could provide comparable cancer protection with improved safety. Why was this study needed?: . The optimal aspirin dose for cancer prevention in Lynch syndrome remains uncertain. . High-dose aspirin is associated with increased gastrointestinal toxicity and bleeding. . Lower doses may improve long-term adherence if efficacy is maintained. . Robust randomized evidence comparing different aspirin doses was lacking. Results: In this multicenter randomized trial involving nearly 1,900 individuals with Lynch syndrome, the 100 mg aspirin dose demonstrated cancer prevention outcomes broadly comparable to the 600 mg dose in the intention-to-treat analysis, although formal non-inferiority criteria were not fully met across all predefined analyses. The 300 mg dose did not demonstrate non-inferiority. Importantly, adverse events increased with higher aspirin doses, and serious bleeding events were least frequent with the 100 mg regimen. Overall, the lower-dose strategy appeared to retain much of the chemopreventive benefit while offering a more favorable safety profile. Clinical Impact: These findings support a shift toward lower-dose aspirin for cancer prevention in individuals with Lynch syndrome. Although the statistical threshold for non-inferiority was not formally achieved, the similar cancer outcomes and substantially lower bleeding risk with 100 mg daily make it an attractive option for long-term chemoprevention. Ongoing follow-up will clarify whether these findings remain consistent over a longer duration. Bottom Line: Low-dose (100 mg) aspirin demonstrated cancer prevention outcomes comparable to high-dose aspirin with fewer bleeding complications, supporting its consideration as the preferred long-term chemopreventive strategy for patients with Lynch syndrome while awaiting longer-term follow-up.

4-Year Benefit of Durvalumab in BTC: JAMA Oncol | July 2026

Introduction: The TOPAZ-1 trial established durvalumab combined with gemcitabine and cisplatin (GemCis) as the first immunotherapy-based first-line standard of care for advanced biliary tract cancer (BTC). However, long-term survival outcomes and durability of benefit beyond the initial analysis remained uncertain. This post hoc analysis reports efficacy and safety after more than four years of follow-up. Why was this study needed?: . Long-term survival data for immunotherapy in advanced BTC were lacking. . The durability of benefit with durvalumab beyond the primary analysis required confirmation. . Long-term safety with prolonged immunotherapy exposure remained uncertain. . Extended follow-up was needed to validate durvalumab plus GemCis as the standard first-line regimen. Results: After more than four years of follow-up, durvalumab plus GemCis continued to demonstrate a sustained overall survival advantage over chemotherapy alone. Long-term survival rates remained consistently higher with the addition of durvalumab, confirming durable clinical benefit in a subset of patients. Importantly, the safety profile remained stable over time, with no increase in treatment-related serious adverse events or treatment discontinuations compared with chemotherapy alone. These findings reinforce the long-term efficacy and tolerability of the regimen. Clinical Impact: This extended analysis provides compelling evidence that adding durvalumab to GemCis delivers durable survival benefits without compromising long-term safety. The persistence of a meaningful survival advantage beyond four years strengthens confidence in immunotherapy as the foundation of first-line treatment for advanced biliary tract cancer and provides reassurance regarding prolonged treatment outcomes. Bottom Line: More than four years of follow-up confirms that durvalumab plus gemcitabine–cisplatin provides durable survival benefit with a manageable long-term safety profile, reinforcing its role as the standard first-line treatment for advanced biliary tract cancer.

The First Standardized PET Response Framework for Neuroendocrine Tumors: The Lancet Oncology | July 2026

Introduction: Somatostatin receptor (SSTR) PET/CT has become indispensable for diagnosing, staging, and monitoring neuroendocrine tumors (NETs). However, until now, there has been no standardized method for assessing treatment response using SSTR PET imaging. This international consensus introduces the SSTR-PeRForm (Somatostatin Receptor PET Response Framework) to harmonize response assessment. Why was this guideline needed? No standardized PET-based response criteria currently exist for NETs. Existing RECIST criteria may not adequately reflect functional changes seen on SSTR PET. Variability in PET interpretation limits consistency across clinical practice and research. Uniform response criteria are needed for clinical trials and routine patient care. Standardized reporting may improve treatment decisions and future research. Key Recommendations: Response assessment should primarily rely on changes in tumor volume of SSTR-expressing lesions rather than SUV-based measurements. Partial Response (PR): ≥40% reduction in target lesion volume with no new lesions. Progressive Disease (PD): ≥40% increase in target lesion volume or appearance of new lesions. Complete Response (CR): Complete disappearance of pathological somatostatin receptor uptake. Unconfirmed Progressive Disease (uPD): A new category for equivocal findings requiring repeat imaging before confirming progression. SUV measurements alone should not be used to define treatment response. Volumetric assessment and identification of new lesions are considered the most clinically relevant imaging parameters. The framework is intended for both clinical trials and routine practice, pending prospective validation against survival outcomes. Clinical Impact: SSTR-PeRForm is the first internationally endorsed framework for SSTR PET response assessment in NETs. It provides a standardized, practical approach that is expected to improve reporting consistency, treatment monitoring, and the design of future clinical trials. Bottom Line: SSTR-PeRForm establishes the first consensus-based PET response criteria for neuroendocrine tumors. By emphasizing volumetric tumor changes and new lesion detection, it lays the foundation for standardized response assessment and future outcome-based validation.

Staging Laparoscopy in Gastric Cancer: Annals of Surgical Oncology | July 2026

Introduction: Staging laparoscopy (SL) is recommended for patients with locally advanced gastric cancer to detect occult peritoneal metastases before curative treatment. However, its real-world utilization across Europe remains uncertain. This large GASTRODATA study evaluated the impact of staging laparoscopy on treatment pathways and clinical outcomes. Why was this study needed? Staging laparoscopy is recommended by current guidelines but remains underutilized. Occult peritoneal metastases may be missed on conventional imaging. The impact of SL on multimodality treatment and surgical outcomes is unclear. Real-world European data on SL practice have been limited. Better staging may improve patient selection for curative treatment. Results: Only one-third of patients underwent staging laparoscopy, highlighting substantial underutilization across European centers. Patients who did not undergo staging laparoscopy experienced higher postoperative complications, higher 90-day mortality, and were less likely to receive neoadjuvant or adjuvant chemotherapy. Absence of staging laparoscopy was associated with greater staging inaccuracy, more advanced pathological disease, and reduced use of multimodal treatment. Clinical Impact: This study reinforces the importance of routine staging laparoscopy in patients with locally advanced gastric cancer. Accurate staging facilitates appropriate multimodal treatment, avoids non-therapeutic surgery in patients with occult metastatic disease, and may improve short-term outcomes through better patient selection. Bottom Line: Staging laparoscopy remains underused despite guideline recommendations. Wider implementation may improve staging accuracy, optimize multimodality treatment, and potentially improve outcomes for patients with locally advanced gastric cancer.

Celecoxib Boosts Neoadjuvant Immunotherapy in dMMR/MSI-H CRC : Lancet Oncol | Jul 2026

Introduction: Neoadjuvant immune checkpoint inhibitors have transformed the management of mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) locally advanced colorectal cancer, achieving unprecedented pathological response rates. Experimental evidence suggests that cyclooxygenase-2 (COX-2) inhibition may enhance antitumor immunity by modifying the inflammatory tumor microenvironment, providing a rationale for combining celecoxib with PD-1 blockade. Problem Statement: Although neoadjuvant PD-1 inhibitor monotherapy produces excellent outcomes in dMMR/MSI-H colorectal cancer, a substantial proportion of patients still have residual viable tumor after treatment. Whether adding celecoxib can further improve pathological complete response without compromising safety has remained uncertain. Summary: The multicenter phase 2 PICC-2 trial evaluated neoadjuvant toripalimab plus celecoxib versus toripalimab alone in patients with locally advanced dMMR/MSI-H colorectal cancer. The combination significantly increased the proportion of patients achieving pathological complete response compared with PD-1 inhibitor monotherapy, while maintaining a comparable safety profile. Nearly all patients successfully completed neoadjuvant treatment and proceeded to surgery, demonstrating the feasibility of this strategy in routine clinical practice. Importantly, the addition of celecoxib did not increase severe treatment-related toxicity, and no new safety concerns emerged. These findings support the concept that targeting COX-2–mediated inflammation can enhance the effectiveness of immune checkpoint blockade in this highly immunogenic tumor subtype. If confirmed in larger phase 3 studies, combining celecoxib with neoadjuvant PD-1 inhibition may become an inexpensive, readily accessible approach to maximize pathological response and further improve organ preservation and long-term oncologic outcomes in patients with dMMR/MSI-H locally advanced colorectal cancer.

Cancer Cachexia: Science | July 2026

Introduction: Cancer-associated cachexia is a devastating syndrome characterized by loss of appetite, weight loss, and muscle wasting, affecting up to half of patients with lung cancer. This landmark study uncovers a previously unrecognized mechanism linking dietary fat, tumor-derived prostaglandin E2 (PGE2), and sensory nerve signaling to the development of cachexia. Why was this study needed? The mechanisms driving cancer cachexia remain poorly understood. Current therapies have limited efficacy in preventing appetite loss and muscle wasting. Cachexia has traditionally been attributed to circulating inflammatory factors. The influence of dietary fat on cachexia progression has been unclear. New therapeutic targets are urgently needed to improve outcomes in cancer patients. Results: A high-fat diet paradoxically worsened cachexia, increasing appetite loss and weight loss in mice with Lkb1-mutant lung cancer. Tumor-derived prostaglandin E2 (PGE2) activated local lung sensory nerves, driving cachexia through neural signaling rather than circulating inflammatory mediators. Blocking PGE2 production or silencing sensory neurons markedly reduced cachexia, identifying a novel therapeutic pathway. Clinical Impact: This study fundamentally changes our understanding of cancer cachexia by demonstrating that local tumor–nerve communication, rather than systemic inflammation alone, can drive appetite loss and wasting. It also raises important questions about the routine use of high-fat nutritional supplementation in selected patients with cancer cachexia. Bottom Line: Cancer cachexia is not solely a systemic inflammatory disorder. Tumor-derived PGE2 activates sensory nerves to promote cachexia, and targeting the PGE2–sensory neuron axis may represent a promising new therapeutic strategy for preventing cancer-associated weight loss.

Liquid Biopsy-Guided Cetuximab Rechallenge in mCRC: ESMO GI Cancers Congress | July 2026

Introduction: Resistance to anti-EGFR therapy has traditionally been considered irreversible in metastatic colorectal cancer (mCRC). However, emerging evidence suggests that resistance is dynamic and can be monitored using circulating tumor DNA (ctDNA). The CAPRI-2 trial evaluated whether liquid biopsy could identify patients who remain sensitive to cetuximab beyond disease progression. Why was this study needed? Most patients eventually develop resistance to anti-EGFR therapy. RAS/BRAF wild-type status alone may not identify patients suitable for cetuximab rechallenge. Liquid biopsy offers a non-invasive method to detect acquired resistance mutations. Better patient selection could maximize benefit while avoiding ineffective therapy. Precision-guided rechallenge strategies require prospective validation. Results: Patients with no ctDNA-detected anti-EGFR resistance mutations ("negative hyperselected") consistently achieved higher response rates, longer progression-free survival, and superior overall survival with continued cetuximab-based therapy. Cetuximab retained meaningful activity beyond disease progression in carefully selected patients, suggesting that EGFR dependence can persist despite radiological progression. These findings support liquid biopsy-guided treatment selection, although randomized studies are still needed before routine clinical adoption. Clinical Impact: This study strengthens the role of ctDNA as a real-time biomarker for guiding anti-EGFR rechallenge in metastatic colorectal cancer. Rather than discontinuing cetuximab solely because of disease progression, clinicians may be able to personalize therapy based on molecular evolution detected by liquid biopsy. Bottom Line: Liquid biopsy is redefining anti-EGFR rechallenge in metastatic colorectal cancer. Patients without ctDNA evidence of resistance mutations appear to derive continued benefit from cetuximab, moving treatment selection from radiological progression to molecular progression.

PD-(L)1 Inhibitors Plus Chemotherapy in Advanced Gastric Cancer: CGH | July 2026

Introduction: Immune checkpoint inhibitors combined with chemotherapy have become the standard first-line treatment for advanced HER2-negative gastric and gastroesophageal junction cancers. This meta-analysis evaluated whether treatment benefits differ between Asian and non-Asian populations. Why was this study needed? Gastric cancer differs across geographic regions in terms of incidence, biology, and clinical practice. Whether these differences influence the efficacy and safety of first-line PD-(L)1 inhibitor-based therapy has remained uncertain. What did the study show? Seven phase III randomized trials involving more than 6,700 patients were included. PD-(L)1 inhibitors plus chemotherapy significantly improved overall survival compared with chemotherapy alone. Progression-free survival was also significantly prolonged with chemoimmunotherapy. Survival benefits were consistent in both Asian and non-Asian patients, with comparable treatment effects across regions. Treatment-related adverse events were similar between chemoimmunotherapy and chemotherapy alone. The findings support the generalizability of first-line PD-(L)1 inhibitor therapy regardless of geographic region. Clinical Impact: This analysis confirms that the survival benefit of adding PD-(L)1 inhibitors to chemotherapy is not restricted to a particular ethnic or regional population. These data reinforce current global recommendations supporting chemoimmunotherapy as first-line treatment for eligible patients with advanced HER2-negative gastric and gastroesophageal junction cancer. Take-Home Message: First-line PD-(L)1 inhibitor plus chemotherapy provides a consistent survival benefit for advanced gastric and gastroesophageal junction cancer in both Asian and non-Asian populations, supporting its worldwide use as a standard-of-care treatment.

CLDN18.2 and Gastric Cancer: Cancer Letters | July 2026

Introduction: The treatment of advanced gastric cancer is rapidly evolving from conventional chemotherapy to biomarker-driven precision medicine. Claudin 18.2 (CLDN18.2), a tight junction protein selectively expressed in gastric epithelial cells and many gastric cancers, has emerged as one of the most promising therapeutic targets. Why was this review needed? Following the approval of zolbetuximab for HER2-negative, CLDN18.2-positive advanced gastric cancer, numerous CLDN18.2-targeted therapies are under development. This review summarizes the current evidence and future directions of this rapidly expanding therapeutic field. What did the review show? CLDN18.2 is an established biomarker and therapeutic target in advanced gastric cancer. Zolbetuximab combined with chemotherapy is now the first approved CLDN18.2-targeted therapy for HER2-negative, CLDN18.2-positive gastric adenocarcinoma. Next-generation monoclonal antibodies are being developed to improve efficacy and durability of response. Antibody-drug conjugates (ADCs) enable selective delivery of cytotoxic agents to CLDN18.2-expressing tumor cells. Bispecific antibodies simultaneously target CLDN18.2 and immune pathways, enhancing antitumor activity. CLDN18.2-directed CAR-T cell therapy has shown encouraging early clinical activity in heavily pretreated patients. Combination strategies with chemotherapy, immunotherapy, and other targeted agents may further improve clinical outcomes. Resistance mechanisms, patient selection, biomarker standardization, and treatment-related toxicities remain important challenges. Clinical Impact: Routine assessment of CLDN18.2 expression is becoming increasingly important in advanced gastric cancer. Expanding CLDN18.2-directed therapies are expected to broaden personalized treatment options and improve outcomes for appropriately selected patients. Take-Home Message: CLDN18.2 has emerged as a major therapeutic target in gastric cancer, marking a shift toward biomarker-guided treatment. As monoclonal antibodies, ADCs, bispecific antibodies, and CAR-T therapies continue to evolve, precision targeting of CLDN18.2 is poised to become a cornerstone of future gastric cancer management.

Pemigatinib Outperforms Chemotherapy in FGFR2-Rearranged Cholangiocarcinoma : JCO | June 2026

Introduction: Cholangiocarcinoma is an aggressive biliary tract malignancy with limited treatment options and poor long-term outcomes. The discovery of fibroblast growth factor receptor 2 (FGFR2) rearrangements in a subset of patients has transformed the therapeutic landscape, enabling the development of precision-targeted therapies. Pemigatinib previously demonstrated meaningful activity in previously treated FGFR2-rearranged cholangiocarcinoma, leading to its approval in the second-line setting. Problem Statement: Although targeted therapy has shown promise after chemotherapy failure, it remained uncertain whether FGFR inhibition could provide superior outcomes when used as first-line treatment. Establishing the role of precision medicine earlier in the disease course is critical for improving outcomes in biomarker-selected patients with advanced cholangiocarcinoma. Summary: The phase 3 FIGHT-302 trial represents the largest randomized study of a targeted therapy conducted in patients with advanced cholangiocarcinoma harboring FGFR2 rearrangements. The trial demonstrated that first-line pemigatinib significantly prolonged progression-free survival compared with standard gemcitabine-cisplatin chemotherapy. Pemigatinib also produced substantially higher objective response rates and more durable tumor responses, highlighting the effectiveness of biomarker-driven therapy in this molecularly defined population. Although overall survival was similar between treatment groups, interpretation is influenced by the study design, which allowed patients progressing on chemotherapy to receive pemigatinib subsequently. Notably, patients who crossed over to pemigatinib continued to derive meaningful clinical benefit, further supporting the activity of FGFR inhibition. The safety profile of pemigatinib was consistent with previous studies, with no unexpected toxicities identified. These findings provide strong evidence that molecular profiling should be routinely incorporated into the management of cholangiocarcinoma to identify patients with actionable FGFR2 alterations. The study marks an important milestone in biliary tract cancer, demonstrating that targeted therapy can outperform conventional chemotherapy in the frontline setting for appropriately selected patients. Overall, FIGHT-302 reinforces FGFR2 rearrangement as a clinically actionable biomarker and supports pemigatinib as a major therapeutic option in the evolving era of precision oncology for cholangiocarcinoma.

Fasting Alone Does Not Stabilize Stomach Volume During Pancreatic SBRT Journal: Practical Radiation Oncology | June 2026

Pancreatic stereotactic body radiotherapy (SBRT) requires highly precise treatment because the pancreas lies immediately adjacent to radiosensitive organs such as the stomach and duodenum. Most centers instruct patients to fast before simulation and treatment, assuming that an empty stomach will reduce daily variation and improve treatment reproducibility. This study evaluated whether a standardized 2-hour fasting protocol actually produces consistent stomach volumes during pancreatic SBRT. Seventy-four patients undergoing pancreatic SBRT were analyzed with repeated imaging throughout treatment. The results showed that fasting instructions alone were insufficient for many patients. Approximately 58% of patients demonstrated substantial day-to-day stomach volume variability despite following identical fasting instructions. Patients with larger stomach volumes at simulation were more likely to show significant variation during treatment. A baseline stomach volume of approximately >200 cc identified patients at higher risk for inter-fraction variability. Surprisingly, total stomach volume correlated poorly with the volume of stomach located near the treatment target. This finding is clinically important because radiation toxicity depends primarily on the stomach immediately adjacent to the planning target volume rather than the total gastric volume. Simply measuring overall stomach size may therefore be inadequate when assessing radiation risk. The study challenges the common assumption that uniform fasting instructions guarantee reproducible anatomy during pancreatic radiation therapy. Adaptive radiotherapy, image guidance, and individualized preparation strategies may remain necessary despite fasting protocols. Baseline simulation imaging may help identify patients who require more intensive motion management or adaptive planning. The findings are particularly relevant as pancreatic SBRT continues to expand and dose escalation strategies increasingly rely on precise organ-at-risk avoidance. Bottom line: A standard 2-hour fasting protocol does not reliably produce consistent stomach volumes during pancreatic SBRT. Patients with larger baseline stomach volumes are particularly prone to day-to-day variability, highlighting the need for individualized image-guided and adaptive treatment strategies.

DOTATATE PET and Poorly Differentiated Extrapulmonary NEC: JNM | June 2026

Somatostatin receptor (SSTR) imaging with ⁶⁸Ga-DOTATATE PET is a cornerstone for well-differentiated neuroendocrine tumours, but its role in poorly differentiated neuroendocrine carcinoma (NEC) has remained uncertain. Previous retrospective studies suggested that up to 40% of NECs might demonstrate strong somatostatin receptor expression, raising interest in peptide receptor radionuclide therapy (PRRT) for these patients. This prospective study was designed to provide a more accurate assessment by evaluating an unselected cohort of metastatic extrapulmonary NEC patients. Thirty patients with metastatic extrapulmonary NEC underwent ⁶⁸Ga-DOTATATE PET, and most also underwent ¹⁸F-FDG PET. Primary tumour sites included pancreas, colorectum, uterus, and cancers of unknown primary origin. Histologies included both small-cell and large-cell neuroendocrine carcinoma. The key finding was that uniform, high-level somatostatin receptor expression was uncommon. Only 13% of patients demonstrated strong, homogeneous DOTATATE uptake consistent with high SSTR expression. The vast majority of tumors showed either: Absent SSTR expression Patchy/heterogeneous receptor expression Predominantly FDG-avid biology These findings suggest that most poorly differentiated NECs retain aggressive glycolytic behaviour rather than the receptor-rich phenotype typically seen in well-differentiated NETs. The study challenges previous reports that may have overestimated SSTR positivity because of selection bias or inclusion of tumours with lower Ki-67 indices. Clinically, this means that routine DOTATATE PET scanning is unlikely to identify large numbers of poorly differentiated NEC patients suitable for PRRT. However, a small subset of NEC patients may still demonstrate strong receptor expression and could remain candidates for receptor-targeted therapies. Dual-tracer imaging with FDG PET and DOTATATE PET may be particularly useful when considering individualised treatment strategies. The findings reinforce the biological distinction between well-differentiated NETs and poorly differentiated NECs. Bottom line: Strong and uniform somatostatin receptor expression is present in only a small minority of patients with metastatic extrapulmonary poorly differentiated NEC. Most NECs remain predominantly FDG-avid tumours, limiting the routine applicability of DOTATATE-based imaging and PRRT in this population.

Fasting Alone Does Not Stabilise Stomach Volume During Pancreatic SBRT: Practical Radiation Oncology | June 2026

Pancreatic stereotactic body radiotherapy (SBRT) requires highly precise treatment because the pancreas lies immediately adjacent to radiosensitive organs such as the stomach and duodenum. Most centres instruct patients to fast before simulation and treatment, assuming that an empty stomach will reduce daily variation and improve treatment reproducibility. This study evaluated whether a standardised 2-hour fasting protocol actually produces consistent stomach volumes during pancreatic SBRT. Seventy-four patients undergoing pancreatic SBRT were analysed with repeated imaging throughout treatment. The results showed that fasting instructions alone were insufficient for many patients. Approximately 58% of patients demonstrated substantial day-to-day stomach volume variability despite following identical fasting instructions. Patients with larger stomach volumes at simulation were more likely to show significant variation during treatment. A baseline stomach volume of approximately >200 cc identified patients at higher risk for inter-fraction variability. Surprisingly, total stomach volume correlated poorly with the volume of stomach located near the treatment target. This finding is clinically important because radiation toxicity depends primarily on the stomach immediately adjacent to the planning target volume rather than the total gastric volume. Simply measuring overall stomach size may therefore be inadequate when assessing radiation risk. The study challenges the common assumption that uniform fasting instructions guarantee reproducible anatomy during pancreatic radiation therapy. Adaptive radiotherapy, image guidance, and individualised preparation strategies may remain necessary despite fasting protocols. Baseline simulation imaging may help identify patients who require more intensive motion management or adaptive planning. The findings are particularly relevant as pancreatic SBRT continues to expand and dose escalation strategies increasingly rely on precise organ-at-risk avoidance. Bottom line: A standard 2-hour fasting protocol does not reliably produce consistent stomach volumes during pancreatic SBRT. Patients with larger baseline stomach volumes are particularly prone to day-to-day variability, highlighting the need for individualised image-guided and adaptive treatment strategies.

Multimodality Therapy Remains Key in Recurrent Rectal Cancer : Cancer | June 2026

Introduction: Locoregionally recurrent rectal cancer (LRRC) remains one of the most challenging scenarios in colorectal oncology. Recurrence within the pelvis is often associated with significant morbidity, impaired quality of life, and limited treatment options. Advances in surgery, radiation therapy, systemic therapy, and imaging have improved outcomes; however, optimal management requires careful integration of multiple treatment modalities and expertise across specialties. Problem Statement: The management of LRRC is highly individualized and influenced by prior treatments, anatomical location of recurrence, extent of disease, and resectability. Given the complexity of these cases, clinicians require evidence-based guidance to determine the most appropriate combination and sequencing of therapies while maximizing the chance of durable disease control. Summary: This American Radium Society Appropriate Use Criteria review provides comprehensive multidisciplinary guidance for the management of locoregionally recurrent rectal cancer. Drawing upon evidence from more than 100 studies and expert consensus, the document reinforces that achieving a margin-negative (R0) surgical resection remains the most important determinant of long-term survival and local disease control. The guidelines emphasize that successful surgery often depends on appropriate use of preoperative therapies, including systemic chemotherapy, radiation therapy, or combined-modality approaches, which can facilitate tumor downsizing and improve resectability. Treatment decisions should be tailored according to prior treatment exposure, recurrence location, and disease extent, highlighting the importance of individualized care planning. The review strongly advocates for management within experienced multidisciplinary teams involving colorectal surgeons, radiation oncologists, medical oncologists, radiologists, and gastroenterologists. While the recommendations do not fundamentally alter current treatment paradigms, they provide important validation of contemporary practice and underscore the continued value of combined-modality therapy in improving outcomes. Overall, the guidance supports a personalized, multidisciplinary strategy focused on maximizing the likelihood of complete resection while integrating systemic and local therapies to optimize survival and local control in patients with recurrent rectal cancer.

Nal-IRI Improves Second-Line Outcomes in Pancreatic Cancer : Pancreatology | June 2026

Introduction: Despite advances in systemic therapy, metastatic and recurrent pancreatic cancer remains associated with poor survival. Following progression on first-line gemcitabine-based chemotherapy, treatment options have historically been limited. The introduction of nanoliposomal irinotecan (nal-IRI) combined with 5-fluorouracil and leucovorin (5-FU/LV) represented an important therapeutic advance, demonstrating improved efficacy in clinical trials. However, whether this benefit translates into routine clinical practice has remained uncertain. Problem Statement: Clinical trial populations often differ from real-world patients encountered in daily oncology practice. Consequently, it is important to determine whether the availability of nal-IRI has meaningfully improved survival outcomes for patients with metastatic or recurrent pancreatic cancer outside controlled trial settings. Summary: This real-world study compared treatment outcomes in patients with metastatic or recurrent pancreatic cancer before and after the introduction of nal-IRI plus 5-FU/LV as a second-line treatment option. The investigators found that while overall survival from the start of first-line therapy remained largely unchanged, patients treated in the era following nal-IRI availability experienced significantly improved outcomes after progression on first-line treatment. Both progression-free survival and overall survival from initiation of second-line therapy were prolonged following the introduction of nal-IRI-based treatment. Furthermore, multivariable analysis identified treatment in the nal-IRI era as an independent predictor of improved second-line survival. These findings suggest that access to effective second-line therapy can meaningfully influence outcomes even in a disease with historically limited treatment options. Importantly, the survival benefits were achieved with an acceptable safety profile, supporting the feasibility of this regimen in routine practice. The study provides valuable real-world evidence confirming that the benefits observed in clinical trials can be translated into everyday clinical care. Overall, the results support nal-IRI plus 5-FU/LV as an important component of the treatment sequence for metastatic and recurrent pancreatic cancer and highlight the growing importance of effective second-line therapy in improving patient outcomes.

Early-Onset Cancers Rising Selectively in Spain : Ann Oncol | June 2026

Introduction: Concerns regarding increasing cancer incidence among adults younger than 50 years have gained global attention over the past decade. Reports from several countries have suggested a rise in early-onset cancers, particularly those affecting the gastrointestinal tract and other obesity-related malignancies. Understanding these trends is essential for guiding prevention strategies, public health policies, and future research into potential environmental and lifestyle drivers. Problem Statement: Although increasing rates of early-onset cancer have been reported internationally, population-based data from Southern Europe remain limited. It is unclear whether similar patterns are occurring in Spain and whether observed trends differ according to cancer type, age group, and sex. Summary: This large population-based study from the Spanish Network of Cancer Registries provides a comprehensive assessment of cancer incidence trends among adults aged 20–49 years over a 25-year period. The investigators found that changes in cancer incidence were highly heterogeneous rather than representing a universal increase across all cancer types. Notably, more rising trends were observed among women than men. Several cancers demonstrated increasing incidence, including pancreatic cancer and lymphomas in women, and kidney, thyroid, and Hodgkin lymphoma in men. Of particular relevance to gastroenterologists and oncologists, stomach, colon, and rectal cancers showed increasing incidence among the youngest adults, supporting growing concerns regarding early-onset gastrointestinal malignancies. In contrast, cancers strongly associated with tobacco exposure—including lung, laryngeal, bladder, and liver cancers—declined substantially in both sexes, reflecting the success of long-term tobacco control efforts. A key finding was that the increase in several obesity-associated cancers was largely confined to individuals aged 20–39 years, suggesting that changing metabolic and lifestyle factors may be contributing to cancer risk in younger generations. These observations reinforce the emerging global pattern linking obesity and metabolic dysfunction to rising early-onset cancer incidence. Overall, the study highlights the need for strengthened cancer prevention initiatives focused on modifiable lifestyle factors and emphasizes the importance of further research to clarify the biological and environmental mechanisms driving the increase in selected cancers among younger adults.

B-Cell Dysfunction Drives Immune Escape in iCCA : Gut | June 2026

Introduction: Intrahepatic cholangiocarcinoma (iCCA) is one of the most aggressive primary liver malignancies, characterized by poor survival and limited therapeutic options. Although recent advances in immunotherapy have offered new treatment opportunities, response rates remain modest. A major obstacle is the highly complex and immunosuppressive tumor microenvironment, which limits effective antitumor immunity. While T-cell biology has been extensively studied in iCCA, the role of B lymphocytes within the tumor microenvironment remains incompletely understood. Problem Statement: B cells are increasingly recognized as important regulators of antitumor immunity, yet their functional significance in iCCA is unclear. Understanding how tumor-associated factors influence B-cell differentiation and activity may identify novel biomarkers of treatment response and uncover new therapeutic strategies to improve immunotherapy outcomes. Summary: This comprehensive translational study provides important insights into the role of B cells in the immune landscape of iCCA. The investigators demonstrated that B cells located in adjacent non-tumorous tissues frequently formed mature tertiary lymphoid structures (TLS), which were associated with more favorable clinical outcomes. In contrast, B cells infiltrating the tumor itself were scarce, immature, and exhibited impaired immune function with prominent immunosuppressive characteristics. Mechanistic analyses revealed that interactions with tumor cells and cancer-associated fibroblasts actively suppress B-cell maturation and effector activity. The cytokines IL-6 and TGF-β emerged as key mediators of this dysfunction, and simultaneous blockade of these pathways restored B-cell activation and differentiation in experimental models. Importantly, patients with higher levels of circulating BAFFR-positive B cells and expanded B-cell clonotypes experienced better responses to chemoimmunotherapy, suggesting potential predictive biomarkers for treatment selection. These findings highlight B cells as previously underappreciated contributors to immune regulation in iCCA and suggest that restoring B-cell function may enhance antitumor immunity. The study provides a strong rationale for developing therapeutic strategies aimed at reversing B-cell suppression and promoting mature TLS formation, potentially improving the effectiveness of immunotherapy in this difficult-to-treat malignancy.

RTOG 0848: Adjuvant Chemoradiotherapy Fails Overall, but Node-Negative Patients May get benifit: JCO| June 2026

RTOG 0848 is one of the largest randomized phase III trials evaluating the role of adjuvant chemoradiotherapy after curative-intent resection of pancreatic head adenocarcinoma. The study addressed a long-standing controversy in pancreatic cancer: does adding fluoropyrimidine-sensitized radiotherapy after adjuvant chemotherapy improve outcomes? Patients first received adjuvant gemcitabine-based chemotherapy and, if disease-free after five cycles, were randomized to receive the sixth cycle alone or combined with chemoradiotherapy. A total of 354 patients were randomized between chemotherapy alone and chemotherapy plus chemoradiotherapy. The primary endpoint was overall survival, and the study was formally negative. Median overall survival was similar between the two groups, and the addition of chemoradiotherapy did not significantly improve overall survival. Disease-free survival showed a favorable trend with chemoradiotherapy, but this did not reach conventional statistical significance. Importantly, adding radiotherapy did not increase grade 4 or grade 5 toxicities. However, grade 3 toxicity was significantly higher in patients receiving chemoradiotherapy. The most clinically relevant finding emerged from subgroup analysis based on lymph node status. Patients with node-negative disease experienced significant improvements in both overall survival and disease-free survival when chemoradiotherapy was added. In contrast, patients with node-positive disease did not derive a similar benefit. These findings suggest that local disease control may be particularly important in node-negative pancreatic cancer, whereas systemic disease biology may dominate outcomes in node-positive patients. The trial was conducted in the gemcitabine era, before widespread use of modern regimens such as modified FOLFIRINOX and gemcitabine-capecitabine. Therefore, the applicability of these findings to contemporary practice remains uncertain and requires validation in the setting of modern systemic therapy. The results may also support renewed interest in selective use of radiation therapy, particularly in biologically favorable patients with node-negative disease. Bottom line: RTOG 0848 did not demonstrate an overall survival benefit for routine addition of adjuvant chemoradiotherapy after pancreatic cancer resection. However, node-negative patients showed significant improvements in survival outcomes, suggesting that carefully selected patients may still benefit from radiation as part of multimodality treatment.

Underwater Endoscopy for Colorectal Neoplasia : Frontline Gastroenterol | Jun 2026

Introduction: Water-assisted and immersion-based endoscopic techniques are increasingly transforming the diagnosis and treatment of colorectal neoplasia. Unlike conventional gas insufflation, these approaches replace luminal gas with water or saline, creating a different optical and mechanical environment within the gastrointestinal tract. This can improve lesion visualisation, facilitate endoscopic resection, and enhance patient comfort. Over the past decade, underwater techniques have evolved from simple insertion methods to advanced therapeutic platforms for complex colorectal lesions. Problem Statement: Despite major advances in colonoscopy and endoscopic resection, challenges remain in optimizing adenoma detection, improving procedural comfort, and achieving safe and effective removal of complex colorectal neoplasms. Conventional techniques may be limited by suboptimal visualisation, difficult lesion access, and procedural complexity. There is growing interest in whether underwater and immersion-assisted approaches can overcome these limitations and improve both diagnostic and therapeutic outcomes. Summary: This review highlights the expanding role of underwater endoscopy across the spectrum of colorectal neoplasia management. Water-aided colonoscopy (WAC) has been associated with improved patient tolerance, enhanced bowel cleanliness, better adenoma detection, and smoother procedural performance. Underwater endoscopic mucosal resection (U-EMR) has emerged as an effective technique for colorectal lesion removal, offering efficient resection with favorable outcomes and reduced recurrence in selected cases. More recently, saline-immersion strategies such as the Saline-Immersion/Irrigation Technique (SITE) have been incorporated into endoscopic submucosal dissection (ESD). By creating a fluid-filled operative field, SITE may enhance visualisation, provide buoyancy-assisted tissue traction, improve electrosurgical performance, and potentially reduce thermal injury. Early experience suggests that SITE-ESD may simplify technically demanding dissections and improve procedural safety. Collectively, underwater endoscopy is evolving into a comprehensive platform for colorectal neoplasia management, with growing evidence supporting its integration into routine and advanced endoscopic practice. Further standardization and prospective studies will help define its optimal role in modern therapeutic endoscopy.

GLP-1 Agonists with TNT in Rectal Cancer: Metabolic Optimization Meets Oncology: British Journal of Surgery | June 2026

* This review explores a novel concept: whether GLP-1 receptor agonists can improve outcomes when combined with total neoadjuvant therapy in locally advanced rectal cancer. * Total neoadjuvant therapy is now a standard approach for locally advanced rectal cancer because it improves treatment completion, pathological complete response, disease control, and sphincter preservation. * Obesity is an important negative prognostic factor in colorectal cancer, associated with higher perioperative morbidity, recurrence risk, technical surgical difficulty, and worse long-term outcomes. * GLP-1 receptor agonists, such as semaglutide, produce substantial weight loss and improve insulin resistance, systemic inflammation, and metabolic dysfunction. * The biological rationale is strong: reducing visceral adiposity, hyperinsulinaemia, and chronic inflammation may improve tumour biology and treatment tolerance. * GLP-1 RAs may also help patients tolerate neoadjuvant chemotherapy and radiotherapy better by improving metabolic reserve and reducing obesity-related treatment complications. * Emerging observational data suggest GLP-1 RA use may be associated with lower incidence of obesity-related cancers, including colorectal cancer, although causality remains unproven. * Potential anticancer mechanisms include improved insulin signaling, reduced inflammatory cytokines, altered tumour metabolism, and modulation of the tumour microenvironment. * The most clinically relevant population may be metabolically vulnerable patients with rectal cancer, especially those with obesity, type 2 diabetes, insulin resistance, or sarcopenic obesity. * GLP-1 RAs may complement prehabilitation, particularly because intensive lifestyle-based weight-loss programs are difficult to complete during neoadjuvant cancer treatment. * Important safety questions remain, including nutritional adequacy during chemotherapy, preservation of muscle mass, gastrointestinal side effects, and timing around surgery. * Current evidence is mainly biological, preclinical, and observational. There is no definitive clinical trial evidence yet showing that GLP-1 RAs improve pathological complete response, survival, or surgical outcomes in rectal cancer. * Future trials should evaluate whether GLP-1 RAs can improve treatment completion, reduce complications, enhance tumour regression, and improve long-term oncological outcomes. Bottom line: GLP-1 receptor agonists represent a promising metabolic adjunct to total neoadjuvant therapy in locally advanced rectal cancer, especially in obese or insulin-resistant patients, but this strategy remains investigational and requires prospective clinical validation.

KRAS + MTAP Loss Defines a Poor-Risk Pancreatic Cancer Subgroup: Clinical Cancer Research | June 2026

* This study highlights the importance of comprehensive genomic profiling in pancreatic adenocarcinoma, not only for identifying targetable alterations but also for defining biologically distinct prognostic subgroups. * The analysis included a large pancreatic adenocarcinoma dataset, with more than 4,000 profiled samples and an additional 2,181-sample meta-cohort, making it a substantial genomic evaluation. * Homozygous MTAP deletion was found in approximately 24% of pancreatic adenocarcinomas, confirming that MTAP loss is a common molecular event in this disease. * Co-occurrence of KRAS mutation and MTAP loss was frequent, present in nearly 19% of all pancreatic adenocarcinomas. * This co-mutated subgroup was associated with worse survival outcomes, suggesting that KRAS-mutant, MTAP-deficient pancreatic cancer represents a clinically aggressive phenotype. * MTAP-deficient tumours showed a more fibrotic and immune-excluded tumour microenvironment, with less immune enrichment compared with MTAP-intact tumours. * This is clinically relevant because pancreatic cancer is already characterized by dense stroma and poor immune infiltration; MTAP loss may further reinforce an immunologically resistant phenotype. * Among KRAS-mutant, MTAP-deleted tumours, the most common KRAS variants were G12D, G12V, and G12R. * KRAS G12R appeared to show slightly more immune-enriched tumour microenvironment features compared with other KRAS variants, suggesting that not all KRAS-mutant pancreatic cancers behave identically. * The study supports the concept that KRAS mutation status alone is insufficient; co-alterations such as MTAP loss may better define prognosis, biology, and therapeutic vulnerability. * MTAP loss may become increasingly important as investigational therapies targeting MTAP-deficient cancers, including synthetic-lethal strategies, continue to develop. * For clinicians, the key message is that pancreatic cancer genomic profiling should include both driver mutations and copy-number alterations, because these can identify high-risk and potentially trial-eligible subgroups. * This study does not immediately change standard treatment, but it strongly supports molecular stratification of pancreatic cancer for prognosis, trial design, and future targeted therapy development. Bottom line: KRAS-mutant pancreatic adenocarcinoma with MTAP loss represents a common, aggressive, fibrotic, immune-excluded subgroup with poor prognosis, reinforcing the need for comprehensive genomic profiling and future MTAP-directed therapeutic strategies.

BREAKWATER Cohort 3: New First-Line Standard for BRAF V600E Metastatic Colorectal Cancer: Annals of Oncology | May 2026

* BRAF V600E-mutant metastatic colorectal cancer represents one of the most aggressive molecular subtypes of colorectal cancer, accounting for approximately 8%–12% of cases and historically associated with poor outcomes. * BREAKWATER Cohort 3 evaluated whether adding targeted therapy with encorafenib plus cetuximab to FOLFIRI could improve outcomes compared with standard FOLFIRI with or without bevacizumab. * The study enrolled previously untreated patients with BRAF V600E-mutant metastatic colorectal cancer in the first-line setting. * The combination of encorafenib + cetuximab + FOLFIRI (EC+FOLFIRI) significantly improved objective response rates compared with standard therapy. * Response rates increased from 39.2% with standard treatment to 64.4% with EC+FOLFIRI, representing one of the highest response rates reported in this molecular subgroup. * Progression-free survival improved substantially, increasing from 8.3 months with standard treatment to 15.2 months with EC+FOLFIRI. * Overall survival was also prolonged, with a 44% reduction in the risk of death compared with standard therapy. * The benefit was observed despite the historically poor prognosis associated with BRAF V600E-mutant disease. * Toxicity was predictable and consistent with the known safety profiles of encorafenib, cetuximab, and FOLFIRI. * No new safety concerns emerged, and adverse events were generally manageable with standard supportive care. * These findings complement earlier BREAKWATER data using EC+mFOLFOX6 and provide clinicians with an additional chemotherapy backbone option. * The availability of both FOLFOX- and FOLFIRI-based targeted approaches allows greater treatment personalization according to patient characteristics, prior neuropathy risk, performance status, and physician preference. * The study further reinforces the importance of early molecular testing for BRAF mutations at the time of metastatic colorectal cancer diagnosis. * BRAF V600E status should now directly influence first-line treatment selection rather than being considered only after progression. * The results represent another major success for biomarker-driven precision oncology in colorectal cancer. Bottom line: BREAKWATER Cohort 3 demonstrates that encorafenib + cetuximab + FOLFIRI significantly improves response rate, progression-free survival, and overall survival in previously untreated BRAF V600E-mutant metastatic colorectal cancer and establishes a new first-line standard of care for this high-risk molecular subtype.

EOCRC Treatment Delays: Language Barriers Are a Modifiable Risk Factor: JAMA Oncology | June 2026

* Early age–onset colorectal cancer is increasing globally and is now a major public health concern, especially because many patients present before routine screening age. * This population-based Texas Cancer Registry study included more than 112,000 patients with colorectal cancer, including over 12,000 patients with early age–onset colorectal cancer. * Early age–onset colorectal cancer accounted for approximately 11% of all colorectal cancer cases in this cohort. * Patients with early age–onset colorectal cancer were more likely to be Hispanic, less likely to be White, and more likely to have left-sided or rectal tumors. * Early age–onset colorectal cancer patients were also more likely to present with advanced-stage disease, reinforcing the need for earlier symptom recognition and timely diagnostic pathways. * Treatment delay was defined as more than 6 weeks from tissue diagnosis to initiation of definitive therapy. * Treatment delays were independently associated with worse overall survival in colorectal cancer. * Importantly, treatment delay remained significantly associated with worse survival even among patients with early age–onset colorectal cancer. * Higher social vulnerability was also associated with poorer survival, highlighting the role of social determinants of health in cancer outcomes. * Language barrier emerged as a key modifiable factor associated with treatment delay in early age–onset colorectal cancer. * After adjusting for demographic and clinical factors, patients with language barriers had a significantly higher likelihood of delayed treatment. * This finding is clinically important because language barriers can be addressed through structured navigation, professional interpretation services, multilingual education, and culturally sensitive cancer care pathways. * The study shifts attention from biology alone to healthcare delivery, showing that outcomes in early age–onset colorectal cancer are influenced by access, communication, and system-level equity. * For clinicians, the message is clear: once colorectal cancer is diagnosed in a young patient, treatment planning must be rapid, coordinated, and barrier-sensitive. * Oncology systems should track time from diagnosis to treatment initiation as a quality metric, especially in younger and socially vulnerable patients. Bottom line: Early age–onset colorectal cancer patients often present with higher-risk clinical features, but treatment delays further worsen outcomes. Language barriers are a practical, modifiable target for improving timely care and survival.

PRISM Study: Real-World Outcomes of First-Line Systemic Therapy for Unresectable HCC: Liver Cancer | May 2026

* PRISM is one of the largest prospective real-world studies evaluating systemic therapy for unresectable hepatocellular carcinoma in routine clinical practice across Japan. * This analysis reports outcomes from the first 1,000 prospectively enrolled patients, providing important validation of results seen in clinical trials. * Among evaluable patients, the vast majority received atezolizumab plus bevacizumab (82.8%), while 15.2% received lenvatinib as first-line therapy. * Median overall survival reached 21.8 months with Atezo+Bev and 20.8 months with lenvatinib, demonstrating excellent real-world outcomes. * Survival outcomes were numerically better than those reported in the original registration trials, suggesting that careful patient selection, multidisciplinary management, and effective sequential therapy may be improving outcomes in practice. * Progression-free survival remained consistent with clinical trial data at 7.7 months for Atezo+Bev and 6.7 months for lenvatinib. * Objective response rates were impressive for both regimens, confirming that real-world effectiveness closely mirrors clinical trial efficacy. * Sorafenib was rarely used and showed substantially lower response rates compared with modern first-line therapies. * Grade 3 or higher treatment-related adverse events occurred in approximately 22% of patients, with no unexpected safety concerns. * Importantly, nearly 50% of patients were able to receive second-line therapy, highlighting the growing importance of sequential treatment strategies in advanced HCC. * The most common sequencing pattern was: * Atezolizumab + bevacizumab → lenvatinib * Lenvatinib → atezolizumab + bevacizumab * Second-line therapy provided a median progression-free survival of approximately 4 months, while benefit progressively decreased with later treatment lines. * The study demonstrates that modern systemic therapies can be safely delivered to a broad real-world population, not just highly selected clinical trial patients. * PRISM also highlights the importance of maintaining liver function and performance status to allow access to sequential therapies, which likely contributes significantly to prolonged survival. * Future analyses are expected to provide valuable information regarding special populations, including elderly patients, those with impaired liver function, and different molecular or clinical subgroups. Bottom line: The PRISM study confirms that atezolizumab plus bevacizumab and lenvatinib achieve reproducible real-world outcomes in unresectable HCC, with median overall survival exceeding 20 months and nearly half of patients successfully receiving subsequent lines of therapy.

DUPAN-2 Enables Biomarker Monitoring in CA19-9 Nonexpressors : JAMA Surg | Jun 2026

Introduction: Introduction: Carbohydrate antigen 19-9 (CA19-9) is the most widely used serum biomarker in pancreatic ductal adenocarcinoma (PDAC), guiding treatment response assessment, prognostication, and postoperative surveillance. However, approximately 5%–10% of patients are CA19-9 nonexpressors, typically due to a Lewis-negative phenotype, resulting in undetectable CA19-9 levels regardless of tumor burden. This leaves a clinically important subgroup without a reliable biomarker for treatment monitoring. Problem Statement: Problem Statement: There is currently no established alternative biomarker for patients with CA19-9 nonexpressing pancreatic cancer. Whether Duke Pancreatic Monoclonal Antigen Type 2 (DUPAN-2) can function as a surrogate biomarker and provide clinically meaningful treatment monitoring and prognostic information remains uncertain. Summary: Summary: This multicenter cohort study evaluated 2,418 patients with resected pancreatic ductal adenocarcinoma treated across nine Japanese academic centers. Among them, 185 patients (7.7%) were classified as CA19-9 nonexpressors (≤2 U/mL), while 2,233 were CA19-9 expressors. Importantly, overall survival was comparable between CA19-9 nonexpressors and expressors, confirming that lack of CA19-9 expression does not inherently indicate a different biological prognosis but rather reflects a limitation in biomarker availability. The investigators examined whether changes in DUPAN-2 levels among nonexpressors paralleled the well-established behavior of CA19-9 in expressors. Remarkably, DUPAN-2 dynamics closely mirrored CA19-9 responses during treatment. Reductions in DUPAN-2 after neoadjuvant therapy and after surgical resection were nearly identical to the decline patterns observed with CA19-9 in biomarker-expressing patients. Most importantly, achieving normalization of DUPAN-2 levels (≤150 U/mL) after neoadjuvant therapy was strongly associated with improved overall survival and disease-free survival. Similar findings were observed after surgery, where patients achieving normal postoperative DUPAN-2 levels experienced substantially better long-term outcomes than those with persistently elevated values. These observations suggest that DUPAN-2 may serve not merely as a diagnostic biomarker but as a dynamic treatment-response marker analogous to CA19-9. From a clinical perspective, this study addresses a major unmet need in pancreatic oncology. Modern treatment strategies increasingly rely on biomarker kinetics to assess response to neoadjuvant therapy, determine surgical timing, identify residual disease risk, and guide postoperative surveillance. Until now, CA19-9 nonexpressors lacked an equivalent tool for biomarker-guided decision-making. The study provides evidence that serial DUPAN-2 measurement may fill this gap, allowing clinicians to monitor treatment effectiveness and risk stratify patients throughout the disease course. The findings are particularly relevant in the neoadjuvant era, where biochemical response has become an important adjunct to radiographic assessment when evaluating treatment success and surgical candidacy. Although prospective validation is required before universal adoption, this large multicenter analysis establishes DUPAN-2 as the first clinically validated surrogate biomarker for CA19-9 nonexpressing pancreatic cancer. Overall, the study suggests that routine DUPAN-2 monitoring can provide meaningful prognostic and treatment-response information for the previously unassessable subgroup of CA19-9 nonexpressor PDAC patients, enabling a more personalized and biomarker-driven management approach.

Quorum-Sensing Signals Drive Colitis-Associated Cancer in UC : Gastroenterology | June 2026

Introduction: Ulcerative Colitis is associated with an increased long-term risk of Colitis-Associated Cancer, particularly in patients with prolonged inflammatory disease activity. Although microbiome dysbiosis is increasingly implicated in carcinogenesis, the molecular mediators linking bacterial signaling to tumor development remain incompletely understood. Problem Statement: Most microbiome studies in ulcerative colitis have focused on bacterial composition rather than bacterial communication systems. Quorum-sensing molecules (QSMs), which regulate bacterial population behavior and host–microbiome interactions, have not previously been well characterized in colitis-associated cancer pathogenesis. Whether these bacterial signaling molecules directly promote carcinogenesis remains uncertain. Summary: This translational study identified bacterial quorum-sensing molecules as novel mediators linking chronic inflammation to colitis-associated cancer development in ulcerative colitis. The investigators focused on three major quorum-sensing molecule classes, particularly short-chain N-acyl homoserine lactones (scAHLs), evaluating their clinical relevance in ulcerative colitis patients and mechanistic role in experimental cancer models. Serum scAHL levels were significantly elevated in ulcerative colitis patients compared with healthy controls. Importantly, patients with long-standing disease duration exceeding 10 years and ongoing inflammatory activity demonstrated particularly elevated levels of autoinducer-2, suggesting a relationship between bacterial signaling burden and cancer risk factors. Mechanistic experiments identified the quorum-sensing molecule C6-scAHL as a key driver of tumour promotion. Administration of C6-scAHL in murine colitis-associated cancer models increased both tumour number and tumour size, establishing a direct pathogenic role for bacterial signaling molecules in colorectal carcinogenesis. Notably, the tumor-promoting effects persisted even in germ-free mice, indicating that C6-scAHL itself exerts direct biologic activity independent of broader microbial ecosystem interactions. The study further demonstrated that C6-scAHL induced microbiome and metabolomic changes resembling highly inflammatory intestinal environments associated with tumor progression. Using murine and human colonic organoid systems, investigators showed that C6-scAHL stimulated production of proinflammatory and protumorigenic cytokines, reinforcing its direct role in epithelial inflammatory signaling and neoplastic transformation. These findings are particularly important because they move beyond conventional dysbiosis models and identify bacterial intercellular communication pathways as active participants in carcinogenesis. The study introduces the concept that microbial signaling metabolites may function similarly to host inflammatory mediators in shaping the tumour microenvironment. Clinically, the work raises the possibility that quorum-sensing molecule profiling could eventually serve as a biomarker strategy for identifying ulcerative colitis patients at elevated risk for colitis-associated cancer. The findings also suggest potential therapeutic opportunities targeting microbial signaling pathways rather than attempting broad microbiome depletion. Interventions directed at quorum-sensing inhibition may theoretically reduce tumor-promoting inflammation while preserving beneficial commensal microbial populations. The work is highly relevant because cancer surveillance in ulcerative colitis remains imperfect, and current risk stratification largely depends on clinical factors such as disease duration and inflammatory burden. Identification of molecular microbiome-derived mediators may help refine individualized cancer prediction models in inflammatory bowel disease. Future studies will need to determine whether circulating quorum-sensing molecules correlate with dysplasia progression in longitudinal human cohorts and whether pharmacologic blockade of these signaling pathways can reduce cancer risk. Overall, this study identifies bacterial quorum-sensing molecules, particularly C6-scAHL, as previously unrecognized drivers of colitis-associated cancer and establishes microbial communication pathways as promising mechanistic and therapeutic targets in ulcerative colitis-associated carcinogenesis.

ESD Outperforms TEM for Early Rectal Tumors : Gastroenterology | June 2026

Introduction: Early Rectal Cancer and advanced rectal adenomas are increasingly managed with organ-preserving local excision strategies. Endoscopic Submucosal Dissection and Transanal Endoscopic Microsurgery are the two principal approaches for early rectal tumors, but comparative prospective evidence evaluating both clinical outcomes and cost-effectiveness has remained limited. Problem Statement: Although both ESD and TEM are widely used for local excision of early rectal tumors, previous comparisons have largely been retrospective and single-center in design, with little evidence addressing long-term oncologic outcomes, procedural quality, or healthcare economic impact. Determining the optimal organ-preserving strategy is increasingly important as minimally invasive rectal cancer management expands. Summary: The multicenter MUCEM study compared ESD and TEM for early rectal tumors through a combined clinical and cost-effectiveness analysis, providing one of the most comprehensive evaluations of these two local excision strategies. The study included patients with rectal adenomas, carcinoma in situ, and uT1N0 rectal cancers suitable for either ESD or TEM depending on institutional expertise. A total of 213 ESD procedures and 117 TEM procedures were analyzed across multiple centers. The primary endpoint was complete resection, while secondary analyses evaluated recurrence, morbidity, quality of life, survival, and healthcare costs. At 1 year, ESD demonstrated superior cost-effectiveness compared with TEM, with a significant incremental net monetary benefit favoring ESD. Importantly, ESD remained the preferred strategy across a broad willingness-to-pay range, supporting its economic advantage from a healthcare system perspective. Procedural quality outcomes strongly favored ESD, particularly regarding en bloc resection rates, which reached 99% with ESD compared with 92.5% with TEM. High-quality en bloc excision is clinically important because it improves histopathologic assessment, margin evaluation, and long-term recurrence control. Despite superior resection quality with ESD, there were no significant differences in overall morbidity or major complication rates between the two approaches, supporting the safety of advanced endoscopic resection. Long-term oncologic outcomes also favored ESD. At 3 years, disease-free survival was significantly higher following ESD compared with TEM, suggesting improved local disease control and lower recurrence risk. Overall survival and health-related quality of life remained similar between the two groups, indicating that the oncologic advantages of ESD did not come at the expense of patient well-being. The study is highly relevant because it challenges the historical assumption that surgical local excision necessarily provides superior oncologic outcomes for early rectal tumors. Instead, the findings support ESD as an effective minimally invasive organ-preserving strategy capable of achieving excellent oncologic control while simultaneously reducing healthcare costs. Clinically, the results reinforce the importance of advanced therapeutic endoscopy expertise in modern colorectal cancer management. The superior disease-free survival observed after ESD may reflect improved margin assessment and lower rates of residual microscopic disease compared with surgical excision techniques. The findings also have major implications for healthcare resource utilization, particularly as healthcare systems increasingly prioritize high-value minimally invasive therapies. Importantly, successful implementation of ESD requires specialized training and institutional experience, highlighting the need for referral pathways to expert therapeutic endoscopy centers. Future research should focus on refining patient selection, standardizing pathological assessment, and evaluating longer-term oncologic outcomes beyond three years. Overall, the MUCEM study demonstrates that ESD is more cost-effective than TEM for early rectal tumors while providing superior en bloc resection quality and improved disease-free survival, supporting ESD as a preferred organ-preserving strategy in appropriately selected patients.

AI-Assisted Endoscopy Reduces Blind Spots, Not Missed Gastric Neoplasia : Gastroenterology | June 2026

Introduction: Gastric Cancer remains a major global cause of cancer mortality, particularly in East Asia, where early detection through upper gastrointestinal endoscopy is central to improving outcomes. Artificial intelligence (AI)-assisted endoscopy has emerged as a promising strategy to enhance lesion recognition and reduce missed neoplasia during routine gastroscopy. Problem Statement: Although multiple retrospective and single-center studies have suggested that AI may improve upper gastrointestinal lesion detection, robust evidence from large multicenter randomized controlled trials evaluating its real-world clinical effectiveness has been lacking. Whether AI meaningfully improves true gastric neoplasm detection beyond enhancing procedural quality metrics remains uncertain. Summary: This large multicenter randomized controlled trial evaluated the real-world impact of AI-assisted esophagogastroduodenoscopy on gastric neoplasm detection across 24 hospitals in China. A total of 29,514 patients were randomized to either AI-assisted or conventional upper endoscopy, making this one of the largest prospective studies assessing AI integration into gastrointestinal endoscopy practice. The primary endpoint was pathologically confirmed gastric neoplasm detection after expert pathological review. Importantly, AI assistance did not significantly improve the final detection rate of gastric neoplasms after pathological confirmation, with rates of 1.42% in the AI group versus 1.25% in the conventional group. However, AI did improve lesion detection before central pathological review, suggesting that AI may enhance initial lesion recognition during live procedures. One of the most important procedural findings was the marked reduction in endoscopic blind spots with AI assistance, decreasing from 2.52 to 1.07 blind spots per examination. This suggests that AI significantly improves procedural completeness and mucosal visualization quality during upper endoscopy. AI-assisted procedures were associated with longer inspection and procedural times, indicating that enhanced scrutiny may partially explain improvements in lesion recognition. Subgroup analyses provided clinically relevant insights, demonstrating potential benefit among less experienced endoscopists and during fatigue-associated procedural periods. These findings support the concept that AI may function most effectively as a quality-support tool rather than a replacement for expert endoscopic interpretation. Importantly, AI demonstrated excellent sensitivity for advanced gastric lesions, correctly identifying 100% of gastric adenocarcinomas and over 90% of high-grade intraepithelial neoplasia cases confirmed on pathology. Performance was less robust for low-grade intraepithelial neoplasia, highlighting ongoing limitations in detecting subtle early lesions. The study is highly relevant because it challenges the widespread assumption that AI universally improves clinically meaningful gastric cancer detection rates. Instead, the findings suggest that the current generation of AI systems may primarily enhance procedural standardization, inspection quality, and operator vigilance rather than independently increasing definitive neoplasm detection. Clinically, the data indicate that AI may have greatest utility in community settings, lower-volume centers, or among less experienced endoscopists where variability in inspection quality is more pronounced. The reduction in blind spots is particularly important because missed lesions remain a major contributor to post-endoscopy upper gastrointestinal cancers. The trial also highlights a critical issue in AI research: improvements in surrogate procedural metrics do not always translate into improved clinically validated outcomes. Future development will likely require more sophisticated multimodal AI platforms capable of integrating lesion morphology, mucosal pattern recognition, and real-time histologic prediction. Further real-world validation studies are needed to determine whether AI-assisted systems can improve long-term gastric cancer outcomes, interval cancer rates, and cost-effectiveness in routine practice. Overall, this landmark randomized trial demonstrates that AI-assisted gastroscopy improves procedural quality and reduces blind spots but does not yet significantly increase pathologically confirmed gastric neoplasm detection, underscoring both the promise and current limitations of AI-enabled endoscopy.

F. prausnitzii–PIA Axis Suppresses CRC Progression : Gastroenterology | June 2026

Introduction: Colorectal Cancer is increasingly recognized as a disease strongly influenced by host–microbiome metabolic interactions. Although gut microbial dysbiosis has been linked to colorectal carcinogenesis, the mechanistic interplay between microbial metabolites, bacterial competition, and host oncogenic signaling remains incompletely understood. Problem Statement: While pathogenic bacteria such as Bacteroides fragilis promote tumorigenesis, protective microbial pathways capable of counteracting these oncogenic effects have not been clearly defined. In particular, there is limited translational understanding of how microbial metabolites influence tumour biology and whether dietary or microbiota-directed interventions can therapeutically modulate these pathways. Summary: This comprehensive multi-omics study identified a novel antagonistic microbial-metabolic pathway in colorectal cancer centered on Faecalibacterium prausnitzii and its tryptophan-derived metabolite picolinic acid (PIA). Using integrated metagenomic, metabolomic, transcriptomic, and genomic analyses from a large Chinese colorectal cancer cohort, investigators demonstrated a consistent enrichment of enterotoxigenic Bacteroides fragilis alongside depletion of Faecalibacterium prausnitzii during colorectal cancer progression. Mechanistically, F. prausnitzii metabolized dietary tryptophan into picolinic acid through the enzyme 2-amino-3-carboxymuconate semialdehyde decarboxylase. PIA subsequently exerted potent antitumour activity against B. fragilis-driven carcinogenesis. The study demonstrated that enterotoxigenic B. fragilis induced expression of the oncogenic genes TCERG1 and CKAP2, both associated with poor differentiation and tumour recurrence in colorectal cancer. Importantly, PIA counteracted these oncogenic effects by suppressing TCERG1 and CKAP2 expression and promoting tumour cell apoptosis. The biological relevance of this pathway was validated across multiple independent patient cohorts, organoid systems, and murine models, substantially strengthening translational credibility. One of the most clinically relevant findings was that a tryptophan-rich diet significantly increased circulating PIA levels in vivo, suggesting a feasible nutritional strategy capable of modulating tumour-associated microbial metabolism. This work is important because it moves beyond descriptive microbiome associations and establishes a functional microbe–metabolite–host regulatory axis directly influencing colorectal cancer progression. The findings reinforce the concept that colorectal cancer development depends not only on microbial composition but also on microbial metabolic output and host transcriptional responses. Clinically, the study raises the possibility of microbiota-guided precision interventions using dietary modulation, metabolite supplementation, or targeted microbial engineering to restore protective pathways such as the F. prausnitzii–PIA axis. The identification of TCERG1 and CKAP2 as downstream oncogenic mediators also provides potential biomarkers for aggressive disease biology and future therapeutic targeting. Importantly, the study supports the growing paradigm that beneficial commensal bacteria may exert direct anticancer activity rather than simply maintaining gut homeostasis. Future studies will need to clarify whether therapeutic restoration of F. prausnitzii or exogenous PIA administration can enhance responses to chemotherapy, immunotherapy, or colorectal cancer prevention strategies. Overall, this study defines a clinically relevant microbial-metabolic checkpoint in colorectal cancer in which the F. prausnitzii–PIA axis antagonizes enterotoxigenic B. fragilis–mediated tumour progression, highlighting promising opportunities for microbiota-based precision oncology and dietary intervention strategies.

Zanidatamab Redefines First-Line HER2+ GEA Therapy : NEJM | May 2026

Introduction Gastroesophageal Adenocarcinoma remains an aggressive malignancy with limited long-term survival despite HER2-directed therapy. Since the ToGA era, trastuzumab-based chemotherapy has remained the standard first-line treatment, but therapeutic resistance and incomplete durability of response continue to limit outcomes. Problem Statement Whether next-generation HER2-targeted strategies can surpass trastuzumab-based therapy and meaningfully improve survival in HER2-positive gastroesophageal adenocarcinoma has remained a major unanswered clinical question. Summary This landmark phase 3 HERIZON-GEA-01 trial evaluated Zanidatamab combined with chemotherapy, with or without Tislelizumab, against standard trastuzumab plus chemotherapy in previously untreated HER2-positive advanced gastroesophageal adenocarcinoma. Zanidatamab is a dual HER2-targeted bispecific antibody engineered to simultaneously bind extracellular domains 2 and 4 of HER2, thereby enhancing receptor clustering, internalization and immune-mediated cytotoxicity compared with conventional single-epitope HER2 targeting. The study demonstrated a major improvement in progression-free survival with both zanidatamab-containing regimens. Median progression-free survival increased from 8.1 months with trastuzumab-based therapy to 12.4 months with both zanidatamab-containing arms, representing a clinically meaningful delay in disease progression. Most importantly, the combination of zanidatamab, tislelizumab and chemotherapy achieved a statistically significant overall survival advantage over trastuzumab-based therapy, with median overall survival extending to 26.4 months versus 19.2 months. Although the zanidatamab-chemotherapy arm numerically improved overall survival, statistical significance was not reached at this interim analysis, suggesting that immune checkpoint inhibition may provide an additive survival benefit in this setting. These findings are highly relevant because durable survival improvements in metastatic gastroesophageal cancer have historically been difficult to achieve. Crossing the two-year median survival threshold in HER2-positive disease represents a major therapeutic advance. The study additionally reinforces the evolving importance of combining targeted therapy with immunotherapy in upper gastrointestinal malignancies. HER2-directed treatment may enhance tumor immunogenicity, potentially amplifying responsiveness to PD-1 blockade. From a toxicity standpoint, zanidatamab-containing regimens demonstrated manageable but increased gastrointestinal toxicity, particularly diarrhea. Grade 3 or higher adverse events were common across all treatment groups, reflecting the intensity of combination systemic therapy in advanced gastroesophageal cancer. Importantly, no unexpected safety signals emerged, supporting the feasibility of integrating dual HER2 targeting with checkpoint inhibition and chemotherapy in frontline practice. The trial also highlights the rapid evolution of antibody engineering in gastrointestinal oncology. Unlike trastuzumab, bispecific antibodies such as zanidatamab provide multi-epitope HER2 engagement, potentially overcoming mechanisms of receptor heterogeneity and resistance. Clinically, the results are likely to reshape frontline management algorithms for HER2-positive gastroesophageal adenocarcinoma. The zanidatamab–tislelizumab–chemotherapy regimen now emerges as a strong candidate for a new first-line standard of care. The findings are also important within the broader context of precision GI oncology, where biomarker-selected therapies are increasingly driving meaningful survival gains in traditionally treatment-refractory malignancies. Future analyses will be important to clarify durability of benefit, subgroup-specific efficacy, mechanisms of resistance and optimal sequencing with subsequent HER2-directed therapies and antibody-drug conjugates. Overall, HERIZON-GEA-01 establishes zanidatamab-based therapy as a major advance in HER2-positive gastroesophageal adenocarcinoma, demonstrating substantial progression-free survival benefit and clinically meaningful overall survival improvement when combined with tislelizumab and chemotherapy.

ctDNA Predicts Early Multiorgan Recurrence in CRLM : BJS | May 2026

Introduction Colorectal Liver Metastases frequently recur despite curative-intent surgery, with nearly half of patients developing relapse within the first postoperative year. Early identification of biologically aggressive disease remains a major unmet need in surgical oncology. Problem Statement Reliable preoperative biomarkers capable of identifying patients with resectable colorectal liver metastases at high risk for rapid multiorgan recurrence and poor survival are lacking. Summary This MIRACLE cohort study evaluated pretreatment circulating tumour DNA using the modified fast aneuploidy screening test-sequencing system (mFast-SeqS) in chemotherapy-naïve patients undergoing curative-intent treatment for colorectal liver metastases. Patients with high pretreatment ctDNA aneuploidy scores experienced markedly worse oncologic outcomes compared with ctDNA-low patients. Recurrence-free survival and overall survival were both significantly reduced, with ctDNA-high patients demonstrating substantially higher rates of rapid relapse. Most notably, elevated ctDNA was strongly associated with early multiorgan recurrence within the first postoperative year. This finding is clinically important because multiorgan relapse often reflects occult systemic dissemination not fully captured by conventional imaging or clinicopathologic risk models. The prognostic value of ctDNA remained independently significant on multivariable analysis for recurrence-free survival, multiorgan recurrence and overall survival, reinforcing its role as a robust biologic marker of aggressive metastatic disease. Importantly, the study focused specifically on chemotherapy-naïve patients, reducing confounding effects from perioperative systemic treatment and providing a clearer assessment of baseline tumour biology. A major practical strength of the work is the use of mFast-SeqS, an affordable and minimally invasive sequencing platform based on genome-wide aneuploidy detection rather than individualized mutation tracking. This may improve scalability and real-world implementation compared with more complex personalized ctDNA assays. The findings support the growing concept that ctDNA reflects minimal residual systemic disease burden even before surgery. Elevated pretreatment ctDNA likely identifies patients with biologically disseminated micrometastatic disease despite technically resectable liver metastases. Clinically, these results may eventually influence perioperative decision-making. Patients with high ctDNA burden could potentially benefit from intensified systemic therapy, closer surveillance or alternative multimodal treatment strategies rather than surgery alone. The association with multiorgan recurrence is particularly relevant because current surgical selection criteria rely heavily on anatomical resectability and radiologic disease burden, which incompletely capture tumour biology. This study therefore contributes to the ongoing transition from anatomy-based toward biology-driven management of metastatic colorectal cancer. The findings also align with broader precision oncology trends where liquid biopsy technologies increasingly guide risk stratification, treatment escalation and postoperative surveillance strategies across solid tumors. Future studies will need to determine whether ctDNA-guided perioperative treatment adaptation can improve outcomes and whether serial postoperative monitoring further refines recurrence prediction. Importantly, prospective validation and integration with molecular, radiologic and clinicopathologic risk models will be essential before widespread implementation into routine surgical oncology practice. Overall, this MIRACLE cohort study demonstrates that elevated pretreatment ctDNA measured by mFast-SeqS independently predicts rapid multiorgan recurrence and inferior survival in resectable colorectal liver metastases, supporting ctDNA as a promising biomarker for biologic risk stratification before curative-intent surgery.

Real-World Data Support Transplant Benefit in Unresectable CRLM : Liver Transpl | Feb 2026

Introduction Colorectal Liver Metastases have historically been considered a contraindication to Liver Transplantation because of high recurrence risk and limited organ availability. However, modern systemic therapies, refined biologic selection and highly favorable outcomes from the TransMet trial have reignited interest in transplantation for carefully selected unresectable CRLM patients. The TransMet study reported unprecedented five-year survival exceeding 70%, challenging conventional transplant oncology paradigms. Problem Statement Although TransMet demonstrated promising survival outcomes, questions remain regarding external validity, reproducibility in real-world populations and the actual magnitude of transplant benefit compared with continued systemic chemotherapy. Robust prognostic stratification tools for patient selection also remain underdeveloped. Summary This multicenter international study provides the first external validation assessment of the TransMet selection criteria using a real-world cohort of 61 patients with unresectable CRLM undergoing liver transplantation across seven centers. Investigators used matching-adjusted indirect comparison methods to improve comparability between the real-world transplant cohort and the original TransMet population. The results demonstrated remarkable consistency with the original TransMet findings. Five-year restricted mean survival time in the weighted real-world cohort closely mirrored outcomes observed in the TransMet liver transplantation arm, supporting reproducibility of the survival benefit outside specialized trial settings. Sensitivity analyses accounting for residual imbalance yielded similarly favorable long-term survival estimates. Importantly, the study quantified transplant benefit relative to chemotherapy alone. Liver transplantation was associated with an estimated five-year survival gain exceeding 22 months compared with systemic therapy, reinforcing the substantial clinical impact of transplantation in highly selected patients with unresectable CRLM. The analysis additionally identified several biologic factors associated with inferior post-transplant survival. KRAS Mutation emerged as one of the strongest adverse prognostic markers, consistent with prior colorectal oncology literature linking KRAS alterations to aggressive tumor biology and treatment resistance. Right-sided primary tumors also demonstrated poorer outcomes, further supporting the increasingly recognized prognostic divergence between right- and left-sided colorectal cancers. Elevated carcinoembryonic antigen levels additionally appeared to predict worse post-transplant outcomes, suggesting that tumor biology rather than technical unresectability alone should drive transplant candidate selection. These findings strengthen the evolving concept of transplant oncology as a biologically guided discipline integrating molecular and clinical risk profiling. The study is particularly important because it moves beyond simple survival reporting toward formal estimation of transplant benefit — a critical consideration given ongoing ethical concerns regarding organ allocation. Demonstrating substantial survival extension relative to systemic therapy strengthens the rationale for considering unresectable CRLM within future liver allocation frameworks, especially as outcomes now approach or exceed those achieved in several accepted transplant indications. Nevertheless, the authors appropriately emphasize the need for larger multicenter datasets and more refined prognostic models. Recurrence after transplantation remains common in CRLM, and optimal integration of molecular biomarkers, chemotherapy response and disease kinetics into candidate selection algorithms is still evolving. Overall, this first real-world validation study supports the external reproducibility of the TransMet trial findings and demonstrates meaningful transplant benefit in selected patients with unresectable colorectal liver metastases. The data further reinforce the emerging role of biologically driven transplant oncology and support continued evaluation of CRLM within future liver transplantation allocation and selection strategies.

TQB2102 Shows Strong Activity Across HER2-Expressing Tumors : Ann Oncol | May 2026

Introduction Antibody-Drug Conjugate development has rapidly transformed treatment paradigms for HER2-expressing malignancies. However, resistance, heterogeneous HER2 expression and toxicity remain major limitations of currently available HER2-targeted therapies. TQB2102 is a next-generation biparatopic HER2 antibody-drug conjugate simultaneously targeting extracellular domain 2 and extracellular domain 4 of HER2 while delivering a topoisomerase I inhibitor payload through an enzyme-cleavable linker. Problem Statement Current HER2-directed ADCs demonstrate variable activity across tumor types and limited efficacy in HER2-low disease or brain metastases. Novel HER2-targeting strategies capable of improving receptor binding, internalization and payload delivery while maintaining manageable toxicity profiles are needed. Summary This first-in-human multicenter phase I trial evaluated TQB2102 in 195 patients with advanced solid tumors, including metastatic breast cancer, colorectal cancer and gastric/gastroesophageal junction adenocarcinoma. The study incorporated both dose-escalation and dose-expansion cohorts using administration every three weeks. TQB2102 demonstrated a favorable safety profile across all dose levels. No dose-limiting toxicities occurred, the maximum tolerated dose was not reached and recommended phase II doses were established at 6.0 mg/kg and 7.5 mg/kg. The most frequent grade ≥3 toxicities were hematologic, including neutropenia, leukopenia and anemia. Importantly, only one patient developed treatment-related interstitial lung disease, a particularly notable finding given ILD concerns with several currently approved HER2 ADCs. Preliminary antitumor efficacy was highly encouraging across multiple HER2-expressing tumor types. Objective response rates exceeded 50% in metastatic breast cancer and approached 40% in both colorectal cancer and gastric/gastroesophageal junction adenocarcinoma. Particularly striking activity was observed in HER2-low metastatic breast cancer, where response rates remained robust despite lower receptor expression. These findings reinforce the possibility that biparatopic HER2 targeting may enhance receptor clustering, internalization and intracellular payload delivery beyond conventional monospecific HER2 ADCs. The activity observed in patients with brain metastases was especially noteworthy. Objective response rates reached 70% in HER2-positive breast cancer brain metastases and 50% even among HER2-low cases, suggesting substantial intracranial activity. Given the major unmet need for effective CNS-penetrant HER2 therapies, these findings may have important implications for future metastatic breast cancer management strategies. Mechanistically, biparatopic targeting of HER2 ECD2 and ECD4 likely improves receptor engagement and enhances lysosomal trafficking compared with traditional single-epitope HER2 antibodies. Combined with a membrane-permeable topoisomerase I inhibitor payload, this design may additionally promote bystander killing within heterogeneous HER2-expressing tumors, potentially explaining activity in HER2-low disease settings. Overall, this first-in-class phase I study positions TQB2102 as a highly promising next-generation HER2 ADC with encouraging efficacy across multiple advanced solid tumors, including HER2-low disease and CNS metastases. The manageable toxicity profile and broad antitumor activity support ongoing phase III development, particularly in HER2-low metastatic breast cancer.

Adjuvant HAI Oxaliplatin Improves Liver Control After CRLM Surgery : J Clin Oncol | May 2026

Introduction Recurrence after curative-intent surgery for Colorectal Liver Metastases remains common, particularly in patients with high metastatic burden. The liver represents the dominant site of relapse, even after modern systemic chemotherapy and complete resection or ablation. Hepatic Arterial Infusion allows selective administration of high-dose chemotherapy directly to hepatic tumors while limiting systemic exposure and has shown promising activity in metastatic colorectal cancer. However, prospective randomized data evaluating adjuvant HAI after resection of extensive CRLM have been limited. Problem Statement Patients undergoing surgery for four or more colorectal liver metastases remain at extremely high risk for hepatic recurrence despite perioperative systemic chemotherapy. Whether postoperative HAI chemotherapy can improve hepatic disease control and survival outcomes compared with standard intravenous chemotherapy alone has remained uncertain. Summary This randomized phase II trial evaluated adjuvant hepatic arterial infusion of oxaliplatin combined with systemic LV5FU2 following curative-intent surgery or ablation of at least four colorectal liver metastases. Ninety-nine high-risk patients previously treated with preoperative systemic chemotherapy were randomized to receive oxaliplatin via hepatic arterial infusion or standard intravenous administration, both combined with intravenous fluorouracil/leucovorin. After nearly five years of median follow-up, hepatic arterial infusion significantly improved hepatic recurrence-free survival, doubling median liver-specific disease control compared with standard intravenous therapy. Median hepatic recurrence-free survival reached 25 months in the HAI arm versus 12 months with intravenous chemotherapy alone. Overall recurrence-free survival was also significantly prolonged, demonstrating broader disease-control benefits beyond isolated liver recurrence reduction. Although overall survival did not reach statistical significance, clinically meaningful improvements were observed. Median overall survival approached 74 months in the HAI group compared with 57 months in the intravenous chemotherapy group, with five-year overall survival rates of 62% versus 47%, respectively. These findings suggest a potentially important long-term survival advantage that may become clearer in larger phase III validation studies. As expected, intensified regional chemotherapy was associated with higher toxicity. Grade 3–4 adverse events occurred more frequently in the HAI arm, although treatment remained feasible overall, with comparable completion rates between groups and no treatment-related deaths. Importantly, toxicity appeared manageable within experienced multidisciplinary hepatobiliary oncology programs. The study reinforces the concept that recurrence after CRLM surgery is predominantly liver-driven and that intensified liver-directed adjuvant strategies may substantially alter postoperative disease biology in selected high-risk patients. The findings are particularly relevant for patients with extensive bilobar disease or multiple metastases, who remain at greatest risk for early hepatic relapse despite technically curative surgery. Overall, this important randomized study supports postoperative oxaliplatin-based hepatic arterial infusion as a promising adjuvant strategy for high-risk colorectal liver metastases and provides strong justification for ongoing phase III evaluation of regional chemotherapy intensification after CRLM resection.

EXTEND Trial Supports MDT in Oligometastatic Disease : J Clin Oncol | May 2026

Introduction The concept of oligometastatic disease proposes that selected patients with limited metastatic burden may benefit from aggressive local treatment directed at metastatic sites in addition to systemic therapy. Metastasis-Directed Therapy, most commonly stereotactic radiotherapy, has demonstrated promising outcomes in several tumor-specific studies, but whether its benefit extends consistently across multiple solid tumor histologies has remained uncertain. The phase II EXTEND trial evaluated the addition of MDT to standard systemic therapy across several oligometastatic solid tumor “baskets.” Problem Statement Although prior studies suggested progression-free survival benefits with local ablative therapy in oligometastatic disease, most trials were small, histology-specific and underpowered for broad oncologic applicability. Reliable biomarkers defining true oligometastatic biology and predictors of MDT responsiveness also remain lacking. Summary The multicenter randomized phase II EXTEND trial enrolled patients with one to five metastatic lesions across six tumor-histology baskets including pancreatic, breast, renal and prostate cancers. Patients were randomized to receive standard systemic therapy alone or combined with metastasis-directed therapy, predominantly stereotactic radiotherapy. After a median follow-up exceeding four years, the addition of MDT significantly improved progression-free survival across all baskets combined. Importantly, this benefit persisted even after exclusion of prostate cancer cohorts, addressing concerns that highly radiosensitive prostate disease might disproportionately drive positive results. Histology-specific analyses demonstrated particularly strong efficacy signals in pancreatic cancer, prostate cancer and the heterogeneous “Other” basket, whereas breast and kidney cancer cohorts yielded less definitive results. These findings support the possibility that oligometastatic biology and sensitivity to local ablative therapy vary substantially according to tumor histology. The study also provided important translational insights. Detectable circulating tumor DNA (ctDNA) at baseline correlated with inferior progression-free and overall survival, whereas ctDNA clearance three months after treatment was associated with improved outcomes. These findings suggest that molecular residual disease assessment may help refine future definitions of oligometastatic disease and identify patients most likely to benefit from aggressive local therapy. Additionally, immune profiling demonstrated enhanced systemic immune activation among patients receiving MDT combined with systemic therapy, particularly within tumor baskets showing the greatest clinical benefit. These observations reinforce the hypothesis that focal radiotherapy may augment systemic antitumor immunity through immunomodulatory and abscopal mechanisms rather than merely improving local disease control. Overall, the EXTEND trial provides one of the strongest multicancer randomized datasets supporting incorporation of metastasis-directed therapy into management strategies for selected oligometastatic solid tumors. The findings support future phase III validation studies and highlight ctDNA-guided stratification and immune activation as important future directions in precision oligometastatic oncology.

Perioperative Toripalimab Improves Survival in Resectable Gastric/GEJ Cancer : J Clin Oncol | May 2026

Introduction Perioperative chemotherapy remains the standard treatment approach for locally advanced resectable gastric and gastroesophageal junction (GEJ) adenocarcinoma. However, recurrence rates remain high despite curative-intent surgery and systemic therapy, particularly because of peritoneal metastasis. Immune checkpoint inhibitors have demonstrated meaningful survival benefits in advanced gastric cancer, prompting investigation in earlier perioperative settings. Problem Statement Although early studies suggested improved pathological response with perioperative immunotherapy, robust long-term survival data in resectable gastric and GEJ cancer remain limited. It is unclear whether addition of PD-1 blockade to perioperative chemotherapy translates into durable event-free and overall survival benefit. Summary This 3-year follow-up analysis of the randomized phase II NEOSUMMIT-01 trial demonstrated significant long-term survival benefits with perioperative toripalimab plus oxaliplatin-based chemotherapy in patients with locally advanced gastric or GEJ adenocarcinoma. Compared with chemotherapy alone, the addition of the PD-1 inhibitor toripalimab significantly improved both event-free survival and overall survival, with approximately three-quarters of patients remaining event-free at 3 years. Importantly, the survival benefit persisted even after excluding patients with deficient mismatch repair tumors, indicating efficacy beyond highly immunotherapy-sensitive MSI-H/dMMR disease subsets. The therapeutic advantage was also consistently observed across most predefined clinical subgroups. A particularly notable finding was the marked reduction in peritoneal metastasis, historically one of the most challenging recurrence patterns in gastric cancer. The toripalimab-containing regimen nearly halved overall relapse rates and substantially reduced peritoneal dissemination compared with chemotherapy alone, suggesting improved micrometastatic disease control. The study further strengthens growing evidence supporting oxaliplatin-based chemotherapy backbones as favorable partners for perioperative immunotherapy in gastric cancer. Unlike the negative survival findings observed with perioperative pembrolizumab in KEYNOTE-585, the NEOSUMMIT-01 results align more closely with the positive MATTERHORN trial, collectively supporting integration of immunotherapy into curative-intent treatment paradigms. Although limited by its phase II design and predominantly Asian study population, the trial provides compelling evidence that perioperative toripalimab combined with SOX or CapOx chemotherapy may represent a promising new treatment strategy for resectable locally advanced gastric and GEJ cancers.

Advanced Adenomas Detected Frequently in Young Endurance Runners : Cancer Epidemiol | May 2026

Introduction Regular physical activity is generally associated with reduced colorectal cancer (CRC) risk. However, extreme endurance exercise may produce repetitive gastrointestinal stress through splanchnic hypoperfusion, ischemia–reperfusion injury, mucosal inflammation and occult gastrointestinal bleeding. Whether chronic exposure to these physiologic insults influences colorectal neoplasia risk remains poorly understood. Problem Statement Although gastrointestinal bleeding and ischemic colitis are recognized complications of endurance running, data linking high-volume endurance exercise with colorectal adenomas or advanced neoplasia are lacking. Understanding whether endurance athletes harbor increased rates of premalignant colorectal lesions could influence screening and evaluation strategies, particularly in younger individuals with post-exercise rectal bleeding. Summary This prospective hypothesis-generating study evaluated colonoscopic findings in endurance runners aged 35–50 years with substantial marathon or ultramarathon exposure. Adenomas were identified in over 40% of participants, while advanced adenomas were detected in 15%, substantially exceeding historical screening benchmarks for average-risk younger adults. Importantly, no colorectal cancers were identified. Most advanced lesions were right-sided and frequently exhibited high-risk features including large size, tubulovillous histology or sessile serrated morphology. Post-exercise rectal bleeding was significantly more common among runners with advanced adenomas, suggesting that gastrointestinal bleeding after endurance exercise should not be routinely dismissed as benign “runner’s colitis.” Notably, advanced adenomas were also detected in asymptomatic runners without bleeding, indicating that clinically silent lesions may occur in this population. Despite the observed adenoma burden, the study did not demonstrate a clear relationship between training intensity and lesion prevalence, underscoring the exploratory nature of the findings. The authors propose several biologically plausible mechanisms including repetitive ischemia–reperfusion injury, oxidative stress, microbiome alterations and mucosal regenerative hyperproliferation. However, the study’s single-arm design, modest sample size and potential selection bias preclude causal inference. Overall, the findings generate an important hypothesis that extreme endurance running may be associated with increased prevalence of advanced colorectal precursor lesions and support larger controlled studies evaluating colorectal neoplasia risk in endurance athletes.

FDA Expands Precision Oncology Approvals Across Hematologic and Solid Tumors : Oncol Times | May 2026

Introduction Recent FDA approvals continue to accelerate the shift toward biomarker-driven and targeted cancer therapy across hematologic malignancies and solid tumors. Novel immunotherapies and molecularly targeted agents are increasingly improving outcomes in diseases previously associated with limited therapeutic options. Problem Statement Despite major advances in oncology, patients with relapsed multiple myeloma, BRAF V600E–mutated metastatic colorectal cancer and HER2-mutated non-small cell lung cancer continue to face poor long-term outcomes and therapeutic resistance. Expanding effective targeted treatment options remains a major unmet clinical need. Summary This FDA update highlights three important regulatory approvals that reinforce the growing role of precision oncology and immune-directed therapy. Teclistamab combined with daratumumab hyaluronidase demonstrated substantial progression-free and overall survival benefit in relapsed or refractory multiple myeloma, establishing an effective early-line bispecific antibody–based strategy. However, the therapy carries important immune-related toxicities including cytokine release syndrome and neurotoxicity, necessitating REMS-based monitoring. In metastatic colorectal cancer, encorafenib combined with cetuximab and fluorouracil-based chemotherapy received traditional approval for treatment-naïve BRAF V600E–mutated disease following strong survival improvements in the BREAKWATER trial. The findings further validate BRAF-targeted therapy as a frontline precision treatment strategy in this historically aggressive colorectal cancer subtype. Meanwhile, zongertinib received accelerated approval for HER2-mutated advanced non-small cell lung cancer after demonstrating high objective response rates and durable responses in previously untreated patients. Collectively, these approvals illustrate several important trends in modern oncology: earlier integration of targeted therapies, expansion of biomarker-defined treatment paradigms and increasing reliance on molecular profiling to guide therapeutic selection. The update also underscores the continuing balance between efficacy and toxicity management as increasingly potent immune and targeted agents move into earlier lines of treatment.

PD-(L)1 Plus Chemotherapy Benefits Advanced Gastric Cancer Across Regions : Clin Transl Gastroenterol | May 2026

Introduction Immune checkpoint inhibitors targeting programmed cell death protein-(ligand) 1 (PD-[L]1) have transformed first-line treatment of advanced gastric cancer (GC) and gastroesophageal junction cancer (GEJC). However, important regional differences in epidemiology, tumor biology, clinical presentation and treatment practices between Asian and non-Asian populations have raised questions regarding the global generalizability of chemoimmunotherapy outcomes. Problem Statement Although PD-(L)1 inhibitors combined with chemotherapy are widely incorporated into treatment guidelines, uncertainty persists regarding whether survival benefits differ between Asian and non-Asian patients with advanced GC/GEJC. Clarifying these regional outcomes is critical for global treatment standardization, regulatory decision-making and equitable access to immunotherapy. Summary This large meta-analysis of phase III randomized trials demonstrates that first-line PD-(L)1 inhibitors combined with chemotherapy significantly improve overall survival and progression-free survival in advanced HER2-negative GC/GEJC irrespective of Asian or non-Asian regional background. Across more than 6700 patients, survival benefits were remarkably consistent between geographic populations, supporting the broad applicability of chemoimmunotherapy across diverse clinical settings. Although progression-free survival appeared numerically more favorable in Asian populations, the difference was not statistically significant and may partly reflect variations in disease burden and patterns of recurrent versus de novo metastatic disease at study entry. Importantly, treatment-related adverse events remained comparable between immunotherapy-based regimens and chemotherapy-alone controls, reinforcing the acceptable safety profile of combined checkpoint inhibition. The findings also support the concept that immunotherapy benefit in advanced GC/GEJC is primarily biology-driven rather than geography-driven. Sensitivity analyses excluding negative studies and PD-L1–enriched cohorts did not materially alter outcomes, strengthening the robustness of the conclusions. The review further highlights persistent limitations in current evidence, including inconsistent reporting of biomarker-defined subgroups, regional genomic differences and immune-related adverse events. Overall, this study provides strong evidence supporting global use of first-line PD-(L)1 inhibitor plus chemotherapy strategies in advanced gastric and gastroesophageal junction adenocarcinoma and may help reduce disparities in worldwide access to modern immunotherapy.

Pancreatic Cancer Care Enters an Era of Biology-Guided Precision Management : Nat Rev Dis Primers | May 2026

Introduction Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal human malignancies, characterized by aggressive tumor biology, late-stage diagnosis and limited long-term survival. Despite decades of therapeutic stagnation, recent advances in systemic therapy, molecular oncology, surgery and translational science are beginning to reshape the management landscape of pancreatic cancer. Problem Statement Traditional treatment paradigms for PDAC have been constrained by poor early detection, high metastatic potential, dense stromal desmoplasia and profound resistance to chemotherapy and immunotherapy. Although multimodal treatment approaches have improved outcomes incrementally, translating biologic discoveries into durable clinical benefit remains a major challenge. Summary This comprehensive primer outlines the ongoing transformation of pancreatic cancer management toward a multidisciplinary, biology-driven precision oncology model. Modern multiagent chemotherapy regimens have improved survival across resectable, locally advanced and metastatic disease settings, while advances in surgical strategy—including vessel-oriented and minimally invasive approaches—have expanded the pool of patients eligible for curative-intent resection. Importantly, resectability is increasingly being defined not only anatomically but also biologically, integrating treatment response, tumor behavior and systemic disease risk into therapeutic decision-making. The review highlights major advances in precision medicine, particularly the emergence of KRAS-directed therapies and individualized RNA vaccine strategies that may overcome longstanding therapeutic resistance in PDAC. The tumor microenvironment remains central to disease progression and treatment failure, with stromal and immune interactions representing both barriers and therapeutic opportunities for future combination approaches. The article also emphasizes rapid progress in early detection strategies, including surveillance of high-risk populations, artificial intelligence–assisted imaging and liquid biopsy technologies aimed at identifying PDAC at more treatable stages. Overall, this review portrays pancreatic cancer as a disease transitioning from purely anatomy-based management toward integrated biologic and molecular stratification, with precision therapeutics, immunologic innovation and advanced multimodal care collectively redefining future treatment paradigms.

COLOSOTO Trial Explores Chemotherapy-Sparing KRAS G12C Strategy in Frail Metastatic Colorectal Cancer : Digestive and Liver Disease | May 2026

Introduction KRAS G12C mutations represent a clinically important molecular subtype of metastatic colorectal cancer (mCRC), occurring in approximately 3–4% of cases and often associated with aggressive disease biology and limited responsiveness to conventional therapies. Recent advances in KRAS G12C inhibitors combined with EGFR blockade have demonstrated promising activity in refractory disease, opening new possibilities for biomarker-driven treatment strategies in colorectal cancer. Problem Statement Frail and elderly patients with unresectable mCRC frequently cannot tolerate standard doublet or triplet chemotherapy regimens because of age, comorbidities or impaired performance status. Current low-intensity fluoropyrimidine-based approaches offer only modest efficacy, and many vulnerable patients never reach later-line targeted therapies. Whether KRAS G12C-targeted combinations can be safely and effectively integrated earlier in treatment using chemotherapy-sparing strategies remains unknown. Summary The COLOSOTO trial is the first prospective study evaluating first-line treatment with 5-fluorouracil, panitumumab and sotorasib in frail or elderly patients with unresectable KRAS G12C-mutated metastatic colorectal cancer who are unfit for intensive chemotherapy. Building on encouraging activity observed with KRAS G12C inhibition plus EGFR blockade in refractory settings, this study investigates whether earlier deployment of this biologically driven combination can improve outcomes while maintaining tolerability in a clinically vulnerable population. The trial specifically targets patients traditionally underserved by standard treatment paradigms, including older adults and patients with impaired performance status. By combining limited-intensity chemotherapy with dual molecular targeting, the strategy aims to balance efficacy and toxicity while potentially avoiding the complications associated with aggressive cytotoxic regimens. The study also incorporates comprehensive geriatric assessment, quality-of-life evaluation and translational biomarker analyses including circulating tumor DNA monitoring, emphasizing a modern personalized oncology approach. Although limited by its single-arm design and relatively small sample size, the trial addresses a major unmet need in gastrointestinal oncology and may establish a new first-line therapeutic paradigm for frail patients with KRAS G12C-mutated colorectal cancer.

Molecular Tumor Boards Improve Survival in Refractory Solid Tumors : The Oncologist | May 2026

Introduction Precision oncology has transformed cancer care through the integration of genomic profiling and targeted therapies. However, translating complex next-generation sequencing data into clinically actionable treatment strategies remains difficult in patients with refractory solid tumors, particularly after multiple prior treatment failures. Molecular tumor boards (MTBs) have emerged as multidisciplinary platforms designed to bridge this gap by integrating genomic, clinical and therapeutic expertise. Problem Statement Although MTBs are increasingly implemented in oncology practice, real-world evidence demonstrating meaningful survival benefit remains limited, especially in heavily pretreated and biologically heterogeneous patient populations. A major unanswered question is whether adherence to MTB-recommended therapies truly improves clinical outcomes beyond the mere identification of actionable molecular alterations. Summary This large real-world study demonstrates that MTB-guided treatment strategies can significantly improve survival outcomes in patients with refractory solid tumors. Patients who received therapies matched to MTB recommendations experienced markedly prolonged overall survival and progression-free survival compared with patients who either did not receive recommended therapies or had no actionable molecular alterations. Importantly, the study suggests that the clinical benefit was not simply due to the presence of actionable genomic findings, but rather the successful translation of these findings into individualized treatment decisions through multidisciplinary interpretation. The MTB framework incorporated not only genomic alterations but also tumor biology, prior therapies, organ function, immunotherapy biomarkers and overall patient condition to guide precision treatment selection. The survival advantage remained consistent even among patients receiving immunotherapy-based regimens, highlighting the broader value of integrated molecular decision-making beyond targeted therapies alone. Notably, many patients had undergone multiple previous treatment lines, emphasizing the potential role of MTBs in highly refractory disease settings where standard therapeutic options are exhausted. The study also reinforces the growing relevance of tier 2 genomic alterations and combinatorial biomarker interpretation in modern oncology. Overall, these findings support the expanding role of multidisciplinary molecular oncology programs as a critical component of precision cancer care and demonstrate that structured MTB-guided treatment selection can meaningfully influence real-world oncologic outcomes.

Pan-RAS Inhibition with Daraxonrasib Shows Promising Activity in Advanced Pancreatic Cancer | New England Journal of Medicine

Introduction Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with limited survival gains despite advances in systemic therapy. More than 90% of PDAC tumors harbor activating RAS mutations, making RAS signaling a central therapeutic target. However, effective inhibition of the broader spectrum of RAS alterations in pancreatic cancer has remained a major challenge. Problem Statement Most currently available targeted therapies address only selected KRAS subtypes, while the majority of RAS-mutated PDAC lacks effective precision treatment options after progression on standard chemotherapy. A therapeutic strategy capable of targeting multiple active RAS variants simultaneously could potentially overcome this limitation and expand the applicability of RAS-directed therapy in pancreatic cancer. Summary This phase 1–2 study demonstrates encouraging clinical activity of daraxonrasib, a multiselective RAS(ON) inhibitor, in previously treated RAS-mutated PDAC. Daraxonrasib targets active guanosine triphosphate-bound mutant and wild-type RAS, enabling broader inhibition across multiple RAS mutation subtypes rather than focusing on a single KRAS alteration. In heavily pretreated patients, the drug produced meaningful objective response rates, particularly in tumors harboring RAS G12 mutations, with durable responses and progression-free survival outcomes that compare favorably with existing second-line therapies in PDAC. Importantly, responses were also observed across broader RAS mutation groups, suggesting potential applicability beyond highly selected molecular subsets. Toxicities were common but largely manageable, with gastrointestinal adverse effects, rash and mucosal toxicity representing the dominant treatment-related events. Approximately one-third of patients experienced grade 3 or higher adverse events, indicating that tolerability remains an important consideration in further development. Overall, this study represents one of the most promising advances in broad-spectrum RAS inhibition for pancreatic cancer and supports the emergence of pan-RAS targeting as a potentially transformative therapeutic strategy in RAS-driven solid tumors.

Pregnancy-Associated Cancer Is Linked to Treatment Delays and Adverse Birth Outcomes | Journal of Gastrointestinal Surgery

Introduction Pregnancy-associated cancers (PACs), defined as malignancies diagnosed during pregnancy or within the first postpartum year, represent a growing and highly complex clinical challenge. Management requires balancing timely maternal cancer treatment with fetal safety, often forcing difficult decisions regarding surgery, chemotherapy and radiation during pregnancy. Problem Statement Despite increasing recognition of PACs, limited large-scale data exist regarding how pregnancy affects timing of cancer treatment and the downstream impact on maternal and neonatal outcomes. Understanding these treatment patterns is essential because delays in oncologic care may compromise cancer control, while treatment modifications can influence obstetric and neonatal health. Summary This large multicenter analysis demonstrates that pregnancy-associated cancer significantly alters cancer treatment timelines and is associated with increased maternal and neonatal morbidity. Patients diagnosed with cancer during pregnancy experienced meaningful delays in locoregional therapies, including surgery and radiotherapy, likely reflecting concerns regarding fetal exposure and procedural risk. In contrast, chemotherapy initiation occurred earlier, suggesting greater clinical acceptance of selected systemic therapies during pregnancy when maternal disease control is prioritized. Importantly, gestational PAC was also associated with substantially higher risks of cesarean delivery, preterm birth, low birth weight and adverse neonatal condition at delivery, emphasizing the broader maternal-fetal consequences of cancer during pregnancy. Postpartum cancer diagnoses demonstrated shorter treatment initiation times, highlighting how pregnancy itself directly influences therapeutic decision making and care pathways. These findings underscore that PACs require highly coordinated multidisciplinary management involving oncology, maternal-fetal medicine, surgery and neonatology to balance oncologic urgency with fetal safety. The study also highlights the need for standardized care pathways and prospective research aimed at minimizing treatment delays while improving maternal and neonatal outcomes in this vulnerable population.

Questioning the Role of Para-Aortic Dissection in Advanced Gastric Cancer | Gastric Cancer

Introduction Gastric cancer with extensive lymph node metastasis carries a poor prognosis and presents major challenges in surgical management. In Japan, neoadjuvant chemotherapy followed by D2 gastrectomy with para-aortic lymph node dissection (PAND) has been explored as an aggressive multimodal strategy for patients with bulky nodal disease and/or para-aortic lymph node (PAN) involvement. However, the true therapeutic contribution of PAND remains uncertain. Problem Statement Although PAND has historically been incorporated into treatment strategies for advanced nodal gastric cancer, improvements in systemic chemotherapy may have altered the clinical relevance of extended lymphadenectomy. Determining whether PAND continues to provide meaningful survival benefit—particularly across biologically distinct nodal subgroups—is essential to avoid unnecessary surgical morbidity while preserving oncologic benefit. Summary This integrated analysis of three JCOG phase II trials evaluated the therapeutic value of PAND in gastric cancer with extensive lymph node metastasis after neoadjuvant chemotherapy. The findings suggest that the clinical utility of PAND differs substantially according to nodal disease pattern. In patients with bulky nodal disease without para-aortic involvement, PAND retained a modest therapeutic value, supporting the possibility that selected patients may still derive benefit from extended nodal dissection. In contrast, patients with clinically evident para-aortic metastasis demonstrated very limited benefit from PAND, particularly in the more recent chemotherapy trials where the therapeutic value index approached zero. Importantly, the incidence of para-aortic metastasis progressively decreased across successive studies, likely reflecting improvements in systemic therapy and better disease control before surgery. These observations suggest that advances in neoadjuvant chemotherapy may be reducing the incremental value of aggressive para-aortic surgery. The study supports a more individualized surgical strategy in advanced gastric cancer and emphasizes that decisions regarding omission or retention of PAND should be tailored separately for bulky nodal disease and para-aortic metastatic disease rather than treating these populations as a single entity.

LLMs Improve Accuracy and Completeness of Cancer Pathology Summaries | JCO Clinical Cancer Informatics

Introduction Modern oncology care depends on rapid interpretation of increasingly complex pathology reports that integrate histopathology, immunohistochemistry and molecular profiling. Synthesizing these data into concise, clinically usable summaries is time-intensive and cognitively demanding, creating workflow burden and increasing the risk of omission in busy oncology practice. Problem Statement Conventional physician-authored pathology summaries are often efficient but may incompletely capture key diagnostic and genomic information, particularly as molecular testing becomes more complex and voluminous. Large language models (LLMs) offer a potential solution, but their clinical reliability, completeness and safety in summarizing oncology pathology reports require careful evaluation before integration into routine practice. Summary This study demonstrates that open-source LLMs can generate clinically useful summaries of complex cancer pathology reports with greater completeness than physician-authored summaries while maintaining comparable correctness. Across 94 thoracic oncology cases, most LLMs outperformed physician summaries on objective measures of fidelity and consistently captured more complete clinicopathologic and genomic information, particularly molecular findings that were frequently omitted in routine documentation. Importantly, top-performing models maintained strong factual accuracy and low rates of clinically meaningful error, suggesting that LLM-assisted summarization can reduce documentation burden without compromising clinical usability. Performance, however, was model dependent: newer systems such as DeepSeek and Llama 3.1/3.2 performed reliably, whereas older or shorter-context models were more prone to omissions, unusable outputs and clinically relevant errors. The study highlights a key practical advantage of LLMs in oncology workflows—the ability to standardize and scale synthesis of increasingly complex pathology and genomic data—while also emphasizing the need for model selection, human oversight and task-specific validation. These findings support LLM-assisted pathology summarization as a promising workflow tool to improve documentation efficiency, reduce cognitive burden and enhance clinical information accessibility in cancer care.

Raltitrexed Shows Limited Clinical Activity in Advanced Colorectal Cancer | The Oncologist

Introduction Thymidylate synthase inhibition remains a central therapeutic strategy in colorectal cancer, most commonly achieved with fluoropyrimidines such as 5-fluorouracil (5-FU). Raltitrexed, a direct thymidylate synthase inhibitor, was developed to provide more selective pathway inhibition and potentially improve efficacy or tolerability compared with indirect fluoropyrimidine-based approaches. Problem Statement Whether direct thymidylate synthase inhibition can improve outcomes in advanced colorectal cancer, particularly after prior fluoropyrimidine exposure, has remained uncertain. Raltitrexed was hypothesized to offer clinical benefit through more specific target inhibition and to potentially overcome resistance to 5-FU-based therapy, but its true efficacy in advanced colorectal cancer required prospective evaluation. Summary This phase II ECOG-ACRIN study found that raltitrexed has minimal clinical activity in advanced colorectal cancer, both in treatment-naïve patients and in those previously exposed to 5-FU-based therapy. Across all treatment strata, objective response rates were very low and insufficient to justify further trial expansion, with only limited disease control and short progression-free survival observed. Survival outcomes were modest and did not suggest a meaningful advantage over existing fluoropyrimidine-based approaches. Toxicity was consistent with the known safety profile of raltitrexed, with no unexpected safety signals, but this did not offset its limited antitumor activity. Importantly, the study also failed to establish thymidylate synthase expression as a useful predictive biomarker, largely due to low response rates and limited discriminatory value. These findings suggest that direct thymidylate synthase inhibition alone is insufficient to meaningfully improve outcomes in advanced colorectal cancer and reinforce the limitations of relying on isolated antifolate pathway targeting in fluoropyrimidine-exposed disease. The study also underscores the broader need for more effective biomarker-driven and mechanistically distinct strategies in advanced colorectal cancer therapeutics.

Dual NAMPT–KRAS Targeting Emerges as a Promising Strategy in PDAC | CancerNetwork

Introduction KRAS remains the dominant oncogenic driver in pancreatic ductal adenocarcinoma (PDAC), yet therapeutic targeting of KRAS has produced only modest and often short-lived responses due to rapid adaptive resistance. As KRAS-directed therapies move into clinical development, understanding and overcoming metabolic escape mechanisms has become a major priority in pancreatic cancer research. Problem Statement Although pan-RAS inhibitors such as daraxonrasib have shown activity in KRAS-driven PDAC, tumor adaptation and acquired resistance remain major limitations. Emerging evidence suggests that KRAS inhibition induces metabolic rewiring, allowing tumor cells to shift survival dependence toward alternative pathways, thereby reducing the durability of RAS-directed therapy. Summary This AACR 2026 report highlights a promising metabolic co-targeting strategy in PDAC based on simultaneous inhibition of KRAS signalling and NAD salvage metabolism. Preclinical work presented by Azmi and colleagues showed that KRAS inhibition induces compensatory metabolic dependence on the NAMPT–NAD pathway, creating a therapeutically exploitable vulnerability. Dual targeting with the NAMPT inhibitor RPT-E-037 and the pan-RAS inhibitor daraxonrasib produced greater tumor regression, enhanced tumor cell death and longer survival in preclinical PDAC models compared with KRAS inhibition alone. Notably, RAS inhibitor–resistant PDAC models demonstrated increased sensitivity to NAMPT inhibition, supporting NAMPT as a biologically plausible resistance target and suggesting a strategy to extend the durability of KRAS-directed therapy. The combination also offers the potential to reduce required RAS inhibitor dosing, which may improve tolerability and enable longer treatment exposure. These findings position metabolic co-targeting as a compelling next step in KRAS-driven PDAC and support early clinical translation of combined NAMPT and pan-RAS inhibition, with phase 1 evaluation anticipated in 2027.

RFA Fails to Improve Outcomes in Locally Advanced Pancreatic Cancer | JAMA Network Open

Introduction Locally advanced pancreatic cancer (LAPC) remains a highly lethal disease with limited therapeutic options and poor long-term survival. For patients who remain unresectable after induction chemotherapy, local ablative strategies such as radiofrequency ablation (RFA) have been explored as a means to improve local control, prolong survival and potentially enhance quality of life. Problem Statement Although RFA has shown feasibility and encouraging outcomes in observational studies, high-quality randomized evidence supporting its use in LAPC has been lacking. Whether adding RFA to standard chemotherapy improves survival or symptom burden in patients with non progressive LAPC after induction chemotherapy has remained an important unanswered clinical question. Summary The PELICAN randomized clinical trial demonstrates that adding RFA to chemotherapy does not improve outcomes in patients with non progressive LAPC after induction chemotherapy. In this multicenter phase 3 trial, RFA combined with chemotherapy failed to improve overall survival or progression-free survival compared with chemotherapy alone. Importantly, the addition of RFA was associated with significantly more serious adverse events and consistently worse quality of life across multiple domains, including global health status, pain and digestive symptoms. These findings directly challenge prior observational data suggesting a benefit for local ablative therapy in LAPC and provide the strongest evidence to date against routine use of RFA in this setting. While RFA had been proposed as a strategy to improve local disease control or augment systemic therapy, this trial found no meaningful oncologic advantage and demonstrated clear treatment-related burden. The study strongly supports continued chemotherapy-based management as the preferred standard for unresectable LAPC after induction therapy and argues against the routine incorporation of RFA outside highly selected investigational settings.

Early-Onset Disease Is Reshaping the Global Burden of Colorectal Cancer | Nature Reviews Clinical Oncology

Introduction Colorectal cancer (CRC) remains the third most commonly diagnosed cancer and the second leading cause of cancer-related mortality worldwide. Although CRC has historically been concentrated in Western high-income countries, its global epidemiology is rapidly changing, with rising incidence now extending across diverse geographic and socioeconomic settings. Problem Statement The global rise in CRC is increasingly driven by early-onset disease, particularly in individuals younger than 50 years, challenging traditional assumptions that CRC is predominantly a disease of older adults in high-income populations. This shift cannot be fully explained by inherited susceptibility or expanded screening alone, suggesting that evolving environmental, metabolic and lifestyle exposures are playing a major role in reshaping CRC risk worldwide. Summary This review highlights a major epidemiologic transition in CRC, with disease burden increasingly shifting beyond Western high-income countries and disproportionately affecting younger populations. The rise in early-onset CRC, first recognized in the 1990s, is now a global phenomenon and appears to reflect a birth-cohort effect implicating shared generational exposures rather than screening patterns alone. The authors emphasize that while hereditary risk remains important, emerging global CRC trends are more likely driven by non-genetic factors, including Westernized dietary patterns, sedentary lifestyle, obesity, gut microbial disruption and increasing exposure to environmental contaminants associated with rapid urbanization. These exposures may contribute not only to carcinogenesis but also to the distinct biology of early-onset CRC. The review further underscores the potential of integrating genomic, epigenomic and microbiome profiling to better define disease mechanisms and support earlier detection and precision prevention. Importantly, the authors highlight a major evidence gap in low- and middle-income regions, where under-representation in molecular and epidemiologic studies risks widening disparities in CRC prevention and control. This review positions early-onset CRC as a defining global oncology challenge requiring both biologic and public health recalibration.

Temab-A in Refractory Colorectal Cancer: JCO | May 2026

Introduction Treatment options for metastatic colorectal cancer (mCRC) in late-line settings remain limited, particularly in patients with microsatellite stable disease. Antibody-drug conjugates (ADCs) targeting tumour-specific pathways represent an emerging strategy to improve outcomes. Temab-A (ABBV-400), a c-Met–targeting ADC linked to a topoisomerase-1 inhibitor payload, is designed to deliver cytotoxic therapy directly to tumour cells. Problem Statement Patients with heavily pretreated mCRC often have a poor prognosis and limited therapeutic options. While targeted therapies and immunotherapy have transformed some subsets, microsatellite-stable, BRAF wild-type mCRC remains a major unmet need. The challenge is to identify treatments that provide meaningful responses with acceptable toxicity. Summary This phase I study evaluated Temab-A in advanced solid tumours, with a focus on mCRC. The maximum tolerated dose was established at 3.0 mg/kg, with 2.4 mg/kg every 3 weeks identified as the optimal dose based on safety and activity. Across 122 patients with mCRC, Temab-A demonstrated promising antitumor activity, with an overall response rate of 15.6% and a disease control rate of nearly 75%. Median progression-free survival was 4.6 months, and overall survival reached 10.4 months, suggesting a clinically meaningful benefit in a refractory population. Toxicities were common but manageable, predominantly gastrointestinal and hematologic. Treatment discontinuation and mortality rates were relatively low. Overall, Temab-A shows encouraging early efficacy as a targeted ADC in late-line mCRC, warranting further evaluation in phase II trials and combination strategies.

Biology-Driven Scoring Is Redefining Risk Stratification in Colorectal Liver Metastases: ESMO Open

Introduction Colorectal liver metastases (CRLM) remain a major determinant of mortality in colorectal cancer, with hepatic resection offering the best chance of long-term survival in selected patients. However, outcomes after surgery remain highly variable, and recurrence is common, highlighting the need for more precise tools to guide treatment selection and timing beyond conventional clinicopathologic assessment. Problem Statement Traditional clinical risk scores for CRLM, although widely used in surgical decision making, are limited by their reliance on static anatomical and morphological variables. These models inadequately capture tumor biology, treatment sensitivity and real-time disease evolution, restricting their ability to predict recurrence, guide systemic therapy or support precision treatment strategies in modern multidisciplinary care. Summary This review outlines the transition from conventional anatomy-based risk scoring toward a more dynamic and biologically informed framework for CRLM management. Classical clinical risk scores remain useful for baseline prognostication, but their predictive value is increasingly constrained in the era of molecular oncology. Emerging biomarkers—including tumor genomics, histological growth patterns and circulating tumor DNA (ctDNA)—provide clinically relevant insight into tumor behavior, metastatic biology and residual disease. Molecular alterations such as RAS, BRAF and mismatch repair status refine prognosis and increasingly influence treatment strategy, particularly with the expansion of targeted therapies and immunotherapy. Histological growth patterns offer additional prognostic value by distinguishing biologically favorable from aggressive liver metastatic phenotypes, while ctDNA has emerged as one of the most promising dynamic biomarkers for real-time monitoring of recurrence risk, treatment response and minimal residual disease after resection. The authors propose that integrating static clinical variables with dynamic molecular and liquid biopsy data can enable adaptive risk stratification across the treatment continuum. This biology-driven approach represents a major step toward precision oncology in CRLM, with the potential to improve patient selection, optimize perioperative therapy and better align surgery with tumor biology.

Standardizing Trial Endpoints for Oligometastatic Cancer Therapy: The Lancet Oncology

Introduction Oligometastatic cancer represents an intermediate disease state characterized by limited metastatic burden and a potentially distinct therapeutic window for metastases-directed therapy (MDT). As MDT becomes increasingly integrated into oncologic care, defining meaningful and consistent clinical trial endpoints has become essential to accurately assess treatment benefit and guide future therapeutic strategies. Problem Statement Clinical trials evaluating MDT in oligometastatic cancer have used highly variable primary endpoints, limiting cross-trial comparability and complicating interpretation of clinical benefit. Traditional endpoints such as overall survival and progression-free survival remain widely used, but they may not fully capture the unique therapeutic intent of MDT, particularly in settings where repeat local therapy can delay systemic progression without constituting treatment failure. Summary This review and Delphi consensus from the EORTC–ESTRO OligoCare consortium proposes a standardized framework for primary endpoints in clinical trials of MDT for oligometastatic cancer. Based on a systematic review of 121 comparative trials and a structured international consensus process involving experts and patient representatives, overall survival emerged as the preferred primary endpoint, reflecting its enduring clinical relevance. However, the panel emphasized that overall survival alone may not adequately capture the distinct benefits of MDT. In addition to progression-free survival, two alternative endpoints reached strong consensus: polymetastatic progression-free survival and systemic therapy-free survival. These endpoints are particularly valuable in MDT-based strategies because they allow repeat local interventions without prematurely defining treatment failure and better reflect the goal of delaying widespread progression or escalation of systemic treatment. Patient representatives also identified preservation of quality of life, particularly time to quality-of-life deterioration, as a major priority. This consensus provides a more clinically meaningful and patient-centered framework for future MDT trials and is expected to improve study design, comparability and translational relevance across oligometastatic oncology.

PancreaSure in Early PDAC: Gastroenterology | May 2026

Introduction Early detection of pancreatic ductal adenocarcinoma (PDAC) remains one of the most critical unmet needs in gastroenterology. Multibiomarker panels like PancreaSure represent an important step toward improving early diagnosis beyond traditional markers such as CA19-9. Initial validation studies have shown encouraging diagnostic performance, particularly in asymptomatic high-risk populations. Problem Statement Despite strong initial results, the key challenge is real-world applicability. Biomarkers that perform well in controlled cohorts often lose specificity in symptomatic and heterogeneous clinical populations. Additionally, lack of organ specificity raises concerns about whether a positive result truly reflects pancreatic cancer or a broader malignancy signal. Summary This commentary highlights important limitations of PancreaSure that may impact its clinical adoption. While specificity was high in asymptomatic high-risk individuals, it declined significantly in symptomatic patients, performing worse than CA19-9. This reduction may be due to common benign conditions such as pancreatic cysts and new-onset diabetes, which can generate false-positive signals. Another major concern is the lack of organ specificity. Several components of the biomarker panel are elevated in multiple malignancies, making it unclear whether a positive test reflects PDAC or other cancers. This creates a clinical dilemma, particularly when imaging is negative. The authors also emphasise the need for subgroup analyses, especially in patients with low or absent CA19-9 expression, where multibiomarker panels may offer added value. Overall, PancreaSure is a promising tool, but requires further validation in real-world populations, better calibration in symptomatic cohorts, and clearer interpretation strategies before routine clinical use.

Perioperative Strategies Are Redefining Curative Pathways in Biliary Tract Cancer Nature Reviews Clinical Oncology | March 2026

Introduction Biliary tract cancers (BTCs), including intrahepatic, perihilar and distal cholangiocarcinoma as well as gallbladder cancer, remain among the most aggressive gastrointestinal malignancies. Curative treatment has traditionally relied on surgical resection, yet most patients present with advanced disease, limiting operability. Even after complete resection, recurrence is common, underscoring the need for more effective perioperative strategies to improve long-term outcomes. Problem Statement Management of BTC in the perioperative setting remains challenging owing to disease heterogeneity, frequent late-stage presentation, and high postoperative recurrence rates. While surgery remains the only established curative option, its benefit is limited by strict resectability criteria and poor long-term disease control. The central challenge is how to safely expand curative-intent treatment through better patient selection, integration of systemic and locoregional therapies, and refinement of transplantation strategies. Summary This review outlines the evolving perioperative landscape in BTC, emphasizing a shift from surgery alone toward a more integrated, multidisciplinary treatment model. Surgical resection remains the cornerstone of curative therapy, with adjuvant capecitabine continuing as the current standard after resection. However, increasing emphasis is being placed on neoadjuvant strategies to improve resectability and optimize oncologic outcomes. Liver transplantation is emerging as a promising curative option in highly selected patients with unresectable perihilar or intrahepatic cholangiocarcinoma, particularly when paired with neoadjuvant therapy and rigorous selection criteria. The review also highlights the growing relevance of immune-checkpoint inhibitors and targeted therapies, which have shown benefit in advanced disease and are now being explored in earlier-stage and perioperative settings. Importantly, earlier molecular profiling may refine prognostication and enable biomarker-guided treatment selection before surgery. Overall, perioperative BTC management is moving toward precision-based, individualized care, where multimodal therapy and biologic stratification are expected to play a central role in expanding curative opportunities.

Refining Classification and Prognosis of Gastric Neuroendocrine Neoplasms: Virchows Archiv | November 2025

Introduction Gastric neuroendocrine neoplasms (gNENs) represent a heterogeneous group of tumors with rising incidence, encompassing well-differentiated neuroendocrine tumors (NETs), poorly differentiated neuroendocrine carcinomas (NECs), and mixed neuroendocrine–non-neuroendocrine neoplasms (MiNENs). Accurate classification is critical, as clinical behavior ranges from indolent lesions amenable to endoscopic surveillance to aggressive malignancies requiring multimodal therapy. Recent advances emphasize the integration of histopathology with clinical and biochemical parameters, particularly in gastric NETs. Problem Statement Traditional classification based solely on proliferative indices (mitotic count and Ki-67) is insufficient in gastric NETs, where tumor biology is strongly influenced by the underlying clinicopathologic context. There is a need for a more practical and prognostically relevant framework that incorporates factors such as gastrin levels, gastric acid secretion, and background mucosal pathology to guide diagnosis and management. Summary This comprehensive review highlights that gNENs are classified into NETs, NECs, and MiNENs, with distinct biological and clinical profiles. Among these, enterochromaffin-like (ECL) cell NETs are most common and uniquely stratified into five subtypes based on pathogenetic mechanisms, including hypergastrinemia and acid secretion status. Type 1 NETs, associated with autoimmune atrophic gastritis, are typically indolent with excellent prognosis, whereas type 3 NETs arise sporadically and demonstrate aggressive behavior with higher metastatic potential. Intermediate forms, such as type 2 NETs linked to MEN1-associated gastrinoma, require targeted evaluation and management. Importantly, the review proposes a simplified, clinically applicable classification based on gastrin levels and gastric acid status, enabling rapid risk stratification and treatment decisions. NECs and MiNENs remain highly aggressive entities with poor prognosis, necessitating early recognition and intensive therapy. Overall, integrating morphologic, immunophenotypic, and clinical data is essential for accurate diagnosis, prognostication, and personalized management of gastric neuroendocrine neoplasms.

KRAS Inhibition in Oncology: Precision Oncology | April 2026

Introduction KRAS mutation has long been considered a key oncogenic driver across multiple cancers, yet historically labeled “undruggable.” Recent therapeutic breakthroughs have changed this paradigm, with KRAS inhibitors now emerging as viable treatment options. However, clinical responses have been highly variable across different tumor types, raising important questions about how best to use these therapies in precision oncology. Problem Statement KRAS mutation status alone is insufficient to predict response to KRAS-targeted therapies, limiting their effectiveness when applied without broader biological context. Summary This perspective highlights a fundamental shift in oncology thinking: mutation is not enough—context defines response. Although KRAS inhibitors represent a major therapeutic advance, their inconsistent efficacy across cancers underscores the complexity of tumor biology. The article proposes a multidimensional framework that integrates several critical layers beyond KRAS mutation status. These include the tissue of origin, co-existing genetic alterations, downstream signaling pathways, and the tumor immune microenvironment. Together, these factors influence how tumors respond to KRAS inhibition. The key implication is that precision oncology must evolve from a single-mutation approach to a context-driven strategy. This has direct relevance for clinical practice and research, including better patient selection, improved biomarker development, and more rational clinical trial design. Ultimately, the paper emphasizes that the future of targeted therapy lies not just in identifying mutations, but in understanding the biological ecosystem in which those mutations operate.

Daraxonrasib in First-Line mPDAC: Cancer Research | April 2026

Introduction Metastatic pancreatic ductal adenocarcinoma remains one of the most lethal cancers, with a 5-year survival of approximately 3%. Current first-line chemotherapy offers limited benefit and significant toxicity. Given that over 90% of PDAC cases harbor RAS mutations, targeting this pathway has long been a major therapeutic goal. Daraxonrasib is a novel oral agent designed to inhibit active RAS across multiple mutations, offering a potentially transformative approach. Problem Statement Effective and tolerable first-line targeted therapies for RAS-mutant pancreatic cancer are lacking, despite the central role of RAS in disease biology. Summary This early-phase study evaluates daraxonrasib as first-line monotherapy in RAS-mutant mPDAC and demonstrates encouraging preliminary results. The treatment showed a manageable safety profile, with common adverse effects including rash, diarrhea, and mucositis, but importantly no grade 4 or 5 toxicities. Although dose modifications were frequent, treatment discontinuation was rare. Efficacy signals are particularly noteworthy. Objective response rates approached 50%, with disease control rates exceeding 90%, which compares favorably to standard chemotherapy benchmarks. Additionally, progression-free survival at 6 months was 71%, and overall survival at 6 months reached 83%, suggesting meaningful clinical activity. A key strength of the study is the incorporation of circulating tumor DNA (ctDNA) analysis, where all evaluable patients demonstrated significant reduction in RAS mutation burden, and more than half achieved complete clearance—supporting a strong biological effect. Overall, daraxonrasib represents a promising targeted strategy in a historically treatment-resistant disease. These findings justify ongoing phase 3 trials and signal a potential shift toward molecularly driven first-line therapy in pancreatic cancer.

KRAS Inhibition in Oncology: Precision Oncology | April 2026

Introduction KRAS mutation has long been considered a key oncogenic driver across multiple cancers, yet historically labeled “undruggable.” Recent therapeutic breakthroughs have changed this paradigm, with KRAS inhibitors now emerging as viable treatment options. However, clinical responses have been highly variable across different tumor types, raising important questions about how best to use these therapies in precision oncology. Problem Statement KRAS mutation status alone is insufficient to predict response to KRAS-targeted therapies, limiting their effectiveness when applied without broader biological context. Summary This perspective highlights a fundamental shift in oncology thinking: mutation is not enough—context defines response. Although KRAS inhibitors represent a major therapeutic advance, their inconsistent efficacy across cancers underscores the complexity of tumor biology. The article proposes a multidimensional framework that integrates several critical layers beyond KRAS mutation status. These include the tissue of origin, co-existing genetic alterations, downstream signaling pathways, and the tumor immune microenvironment. Together, these factors influence how tumors respond to KRAS inhibition. The key implication is that precision oncology must evolve from a single-mutation approach to a context-driven strategy. This has direct relevance for clinical practice and research, including better patient selection, improved biomarker development, and more rational clinical trial design. Ultimately, the paper emphasizes that the future of targeted therapy lies not just in identifying mutations, but in understanding the biological ecosystem in which those mutations operate.

CRLM Prognosis Reimagined: From Static Scores to Dynamic Precision Oncology ESMO Open | April 2026

Introduction Colorectal cancer liver metastases represent a major determinant of survival in colorectal cancer, affecting more than half of patients. While hepatic resection remains the cornerstone of curative therapy, recurrence rates remain high, reflecting the biological heterogeneity of disease. Traditionally, clinical risk scores such as the Fong score have guided decision-making, but these models are largely based on static anatomical and clinical parameters, limiting their relevance in the era of precision oncology. Problem Statement Conventional clinical risk scores fail to capture tumor biology and dynamic disease behavior, limiting accurate prognostication and personalized treatment decisions in CRLM. Summary This review highlights a paradigm shift in CRLM risk stratification—from static clinical models to biologically informed and dynamic frameworks. Classical scores, although useful, are insufficient to predict long-term outcomes or treatment response. Emerging tools now incorporate molecular profiling (e.g., RAS, BRAF, MSI status), histological growth patterns, and liquid biopsy techniques such as circulating tumor DNA (ctDNA). Molecular markers refine prognosis and guide therapy, with KRAS and BRAF mutations indicating worse outcomes, while MSI tumors may respond better to immunotherapy. Histological growth patterns further stratify risk, with desmoplastic patterns associated with better prognosis and replacement patterns linked to aggressive disease. Most importantly, dynamic biomarkers such as ctDNA are transforming management. Preoperative ctDNA predicts recurrence risk, while postoperative ctDNA identifies minimal residual disease and can guide adjuvant therapy decisions with high accuracy. Overall, the integration of clinical, molecular, and dynamic data enables adaptive, real-time risk stratification. This evolving approach supports better patient selection, optimized timing of surgery and systemic therapy, and represents a major step toward true precision oncology in CRLM.

MORPHEUS-PDAC Umbrella Trial: The Oncologist | April 2026

Introduction Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with a 5-year survival of only 10–13%. A major biological challenge is its “cold tumor” microenvironment—characterized by dense stroma and poor immune cell infiltration—which renders conventional immunotherapy largely ineffective. Despite multiple trials, chemotherapy continues to dominate both first- and second-line treatment, with only modest survival benefits. Given repeated failures of traditional drug development in PDAC, there is an urgent need not only for effective therapies but also for innovative trial designs that can rapidly identify promising treatment combinations. Problem statement The central challenge is whether combining immunotherapy with agents targeting the tumor microenvironment can overcome immune resistance in PDAC and improve outcomes in previously treated patients. Summary The MORPHEUS-PDAC umbrella trial represents an innovative platform study designed to evaluate multiple atezolizumab-based combinations simultaneously in advanced, pretreated PDAC. The rationale was biologically strong: combining PD-L1 blockade with agents that enhance immune infiltration (motixafortide), improve antigen presentation (cobimetinib), or stimulate cytotoxic immune cells (simlukafusp alfa). However, despite this mechanistic promise, clinical efficacy was disappointing. In the second-line setting, objective response rates were very low (0–7%), comparable or inferior to standard chemotherapy. Even in the third-line setting, modest responses (14–16%) were observed, but without meaningful clinical impact. Safety profiles were manageable but did not translate into therapeutic benefit. The most important takeaway is not the failure of individual combinations but the confirmation of PDAC’s profound resistance to immunotherapy—even when biologically rational combinations are used. Importantly, the study highlights the value of platform trial designs, which allow rapid screening of multiple strategies with fewer patients and faster decision-making. In essence, while atezolizumab-based combinations failed to deliver clinical benefit, the MORPHEUS model may represent the future of drug development in difficult cancers like PDAC.

Duloxetine for Prevention of Oxaliplatin-Induced Neuropathy (OIPN): JCO Oncology Advances | April 2026

Introduction Oxaliplatin-induced peripheral neuropathy (OIPN) is a common, dose-limiting toxicity in colorectal cancer treatment, significantly impacting quality of life and long-term functional outcomes. Duloxetine, already proven effective for the treatment of established chemotherapy-induced neuropathy, has been explored as a preventive strategy. Problem Statement Despite multiple attempts, there is no established therapy to prevent OIPN. Whether early initiation of duloxetine (30 mg or 60 mg) can reduce the incidence or severity of neuropathy during oxaliplatin-based chemotherapy remains unclear, representing a critical unmet clinical need. Summary This randomised, double-blind phase II trial demonstrated that duloxetine, at both 30 mg and 60 mg doses, did not significantly reduce the incidence or severity of OIPN compared to placebo. Response rates were similar across all groups (~65–68%), indicating no preventive benefit. Importantly, duloxetine was well-tolerated with manageable toxicity. Overall, the study confirms that duloxetine should not be used for the prevention of OIPN and highlights the continued lack of effective preventive strategies in this setting.

Subcutaneous Pembrolizumab: Journal of Clinical Oncology | April 2026

Introduction Immune checkpoint inhibitors like Pembrolizumab have transformed oncology care across multiple solid tumours. Recently, a subcutaneous (SC) formulation has been introduced using hyaluronidase technology, promising faster administration, improved patient convenience, and reduced infusion burden. This transition from intravenous (IV) to SC delivery is being positioned as a patient-centred innovation in cancer care. Problem Statement Despite enthusiasm, the key question remains: does SC pembrolizumab truly improve patient outcomes or system efficiency—or is it primarily a commercial strategy? Several concerns emerge: Approval is based on pharmacokinetic non-inferiority, not clinical superiority No meaningful improvement in survival, efficacy, or safety Timing coincides with patent expiry, suggesting “patent hopping” Fixed high-dose SC regimens limit: Dose optimization Cost-saving strategies (e.g., weight-based dosing, vial sharing) Real-world “convenience” may be overestimated due to: Pre-injection logistics (drug warming, scheduling) Combination therapy with chemotherapy (no time saving) Increased system complexity (home administration challenges) Core issue: Is convenience being used to justify increased healthcare costs without added value?

FOLFIRINOX in Digestive NEC: J of Neuroendocrinology | April 2026

Introduction Digestive neuroendocrine carcinomas (NEC) are rare but highly aggressive malignancies with poor prognosis and limited therapeutic options. Standard first-line therapy consists of platinum plus etoposide, extrapolated from small-cell lung cancer, but outcomes remain suboptimal, particularly in colorectal NEC and tumours with intermediate Ki67 (20%–55%). In the absence of established second-line therapies, regimens effective in adenocarcinomas, such as FOLFIRINOX, are increasingly being explored in this setting. Problem Statement There is a significant unmet need for effective second-line or later-line treatment in digestive NEC. Current evidence is scarce, and treatment decisions are largely empirical, especially for patients progressing after platinum-based therapy or those with biologically distinct subgroups such as lower Ki67 tumours. Summary This Scandinavian multicenter retrospective study evaluated FOLFIRINOX in 50 patients with digestive NEC. The regimen demonstrated promising activity with an overall response rate of 44% and a disease control rate of 72%, alongside a median progression-free survival of 5.6 months. Notably, efficacy was maintained in challenging subgroups, including colorectal primaries, Ki67 <55%, and patients previously treated with platinum–etoposide. These findings suggest that FOLFIRINOX may represent a valuable therapeutic option beyond first-line treatment in NEC. Although limited by retrospective design, this study provides important real-world evidence supporting broader consideration of FOLFIRINOX in aggressive neuroendocrine malignancies.

Tumour Location in Resected Pancreatic Cancer: AJS | April 2026

Introduction Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with survival rates rarely exceeding 10% at 5 years despite advances in surgery and systemic therapy. While tumour biology and stage are well-established prognostic factors, the role of tumour location—head versus body/tail—has remained controversial, with prior studies yielding inconsistent results. Problem Statement Existing evidence on the prognostic impact of tumour location in PDAC is limited by heterogeneity in study design, small sample sizes, and inadequate adjustment for confounding variables. This uncertainty creates difficulty in clinical decision-making, particularly regarding surgical risk stratification, perioperative planning, and patient counselling. Summary This large multi-institutional TriNetX analysis provides robust evidence that tumor location significantly influences outcomes after resection. Tumors located in the pancreatic head are associated with higher perioperative mortality, increased risk of sepsis, and worse long-term survival compared to body/tail tumors. Even after propensity matching, head tumors demonstrated shorter median survival and higher overall mortality, confirming tumor location as an independent prognostic factor. These findings highlight the need for location-specific surgical strategies, risk assessment, and postoperative management to improve outcomes in PDAC.

Top 10 GI Oncology Updates: Oncology News/ March 2026

1. ESOPEC Trial (Oesophagal Cancer) Neoadjuvant chemoradiotherapy may have underperformed due to radiotherapy quality issues (e.g., lymphopenia). Do not abandon the CROSS approach yet—patient selection remains key. 2. ORCHESTRA Trial (Metastatic CRC) Adding tumour debulking to chemotherapy in multiorgan metastatic CRC does not improve outcomes → systemic therapy remains the mainstay. 3. Rare Pancreatic Cancer – Targeted Therapy Molecular profiling of rare subtypes is opening new precision treatment pathways, highlighting heterogeneity in pancreatic cancer. 4. Federated Learning in Rare Tumours Global collaboration without sharing patient data is now possible → enables large-scale research in rare cancers with privacy preserved. 5. PERISCOPE II Trial (Gastric Cancer) CRS + HIPEC does not improve survival in gastric cancer with peritoneal spread and increases toxicity → systemic therapy remains standard. 6. AI-Based Treatment Selection (PDAC) AI models can personalise second-line therapy → FOLFIRINOX for fit patients Nal-IRI + 5FU for selected subgroups 7. BBOpCo Trial (MSS Colorectal Cancer) First signal that immunotherapy may work in MSS CRC → opens door for biomarkers and combination strategies. 8. Organoids in Oncology Patient-derived organoids may reduce drug failure rates and improve personalised therapy → future of translational oncology. 9. FLOT + Durvalumab (Gastroesophageal Cancer) Now approved → new perioperative standard, aiming to improve cure rates. 10. Aspirin in PIK3CA-Mutated CRC Adjuvant aspirin shows DFS benefit in selected patients → strong move toward biomarker-driven therapy.

Atezolizumab + FOLFOX in Stage III CRC: NEJM| March 2026

Introduction Stage III colon cancer is traditionally treated with adjuvant oxaliplatin-based chemotherapy such as FOLFOX. However, tumours with mismatch repair deficiency (dMMR) represent a biologically distinct subgroup with high immunogenicity and responsiveness to immune checkpoint inhibition in metastatic settings. Whether this immunotherapy benefit can be translated into the curative, adjuvant setting has remained a critical unanswered question. The ATOMIC trial addresses this gap by evaluating the addition of atezolizumab, a PD-L1 inhibitor, to standard mFOLFOX6 in resected stage III dMMR colon cancer. Problem Statement Despite standard adjuvant chemotherapy, recurrence rates in high-risk stage III colon cancer remain significant. dMMR tumours, although prognostically favourable in early stages, still demonstrate recurrence risk in stage III disease. The key clinical challenge has been whether incorporating immunotherapy early—before recurrence—can meaningfully improve disease-free survival and potentially cure rates. Summary In this phase III trial, adding atezolizumab to mFOLFOX6 significantly improved outcomes. At a median follow-up of 40.9 months, 3-year disease-free survival was 86.3% in the combination group compared to 76.2% with chemotherapy alone, translating to a 50% reduction in recurrence or death risk. This represents one of the first strong pieces of evidence supporting immunotherapy in the adjuvant setting for colon cancer. However, this benefit came with increased grade 3–4 adverse events (84.1% vs 71.9%), highlighting the need for careful patient selection. Overall, this study marks a major step toward precision oncology in early-stage colon cancer, potentially redefining the standard of care for stage III dMMR disease.

Adjuvant Therapy After Neoadjuvant Treatment in Resected Pancreatic Ann of Surg Onco — March 2026

Introduction The management of pancreatic ductal adenocarcinoma (PDAC) has increasingly shifted toward the use of neoadjuvant therapy (NAT) before surgical resection. NAT aims to improve resectability, treat micrometastatic disease early, and select patients with favourable tumour biology. However, an important unresolved question is the role of adjuvant therapy (AT) after patients have already received NAT followed by surgery. It remains unclear whether additional postoperative chemotherapy provides a survival benefit and how the type and duration of NAT influence the need for AT. Summary This multicenter study analysed 651 patients with PDAC who received NAT followed by surgical resection between 2010 and 2019. Patients were categorised according to the NAT regimen: Gemcitabine-based NAT: 200 patients (30.7%) 5-fluorouracil (5-FU)–based NAT: 362 patients (56%) Switched NAT regimen: 89 patients (13.7%) Key findings: Median overall survival (OS): Gemcitabine-based NAT: 19 months 5-FU–based NAT: 26 months Switched regimen: 21 months 5-FU–based NAT was associated with improved survival compared with gemcitabine-based NAT (HR 0.81, p = 0.04). The optimal NAT duration was approximately 3.6 months. Adjuvant therapy significantly improved survival overall (HR 0.61, p < 0.001). However, the survival benefit of AT diminished when NAT duration exceeded 5 months, suggesting that prolonged preoperative treatment may reduce the need for postoperative chemotherapy. Clinical Implication In patients undergoing resection for PDAC after NAT, 5-FU–based neoadjuvant regimens appear superior to gemcitabine-based therapy. Adjuvant chemotherapy remains beneficial, particularly when preoperative NAT duration is short, highlighting the importance of personalising postoperative therapy based on prior treatment exposure.

First-Line Chemotherapy and Durvalumab in Advanced BTC: Oncology Advances — March 2026

Patients with advanced biliary tract cancer (BTC) often have limited life expectancy, making quality of life and time spent receiving medical care (“time toxicity”) important considerations when selecting systemic therapy. This multicenter retrospective study evaluated whether adding durvalumab to gemcitabine–cisplatin (GCD) increases healthcare-related time burden compared with gemcitabine–cisplatin alone (GC). The study included 193 patients treated between 2019 and 2024 across centres in the United States, Japan, and Brazil. Among them, 102 received GCD and 91 received GC. The median time on treatment was 156 days, and the median proportion of time spent in healthcare systems was 14.4%. Most healthcare contacts consisted of planned visits (11.9%), while unplanned visits were uncommon (1.8%). Although patients receiving GCD remained on treatment longer than those receiving GC (212 vs 134 days), the overall time to toxicity was similar between groups (27 vs 18 days). Time toxicity strongly correlated with treatment duration and progression-free survival, indicating that longer treatment exposure naturally increases healthcare contact time. Multivariable analysis showed that younger patients and those with poorer performance status experienced higher time toxicity. Overall, the study highlights time toxicity as an important patient-centred metric in advanced cancer care. The addition of durvalumab to gemcitabine–cisplatin prolongs treatment duration without increasing the proportion of time spent receiving healthcare, providing useful information for shared decision-making between clinicians and patients when balancing survival benefits and quality of life.

Quality of Life vs Survival in Older Adults With Advanced Cancer Source: JAMA Oncology, March 2026

Introduction Treatment decisions in advanced cancer often involve a balance between extending survival and preserving quality of life (QoL). Older adults frequently face complex choices because aggressive treatments may prolong life but also increase toxicity, hospitalisations, and functional decline. Understanding whether patient preferences influence real-world outcomes is essential for patient-centred oncology care. Summary This secondary analysis evaluated 706 adults aged ≥70 years with advanced incurable cancers enrolled in the GAP70+ trial. Patients were categorised based on whether they prioritised maintaining quality of life or prolonging survival when starting systemic therapy. 71.7% (506 patients) prioritised quality of life 8.4% (59 patients) prioritised survival The most common cancers were gastrointestinal (34.6%), lung (24.8%), and genitourinary (15.4%) Despite differing priorities, clinical outcomes were similar between groups: No difference in treatment modifications No difference in grade 3–5 treatment-related adverse effects No difference in hospitalisation rates No difference in survival at 6 months or 1 year Key Message Most older adults with advanced cancer prefer maintaining quality of life over extending survival, yet this preference did not translate into different treatment approaches or outcomes, suggesting that current oncology care systems may not adequately align treatment decisions with patient preferences.

Rethinking TNT in Rectal Cancer: J Clin Oncol March 26

Introduction Total neoadjuvant therapy (TNT) has become a major advance in locally advanced rectal cancer, helping improve systemic control, increase tumor response, and expand the possibility of organ preservation. However, most trials and guidelines still treat rectal cancer as a single disease entity. This review argues that this is an oversimplification. Tumor location matters, especially when comparing mid-rectal and low-rectal cancers, because anatomy, lymphatic drainage, surgical difficulty, functional impact, and treatment goals differ substantially. Summary This review highlights that low-rectal cancers and mid-rectal cancers should be approached as distinct clinical entities rather than managed uniformly. Low-rectal tumors, particularly those within 1 cm of the anal ring, present special challenges. They have more complex local anatomy, more difficult lymphatic patterns, a higher risk of positive circumferential margins, and major implications for continence, sphincter preservation, and quality of life. In these tumors, a more intensive TNT strategy may be justified, especially when the goal is organ or sphincter preservation. In contrast, mid-rectal tumors are often more straightforward surgically, with a better chance of standard resection and preservation of function. For these cancers, the review suggests that treatment de-escalation, particularly regarding radiotherapy, may be reasonable in selected patients. Drawing on data from more than 80 studies and trials, the authors propose a location-specific, patient-centred strategy: De-escalate treatment in selected mid-rectal cancers Intensify or optimise TNT in low-rectal cancers when preservation is a priority Take-home message The key disruptive idea is simple: rectal cancer is not one disease anatomically or functionally. Future TNT strategies should be tailored by tumor height, oncologic risk, and patient priorities, not applied uniformly.

Obesity and Cancer: JAMA March 2026

Why this review matters Obesity is no longer viewed only as a metabolic disorder; it is now a major cancer-promoting state. This review explains how excess adiposity drives cancer through intertwined biologic pathways, including chronic inflammation, hormonal dysregulation, immune suppression, altered energy metabolism, DNA damage, and gut microbiome disruption. For clinicians, the key message is practical: obesity is a modifiable cancer risk factor, and meaningful weight loss may reduce future cancer burden. Main clinical message Overweight and obesity are associated with higher rates of multiple cancers, especially endometrial, colorectal, liver, gallbladder, pancreas, kidney, postmenopausal breast, oesophagal adenocarcinoma, ovarian, thyroid, gastric, prostate, and multiple myeloma. The review estimates that obesity contributes to about 10% of new cancers annually in the US, and even more in selected tumour types such as endometrial and hepatobiliary malignancies. Key biologic pathways The review highlights 5 major mechanisms: 1. Adipose tissue dysfunction: enlarged adipocytes produce excess estrogens, leptin, inflammatory cytokines, and less adiponectin. 2. Chronic inflammation: IL-6, TNF-α, prostaglandin E2, and related mediators create a pro-tumor microenvironment. 3. Immune escape: obesity impairs cytotoxic T cells and NK cells while increasing immunosuppressive myeloid-derived suppressor cells. 4. Metabolic support for tumours: adipose tissue supplies free fatty acids and other fuels for cancer growth. 5. DNA damage and microbiome changes: oxidative stress and dysbiosis increase genomic instability and mucosal inflammation. Important epidemiologic insights Cancer risk is not determined by BMI alone. Patients with metabolically unhealthy obesity appear to have the highest cancer risk. The review also stresses that childhood and adolescent obesity trajectories may influence cancer risk later in life. Interestingly, obesity increases postmenopausal breast cancer risk, but may show a different association before menopause. Weight loss and cancer prevention The review suggests that modest weight loss may not be enough. A threshold of more than 10% body weight reduction may be needed to produce measurable reductions in obesity-related cancer risk. Observational data suggest benefit with: Bariatric surgery, especially for endometrial cancer risk reduction GLP-1 receptor agonists, with retrospective data suggesting a lower incidence of some obesity-related cancers Metformin and related metabolic therapies, though stronger prospective evidence is still needed Practice implications Clinicians should view obesity management as part of long-term cancer prevention, not only cardiovascular and metabolic risk reduction. Counselling should move beyond BMI to include metabolic health, waist circumference, adiposity pattern, and sustained weight-loss strategies. Multimodal care combining lifestyle measures, pharmacotherapy, and, in selected patients, bariatric surgery may have future oncologic relevance. Limitations of the review Much of the evidence linking weight loss interventions to lower cancer incidence remains observational, not randomised. Several mechanistic pathways are strongly biologically plausible but not yet fully translated into cancer prevention trials. Bottom line Obesity promotes cancer through multiple biologic pathways, and meaningful sustained weight loss may reduce this risk. This review strengthens the concept that treating obesity is also part of cancer prevention.

FIT vs Colonoscopy: COLONPREV Trial- Gastroenterology | March 2026

Introduction Colorectal cancer (CRC) screening strategies vary worldwide, with fecal immunochemical testing (FIT) widely used in population programs and colonoscopy dominating screening in the United States. The COLONPREV randomized trial previously showed that FIT-based screening was not inferior to colonoscopy for CRC incidence and mortality at 10 years, despite higher participation rates with FIT. However, colonoscopy consistently detects more premalignant lesions. This analysis explored an important clinical question: are the characteristics of precursor lesions different when detected through FIT-triggered colonoscopy versus primary screening colonoscopy? Summary This analysis from the COLONPREV trial compared colonoscopic findings in individuals undergoing primary screening colonoscopy with those undergoing colonoscopy after a positive FIT result. While colonoscopy detected more overall precursor lesions, individuals referred after abnormal FIT were significantly more likely to harbor advanced neoplastic lesions, including larger polyps (mean size 7.8 mm vs 5.6 mm), higher rates of villous architecture, and high-grade dysplasia. FIT-detected lesions were also more difficult to manage endoscopically, with higher rates of incomplete resection and surgical treatment. Despite these differences, lesion histology and anatomical distribution were similar between strategies. These findings suggest that FIT acts as a risk-stratification tool, enriching for clinically significant lesions among those referred for colonoscopy. Conversely, screening colonoscopy may detect and remove lesions at earlier stages, raising ongoing debate about potential overdiagnosis versus true cancer prevention. Long-term follow-up will determine whether these differences influence CRC incidence and outcomes.

Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update: J Clin Oncol | Feb. 2026 | DOI: 10.1200/JCO-25-02958

Introduction Advanced gastroesophageal cancers (gastric, GEJ, oesophagal adenocarcinoma, and ESCC) have entered a biomarker-led era. This ASCO update reframes first-line choices around four core actionable domains—PD-L1, HER2, dMMR/MSI-H, and CLDN18.2—and then clarifies second/third-line options when disease progresses. The practical message is simple: get key biomarkers early, start chemotherapy without delay if needed, and layer immunotherapy/targeted therapy only where the signal is strongest. 20 Key Takeaways for Clinicians (ASCO 2026) Test early, treat smart: For gastroesophageal adenocarcinoma, ASCO recommends upfront testing for HER2, PD-L1, dMMR/MSI-H, and CLDN18.2; for ESCC, test PD-L1 and dMMR/MSI-H. Consider broad NGS where feasible. Do not delay chemotherapy while waiting for biomarker results if the patient is symptomatic or unwell—start the backbone and add targeted/IO once results return. PD-L1 matters, and “higher is better”: The likelihood of benefit from adding immunotherapy increases with higher PD-L1 expression (largest signal at higher cutoffs such as CPS ≥10 in trials). DPYD testing before fluoropyrimidines: ASCO includes a safety note—screen for DPYD variants before 5-FU/capecitabine; avoid fluoropyrimidines in complete DPD deficiency and individualise dose in partial deficiency. pMMR/MSS, HER2-negative adenocarcinoma + PD-L1 ≥1 (and CLDN18.2 negative): Doublet chemo + immunotherapy is recommended as a reasonable first-line option. pMMR/MSS, HER2-negative + PD-L1 <1 + CLDN18.2 positive: Chemo + zolbetuximab should be offered. Dual-positive PD-L1 ≥1 and CLDN18.2 positive (HER2-negative): Either chemo + immunotherapy or chemo + zolbetuximab may be used—shared decision-making is explicitly advised. pMMR/MSS, HER2-negative + PD-L1 <1 + CLDN18.2 negative: Chemo alone remains the standard default. HER2-positive gastric/GEJ adenocarcinoma (pMMR/MSS): Trastuzumab + doublet chemo is standard; if PD-L1 ≥1, add pembrolizumab. dMMR/MSI-H disease (any histology in scope): Immunotherapy is central—ASCO supports immunotherapy with chemo and also allows immunotherapy alone in selected patients (case-by-case). ESCC (unresectable/advanced): If PD-L1 ≥1, offer immunotherapy + chemo; nivolumab + ipilimumab is another option in appropriate patients. ESCC with PD-L1 <1: Chemo alone is acceptable; immunotherapy benefit is less certain at very low PD-L1. Second-line adenocarcinoma backbone: Ramucirumab + paclitaxel remains a key recommended option after progression on first-line therapy. Second-line alternative when taxanes are problematic: Ramucirumab + FOLFIRI can be considered for patients previously exposed to docetaxel or those with troublesome neurotoxicity. Second-line for HER2-positive after progression: Trastuzumab deruxtecan (T-DXd) should be offered. Re-test HER2 after progression on HER2-directed first-line therapy—HER2 can be lost, and treatment should match current biology. Later-line ESCC immunotherapy: If a patient did not receive immunotherapy upfront and has PD-L1 ≥1, nivolumab or tislelizumab may be used; pembrolizumab is a stronger consideration at higher PD-L1 thresholds (e.g., ≥10 in the evidence base). Zolbetuximab toxicity is predictable and manageable: expect nausea/vomiting early, use proactive antiemetics, adjust infusion strategies, and maintain hydration—don’t abandon an effective drug prematurely. Actionable biomarkers are not mutually exclusive: A meaningful minority will have >1 target (e.g., PD-L1 + CLDN18.2). The guideline emphasises patient-centred choice based on PD-L1 level, symptom burden, toxicity profiles, comorbidities, and patient preference. If no actionable biomarker or patient is not a candidate for IO/targeted therapy, fluoropyrimidine + platinum doublet chemotherapy remains the universal fallback—still the most practical global standard.

ICIs in Locally Advanced Rectal Cancer- Gut | Feb. 2026

Introduction Locally advanced rectal cancer (LARC; stage II–III) has traditionally been treated with neoadjuvant chemoradiotherapy (CRT) and total mesorectal excision (TME). While effective for local control, this pathway often delivers modest complete response rates and exposes many patients to long-term bowel, urinary, and sexual dysfunction—especially those with low rectal tumors where a stoma risk and quality-of-life trade-offs are substantial. In parallel, immune checkpoint inhibitors (ICIs) have rapidly shifted the landscape for the dMMR/MSI-H subtype—where deep responses can enable organ preservation in selected patients—while combination strategies (ICI + CRT/TNT) are being explored for pMMR/MSS disease. This Chinese Society of Colorectal Surgery (CNSCRS) consensus provides practical standards for who to treat, how to treat, how to assess response, and how to follow patients, with a strong emphasis on perioperative safety and organ-sparing pathways. Why was this guidance required? Evidence in LARC has expanded quickly over the last ~5 years, with multiple phase 2 programs and evolving real-world practice—particularly around non-operative management after complete response. The “new bottleneck” is no longer whether ICIs work in dMMR/MSI-H disease, but how to operationalise testing, MDT decision-making, response assessment (including pseudoprogression), and safe perioperative management. For pMMR/MSS LARC, enthusiasm for adding ICIs to CRT/TNT is growing, but benefit is heterogeneous, and toxicity attribution is complex—needing standardisation. Key takeaways (Guidance distilled for clinicians) A. Diagnostics and decision-making (Foundational steps) Test MMR/MSI in all LARC before treatment—this is the gateway decision for immunotherapy strategy and Lynch screening. Preferred testing approach: IHC for MMR proteins + PCR for MSI (with validated panels); use certified labs where possible. Do not assume dMMR ≡ MSI-H in every case—discordance exists; dual testing can prevent missed eligibility. Manage LARC with ICIs through a formal MDT (surgery, medical oncology, radiation, radiology, pathology ± gastroenterology/pharmacy) and adjust strategy dynamically as response evolves. B. dMMR/MSI-H LARC (where immunotherapy is most established) Neoadjuvant ICI is a core strategy for stage II–III dMMR/MSI-H LARC; response depth can be substantial and may enable organ preservation in selected patients. Practical rhythm endorsed: treat → assess at ~3 months; if not at a complete clinical response, consider continuing ICIs and reassessing rather than rushing to surgery (with vigilance for non-responders). Organ preservation (watch-and-wait) becomes a realistic goal for motivated mid/low rectal dMMR/MSI-H patients who achieve a robust clinical complete response after adequate ICI exposure. This guidance places strong weight on structured surveillance during watch-and-wait to detect regrowth early (because salvage surgery must remain feasible). If the response is incomplete at ~6 months in a patient seeking organ preservation, the document supports CRT as a “rescue/bridge” strategy in selected high-risk settings, with watch-and-wait still possible if a complete response is achieved after CRT. Pseudoresidual disease/pseudoprogression is real after ICIs: imaging may overcall residual tumour; decisions should integrate endoscopy, MRI, biopsy, and MDT judgment. Adjuvant therapy after neoadjuvant ICI is not standardised; if a patient achieves pathological complete response, observation is reasonable; if residual disease persists, options include continuing the same regimen or switching to standard adjuvant chemotherapy—best individualised. C. pMMR/MSS (or unknown status) LARC (where combinations are exploratory) ICI monotherapy is not a reliable strategy for pMMR/MSS LARC; the guidance focuses on combinations (ICI + CRT/TNT/SCRT) rather than ICI alone. For pMMR/MSS LARC, the consensus supports considering LCRT + 3–6 cycles of ICI (concurrent or sequential) before TME in selected settings, recognising evidence is still largely phase 2 and heterogeneous. For higher-risk disease or technically challenging rectal preservation, TNT + ICI is a reasonable consideration (ideally in trials), with careful monitoring for cumulative toxicity. SCRT-based pathways (SCRT → chemo + ICI) are presented as another acceptable neoadjuvant option, with a practical cap that total immunotherapy duration generally should not exceed ~6 months in these perioperative constructs. Organ preservation in pMMR/MSS should be approached more cautiously than in dMMR/MSI-H; if a true clinical complete response occurs, watch-and-wait can be considered, but patients must be counselled that cCR is less predictable. Dual checkpoint blockade (PD-1 + CTLA-4) is not recommended routinely for pMMR/MSS neoadjuvant/organ-sparing therapy outside trials due to limited efficacy evidence and toxicity concerns. D. Local excision and organ preservation pathways After neoadjuvant ICI-based therapy, local excision can be an organ-sparing option in carefully selected downstaged cases (typically small residual disease), but must be MDT-led with clear salvage plans and high-quality pathology. E. Safety and perioperative management (non-negotiable) Implement baseline screening + active monitoring for immune-related AEs; the guidance flags myocarditis and pneumonitis as rare but high-risk entities requiring early detection systems. Surgery is generally advised after irAEs have recovered to ≤ grade 1, with enhanced perioperative vigilance; an MDT model for irAE management improves diagnostic speed and consistency. Practice-changing or confirmatory? Practice-changing for dMMR/MSI-H LARC (selected patients): This consensus operationalises a real shift: biomarker-first rectal cancer, where dMMR/MSI-H disease can be routed toward ICI-driven organ preservation pathways in experienced centres. The direction of travel is consistent with transformative response signals seen with PD-1 blockade in dMMR rectal cancer. More confirmatory / still-evolving for pMMR/MSS LARC: For MSS disease, this guidance is best read as a structured framework for carefully selected use (preferably trial-enriched) rather than a universal new standard, because long-term survival data and regimen-to-regimen comparisons remain unsettled. Compared with landmark trials MSK dostarlimab (dMMR LARC): The landmark signal that dMMR rectal tumours can achieve profound responses with PD-1 blockade underpins the organ-preservation ambition reflected in this consensus. OPRA (TNT → selective watch-and-wait): OPRA established a modern framework for response-adapted non-operative management after neoadjuvant therapy, showing that structured surveillance and salvage can be oncologically acceptable in well-managed systems—this consensus essentially extends that philosophy into the immunotherapy era (especially for dMMR). NRG-GI002 / pembrolizumab + TNT (mostly MSS): This program highlights the mixed and evolving nature of adding immunotherapy in unselected LARC—supporting the consensus’ cautious tone for pMMR/MSS strategies and its emphasis on trials and careful toxicity attribution. Controversies & unanswered questions What is the “minimum effective duration” of neoadjuvant PD-1 therapy for durable organ preservation in dMMR LARC? (6 months is common, but precision remains uncertain.) How should we define and validate cCR after ICIs? Imaging and endoscopic findings can be misleading due to immune infiltration/fibrosis; standardised response criteria are still maturing. Long-term oncologic safety of watch-and-wait after ICIs: early outcomes are excellent in series, but large, long follow-up datasets are still limited. Best regimen for pMMR/MSS LARC: Which combination (LCRT+ICI vs SCRT+chemo+ICI vs TNT+ICI), which sequencing, and which patients truly benefit remains an open field. Biomarkers beyond MSI/MMR (microbiome, immune microenvironment, novel checkpoints) are promising but not ready for routine perioperative decision-making. Bottom line for clinicians This Gut 2026 CNSCRS consensus converts a fast-moving evidence base into a workable clinical playbook: test MSI/MMR upfront, decide in MDT, use ICIs decisively in dMMR/MSI-H LARC (including structured organ preservation when cCR is achieved), and approach pMMR/MSS strategies with selection, vigilance, and trial-minded discipline.

SCREESCO Trial: Colonoscopy + FIT and Early CRC Detection? Nature Medicine | February 2026

The SCREESCO randomised controlled trial provides rare population-level evidence comparing primary colonoscopy, low-threshold faecal immunochemical testing (FIT), and usual care in colorectal cancer (CRC) screening. Over 278,000 Swedish adults aged 60 years were randomised and followed for nearly five years during the diagnostic phase. During this early period, overall CRC incidence was similar between colonoscopy and usual care, and slightly lower in the FIT arm. However, both screening strategies detected significantly more stage I–II cancers compared with controls—particularly colonoscopy—suggesting a stage shift toward earlier diagnosis rather than immediate reduction in overall incidence. Adverse events were modestly increased in the first year among screened participants, including gastrointestinal and cardiovascular events, but differences attenuated over time. Participation rates were 35% for colonoscopy and 55% for FIT, highlighting real-world uptake challenges. These findings emphasise that the early benefit of CRC screening lies in increased detection of localised disease, while harms appear small and largely front-loaded. Long-term follow-up will determine whether this stage shift translates into reduced CRC mortality. Clinical Implication: Both colonoscopy and FIT enhance early cancer detection, but participation, safety balance, and long-term mortality outcomes remain central to screening policy decisions.

Chemotherapy-Only Neoadjuvant Strategy in High-Risk Rectal Cancer- BJS Open Feb.26

This multicentre phase II Japanese trial evaluated a chemotherapy-only neoadjuvant approach—FOLFOXIRI plus bevacizumab without radiotherapy—for MRI-defined high-risk locally advanced rectal cancer (LARC). Thirty-one patients with at least one high-risk feature (cT4 disease, mesorectal fascia involvement, extramural vascular invasion, or lateral pelvic lymph node metastasis) received four cycles of FOLFOXIRI plus bevacizumab followed by two cycles of FOLFOXIRI before total mesorectal excision. All patients proceeded to surgery. The pathological complete response (pCR) rate was modest at 10%, but the R0 resection rate was high (97%), indicating strong local resectability. At a median follow-up of nearly 3 years, local recurrence was low (3%), with 3-year recurrence-free survival and overall survival of 73% and 81%, respectively. Toxicity was manageable: grade ≥3 neutropenia occurred in 29%, and grade ≥III postoperative complications in 23%, including 7% anastomotic leak. Notably, no gastrointestinal perforations were observed. Although the pCR rate was lower than that of typical chemoradiotherapy-based regimens, the study suggests that intensive systemic chemotherapy may achieve good local control in selected high-risk patients. This strategy could be considered in patients unsuitable for pelvic radiotherapy, but larger comparative trials are needed before broader adoption.

Pan-Tumour Pathologic Response Guidelines Standardise Neoadjuvant Assessment Across Cancers - ASCPO Post

As neoadjuvant therapy expands across tumor types, pathologic response after surgery is increasingly used as a predictor of long-term survival and as a key clinical trial endpoint. However, response scoring systems have historically varied by tumor type, creating inconsistency in reporting and limiting cross-trial comparisons. A joint effort by the Society for Immunotherapy of Cancer (SITC) and the International Neoadjuvant Melanoma Consortium has now produced the first unified, pan-tumor framework for assessing pathologic response to neoadjuvant therapy. The updated consensus guidelines harmonize evaluation across cancer types by focusing on three core components: percentage of residual viable tumor, necrosis, and regression in both primary tumor and lymph nodes. The guidelines also standardize tissue sampling. Tumors ≤3 cm should be submitted entirely for embedding; larger tumors require at least one full cross-section from the longest dimension, including the tumor–host interface when feasible. A multi-institutional reproducibility study demonstrated strong interobserver agreement among trained pathologists across 12 tumor types, supporting reliability of the unified approach. Correlation coefficients exceeded 0.8 for all key measures. This harmonised system simplifies reporting, enhances comparability across studies, and may facilitate future regulatory use of pathologic response endpoints. Ongoing efforts aim to refine tumor-specific response thresholds while maintaining the overarching standardized framework.

Exercise Boosts Anticancer Immunity via Gut Microbiome Formate- Gastroenterology Feb.26

Introduction Physical exercise has long been associated with better cancer outcomes and improved response to immune checkpoint inhibitors (ICIs). Separately, the gut microbiome is now known to influence ICI efficacy. What has been missing is a direct mechanistic bridge connecting these two observations. This work provides that missing link: exercise alters the gut microbiome, which produces metabolites that directly enhance antitumor CD8 T-cell immunity—and can improve immunotherapy response in preclinical models. Problem statement We have strong associations: Exercise → improved cancer outcomes, microbiome composition → ICI response. But until now, it was unclear whether: Exercise benefits are caused by microbiome changes, and whether specific microbial metabolites drive the immune effects. What the study did: Using a melanoma mouse model resistant to ICIs, researchers compared: exercised mice (treadmill + wheel running) vs sedentary mice. They then tested causality by: transferring faecal microbiota from exercised vs sedentary mice, using antibiotics, germ-free mice, and co-housing, and separating the effects of live bacteria vs sterile-filtered metabolites. Finally, they identified a candidate metabolite and validated it through: oral supplementation experiments, bacterial genetics (a formate-producing enzyme knockout), and human donor FMT stratified by formate production. Key findings clinicians should understand 1) Exercise strengthens antitumor immunity—CD8 T cells are essential Exercise restrained tumour growth and enhanced CD4/CD8 function. When lymphocytes were absent, the benefit disappeared, pinpointing adaptive immunity—especially CD8 cells—as the key effector. 2) The gut microbiome is a causal mediator (not just a bystander) Faecal microbiota transplantation (FMT) from exercised mice transferred the antitumor benefit to sedentary mice, improving tumour control and cytotoxic CD8 (Tc1) responses. Antibiotics and germ-free conditions removed the benefit, reinforcing that microbes are required. 3) The “active ingredient” is microbial metabolites, not just bacteria Heat-killed faeces lost the effect. Sterile-filtered faecal metabolites preserved it. That strongly suggests metabolites produced by live bacteria are the functional mechanism. 4) A single metabolite stood out: formate Exercise increased formate levels systemically and in the tumor environment. Higher formate tracked with better tumour control and stronger Tc1 activity. 5) Formate can reproduce the benefit if adaptive immunity is intact Oral formate supplementation limited tumor progression and prolonged survival, but only when adaptive immunity was present. 6) Mechanism: formate activates Nrf2 in CD8 T cells Formate enhanced CD8 T-cell proliferation and cytotoxic function through Nrf2 activation. Blocking or deleting Nrf2 eliminated benefits; an Nrf2 agonist reproduced them. 7) Translational signal: human “high-formate” microbiomes mattered FMT from human donors with high formate production promoted stronger antitumor immunity in mice compared with low-formate donors—suggesting a plausible human-relevant axis. Clinical interpretation This is not a “go prescribe formate” clinical recommendation yet. It is a strong mechanistic proof-of-concept: Exercise may improve antitumor immunity partly by shifting the microbiome toward formate-producing metabolism. Formate behaves like a postbiotic capable of enhancing CD8 T-cell function. The microbiome’s metabolic output (not just taxonomy) may help explain variable immunotherapy responses. Bottom-line takeaway: Exercise enhances anticancer immunity through a microbiome-derived metabolite—formate—which activates Nrf2 in CD8 T cells and boosts cytotoxic antitumor function. This opens a credible path toward combined strategies: exercise + microbiome modulation + metabolite-based “postbiotics” to augment immunotherapy. One-line GastroAGI takeaway Exercise may “train” immunity through the gut microbiome—via formate-driven CD8 activation.

ENCODER: Liquid Biopsy for Young-Onset Colorectal Cancer- Gastroenterology Feb.26

Introduction Early-onset colorectal cancer (EOCRC), defined as CRC diagnosed before the age of 50, is rising globally and has become a leading cause of cancer-related death in young adults, particularly men. Despite this, screening uptake in younger populations remains poor, largely because current strategies rely on age thresholds and invasive tests. This study asks a critical question: Can a simple blood-based test help identify EOCRC early—before symptoms or advanced disease develop? The clinical problem Most EOCRC cases are diagnosed outside traditional screening programs, often at more advanced stages. Colonoscopy is effective but impractical as a population-wide tool in young adults. Stool-based tests may help, but still suffer from limited acceptance. A highly accurate, noninvasive blood test could dramatically change early detection and screening strategies for this growing at-risk population. What the ENCODER study did: Large international, multicenter study across the US, Europe, and Japan. Identified a panel of 6 circulating biomarkers, including exosome-derived small RNAs, using advanced sequencing techniques. Built a machine-learning model to distinguish EOCRC from non-cancer controls. Tested the model in an independent external cohort, ensuring real-world robustness. Evaluated biomarker changes before and after surgical resection to assess biological relevance. Key findings clinicians should understand 1) High accuracy for EOCRC detection The liquid biopsy reliably distinguished EOCRC patients from healthy controls across multiple cohorts and countries, demonstrating strong generalizability. 2) Works even in very young adults Remarkably, the test performed well even in individuals aged 20–35 years, a group in whom CRC is often least suspected. 3) Strong performance in early, screen-relevant stages The assay was particularly effective for stage I–III EOCRC, the window where early detection has the greatest impact on survival. 4) Detects advanced precancerous lesions The test showed moderate ability to detect high-grade dysplasia, suggesting potential utility not only for cancer detection but also for interception. 5) Biomarkers track with tumour removal Liquid biopsy signals dropped rapidly after surgery, supporting a direct biological link to tumour burden and raising the possibility of future use in surveillance or minimal residual disease monitoring. How this could fit into practice This study does not suggest replacing colonoscopy. Instead, it points toward a complementary screening strategy, particularly for: Young adults below the standard screening age, individuals reluctant to undergo invasive testing, and populations with rising EOCRC incidence but low screening participation. A blood-based test could serve as a first-line risk stratification tool, identifying individuals who should proceed to diagnostic colonoscopy. Key limitations to keep in mind This was a case–control design, not a population screening trial. Performance in real-world, low-prevalence screening settings remains to be tested. Cost-effectiveness, implementation logistics, and comparison with stool-based tests are still unknown. Bottom-line takeaway: The ENCODER study provides compelling proof-of-concept that an exosome-based liquid biopsy can accurately detect early-onset colorectal cancer—even in very young adults—and may become a valuable adjunct to future screening strategies. One-line GastroAGI takeaway A simple blood test could help close the screening gap for early-onset colorectal cancer.

Metastasis Directed Therapy- JAMA Oncol 2026

**Metastasis-Directed Therapy (MDT) Overview:** MDT refers to localised treatments aimed specifically at metastatic lesions in patients with cancer. These therapies include techniques such as stereotactic body radiotherapy (SBRT), surgical resection, and thermal ablations (e.g., radiofrequency or cryoablation). MDT is particularly valuable for patients with oligometastatic disease, where the number of metastases is limited and potentially treatable. **Utility in Metastatic Disease:** MDTs have redefined the therapeutic approach to metastatic cancer by offering the possibility of long-term disease control or even cure in select patients. Rather than focusing solely on systemic therapies, MDT targets visible metastatic lesions, suppressing prometastatic signalling and disrupting interlesional communication. Clinical evidence suggests that MDT can delay systemic therapy initiation, extend progression-free survival, and improve overall outcomes when applied iteratively or comprehensively. Emerging research highlights the importance of treating all visible disease to prevent reseeding and progression. MDT's effectiveness is influenced by factors such as tumour biology, immune phenotype, and metastatic kinetics, underscoring the need for personalised strategies. MDT represents a shift toward transforming metastatic cancer into a manageable or potentially curable condition.

ACS 2026 Statastical Report

The ACS publishes an annual "Cancer Facts & Figures" report, which provides comprehensive statistics on cancer incidence, survival rates, mortality, and trends in the United States. The report typically highlights progress in early detection, advancements in treatment, and disparities in cancer outcomes. For example, recent statistics have shown that the 5-year cancer survival rate has reached 70%, a significant milestone reflecting decades of improvement in cancer research, early screening, and innovative therapies such as immunotherapy and targeted treatments. However, underlying challenges persist, including disparities in access to care, variations in survival rates by cancer type, and missed opportunities for early detection. The ACS continues to emphasize the need for equitable and personalized approaches to cancer prevention, treatment, and survivorship care.

GEP-NET- Gastroenterology Jan.26

### Overview of GEP-NETs Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a subtype of neuroendocrine neoplasms (NENs) that arise from neuroendocrine cells within the gastrointestinal (GI) tract and pancreas. These tumors are relatively rare but are increasingly recognized due to advancements in diagnostic techniques, particularly in gastroenterology. #### Common Sites of GEP-NETs - **Stomach (gastric NETs, gNETs)** - **Pancreas (pancreatic NETs, pNETs)** - **Small intestine (small intestinal NETs, siNETs)** - **Rectum (rectal NETs, rNETs)** - **Appendix** --- ### Epidemiology - **Increasing Incidence:** The incidence of GEP-NETs has risen significantly over the past few decades. For example, in the United States, the incidence of NETs increased more than sixfold between 1973 and 2012. - **Geographic and Racial Variations:** The prevalence of specific GEP-NET subtypes varies by region. For instance, rectal NETs are more common in North America, while pancreatic NETs are frequently seen in Europe and Asia. Black individuals in the U.S. have a higher incidence of GEP-NETs compared to other racial groups. - **Prevalence:** The overall prevalence of NETs is about 0.05% (1 in 2,000), with rectal and small intestinal NETs being the most common subtypes. --- ### Classification and Pathology The **2022 World Health Organization (WHO) classification** divides GEP-NETs based on: 1. **Differentiation**: Well-differentiated neuroendocrine tumors (NETs) versus poorly differentiated neuroendocrine carcinomas (NECs). 2. **Grade**: Tumor grade is determined by the **Ki-67 index** or **mitotic count**, which reflect the tumor's aggressiveness. - **Grade 1 (low-grade):** Indolent behavior. - **Grade 2 (intermediate-grade):** Moderate aggressiveness. - **Grade 3 (high-grade):** More aggressive, but distinct from poorly differentiated NECs. Immunohistochemical markers like **chromogranin-A (CgA)**, **synaptophysin**, and **INSM1** support the diagnosis of GEP-NETs. --- ### Clinical Features GEP-NETs can be classified as **functional** or **nonfunctional**: - **Functional tumors** secrete bioactive hormones, leading to specific syndromes. For example: - **Carcinoid Syndrome (CS):** Caused by serotonin secretion, leading to flushing, diarrhea, and valvular heart disease. - **Insulinomas:** Hypoglycemia due to insulin overproduction. - **Gastrinomas (Zollinger-Ellison Syndrome):** Hypersecretion of gastrin causing peptic ulcers and diarrhea. - **Nonfunctional tumors** do not secrete hormones and may present with nonspecific symptoms like abdominal pain or mass effects. --- ### Diagnostic Strategies #### 1. **Laboratory Tests** - **24-hour urinary 5-HIAA (5-hydroxyindoleacetic acid):** - Preferred for diagnosing Carcinoid Syndrome (sensitivity >90% for small intestinal NETs). - **Serum markers:** - Chromogranin-A (CgA): Limited utility due to false positives (e.g., with proton pump inhibitors or chronic atrophic gastritis). - Hormone levels: Useful for functional NETs (e.g., insulin, gastrin, glucagon). #### 2. **Imaging** - **Anatomic Imaging:** - **CT Scan (Triple-Phase):** Best for detecting hypervascular liver metastases and staging. - **MRI:** Ideal for pancreatic NETs and hepatic metastases. - **Functional Imaging:** - **Somatostatin Receptor PET (SSTR PET):** - Uses tracers like 68-Gallium or 64-Copper DOTA-TATE. - Superior sensitivity compared to traditional octreotide scans. - Recommended for staging, identifying occult primary tumors, and determining eligibility for radioligand therapy (RLT). --- ### Management of GEP-NETs #### 1. **Endoscopic Management** - Endoscopic techniques play a significant role in diagnosis and treatment of smaller, localized GEP-NETs. - **Endoscopic Mucosal Resection (EMR):** For small, low-grade tumors. - **Endoscopic Submucosal Dissection (ESD):** Allows deeper resection for larger lesions. - **Endoscopic Ultrasound (EUS):** Critical for biopsy and staging. #### 2. **Surgical Resection** - Surgical removal remains the cornerstone for localized or resectable metastatic disease, especially in higher-grade tumors. #### 3. **Medical and Systemic Therapies** - **Somatostatin Analogs (SSA):** First-line treatment for hormone control and tumor growth inhibition. - **Radioligand Therapy (RLT):** Targets tumors expressing somatostatin receptors. - **Targeted Therapies:** - **mTOR inhibitors (e.g., everolimus):** For advanced disease. - **Antiangiogenic agents (e.g., sunitinib):** For pancreatic NETs. - **Chemotherapy:** Reserved for high-grade or poorly differentiated NECs. --- ### Future Directions and Research 1. **Molecular Markers:** Identifying biomarkers to improve diagnostic accuracy and personalize treatment. 2. **Endoscopic Techniques:** Refining criteria for endoscopic therapy and understanding long-term outcomes after resection. 3. **Immunotherapy:** Investigating its role in treating high-grade GEP-NETs. 4. **Disparities in Care:** Addressing racial and socio-economic disparities in survival outcomes. --- ### Conclusion GEP-NETs are increasingly encountered in gastroenterology practice due to advancements in diagnostic modalities like endoscopy and imaging. Early detection and a multidisciplinary approach, including endoscopic, surgical, and systemic therapies, are critical for improving outcomes. Continued research into molecular markers and treatment strategies will further refine management and enhance survival for patients with GEP-NETs.

T1 CRC and ESD(GIE, Jan-2026)

### T1 Colorectal Cancer (CRC) - **T1 CRC** refers to early-stage colorectal cancer where the tumor has invaded the submucosa but has not yet spread further. - It is subdivided into **superficial submucosal invasive cancer (s-SMIC)** and **deep submucosal invasive cancer (d-SMIC)** based on the depth of invasion. - **s-SMIC**: Less invasive; better prognosis. - **d-SMIC**: More invasive; higher risk of lymphovascular invasion and metastasis. ### Endoscopic Submucosal Dissection (ESD) - **ESD** is a minimally invasive endoscopic technique used to remove early-stage gastrointestinal tumors, including T1 CRC, en bloc (in one piece) to achieve clear margins. - It is increasingly being used as an alternative to primary surgery for patients with suspected T1 CRC, especially for those with s-SMIC. ### Key Findings from the Study (2011–2022) 1. **Effectiveness of ESD**: - ESD was more effective in achieving a free vertical margin (VM-R0) in suspected s-SMIC cases compared to d-SMIC cases. - The VM-R0 rate for suspected s-SMIC was 90.6%, while it was significantly lower for suspected d-SMIC at 55.4%. - The en bloc resection rate was also higher in s-SMIC (90.5%) compared to d-SMIC (61.9%). 2. **Challenges in d-SMIC**: - For suspected d-SMIC cases, the VM-R0 rate particularly decreased for pT1Sm2-3 lesions (55.7%). - None of the investigated clinical or polyp-related features (age, sex, polyp location, size, morphology, and Hiroshima classification) could predict VM-R1 resections in d-SMIC cases. 3. **Adverse Events**: - The adverse event rate was slightly higher in d-SMIC cases (5.8%) compared to s-SMIC cases (3.6%). 4. **Implications for Treatment**: - The lower success rate of ESD (in terms of VM-R0) for d-SMIC highlights the need for careful patient selection. - For suspected d-SMIC cases, alternative treatment strategies, including surgery, may be more appropriate to ensure complete resection and reduce the risk of recurrence. ### Clinical Significance - For **s-SMIC**, ESD is a highly effective and safe option, offering high rates of curative resection with minimal complications. - For **d-SMIC**, the lower VM-R0 rates suggest that ESD alone may not always be sufficient, and primary surgery may be considered for better oncological outcomes. ### Future Perspectives (2026 and Beyond) - As ESD techniques continue to evolve, future studies may focus on improving the success rates for d-SMIC cases. - The development of advanced imaging techniques and predictive tools could help in better identifying patients who are suitable for ESD versus surgery. - Long-term follow-up data from ongoing or future studies (such as the one in 2026) will be crucial in determining the role of ESD in managing T1 CRC, particularly for d-SMIC cases.

Novel Therapeutic approach for pancreatic cancer(GIE,Jan-2026)

The novel therapeutic approach for pancreatic cancer, as detailed in the study published in *Gastrointestinal Endoscopy (GIE), January 2026*, involves the combination of intratumoral phosphorus-32 (32P) implantation with systemic chemotherapy. This innovative strategy is aimed at addressing the unmet need for improved treatment outcomes in patients with locally advanced pancreatic cancer (LAPC), a condition that traditionally has poor prognosis and limited treatment options beyond chemotherapy. ### Key Highlights of the Approach: 1. **Combination Therapy:** - The study evaluates the efficacy of combining phosphorus-32 implantation with chemotherapy compared to chemotherapy alone, marking the first comparative analysis of its kind. - Phosphorus-32 is a radioactive isotope that delivers targeted intratumoral radiation, minimizing exposure to surrounding healthy tissues. 2. **Improved Outcomes:** - **Overall Survival:** Patients receiving the combination therapy demonstrated significantly longer overall survival compared to those on chemotherapy alone. - **Local Disease Control:** The addition of phosphorus-32 improved local progression-free survival, highlighting its ability to control tumor growth at the primary site. - **Tumor Response and Downstaging:** Combination therapy resulted in greater tumor size reduction over time and higher rates of downstaging, increasing the likelihood of converting unresectable tumors to borderline resectable disease. - **Surgical Resection:** Patients treated with phosphorus-32 had a higher chance of undergoing surgical resection, offering a potential for curative intervention. 3. **Mechanistic and Practical Advantages:** - **Targeted Radiation:** Phosphorus-32 provides localized radiation that synergizes with chemotherapy, potentially enhancing its effectiveness within the tumor microenvironment. - **Outpatient Feasibility:** The implantation procedure is minimally invasive and performed as a single outpatient endoscopic procedure, adding convenience for patients. - **Safety Profile:** The study reported no major short-term complications related to the phosphorus-32 implantation, underscoring its favorable safety profile. - **Chemotherapy Continuity:** Unlike external-beam radiation, phosphorus-32 does not interrupt systemic chemotherapy, allowing uninterrupted systemic treatment. 4. **Real-World Evidence:** - The study utilized retrospective data from two tertiary centers, reflecting real-world clinical practice. - Advanced statistical methods, including propensity score–weighted and landmark analyses, were employed to mitigate bias and ensure robust findings. 5. **Limitations and Future Directions:** - As a nonrandomized, retrospective study, the findings are subject to residual confounding and cannot definitively establish causality. - The results strongly support the need for prospective randomized controlled trials to confirm the efficacy and safety of this novel combination approach. ### Conclusion: The combination of intratumoral phosphorus-32 implantation with chemotherapy represents a promising therapeutic strategy for locally advanced pancreatic cancer. It offers improved local tumor control, prolonged survival, enhanced tumor downstaging, and increased opportunities for surgical resection, all with a favorable safety profile and practical feasibility. The study paves the way for future randomized trials to validate these findings and potentially establish this approach as a new standard of care for LAPC.

Screening for Esophageal Cancer

Screening for esophageal cancer is a critical strategy to improve early detection and survival rates, given the disease's poor prognosis due to late-stage diagnosis. However, effective screening approaches differ based on the subtype of esophageal cancer (Esophageal Squamous Cell Carcinoma [ESCC] vs. Esophageal Adenocarcinoma [EAC]), regional disease patterns, and individual risk factors. ### **Key Considerations for Esophageal Cancer Screening:** #### **1. Subtypes of Esophageal Cancer:** - **Esophageal Squamous Cell Carcinoma (ESCC):** - Dominates globally, especially in high-incidence regions such as East Asia, Africa, and parts of South America. - Strongly linked to environmental risk factors like tobacco, alcohol, dietary carcinogens, air pollution, and socioeconomic factors. - Often associated with "field cancerization," where synchronous or metachronous cancers occur in the head, neck, and esophagus. - **Esophageal Adenocarcinoma (EAC):** - Increasing in Western countries, driven by obesity, gastroesophageal reflux disease (GERD), and Barrett’s esophagus (a precursor lesion). - Screening focuses on identifying individuals with Barrett’s esophagus and other high-risk features. #### **2. Screening Strategies by Subtype:** - **ESCC Screening:** - **Population-Based Screening:** Recommended in high-incidence regions (e.g., East Asia) using endoscopic methods to detect early-stage disease. - **Endoscopy:** High-definition white-light endoscopy is the cornerstone, often enhanced by advanced imaging techniques like narrow band imaging and virtual chromoendoscopy for better detection of early neoplastic lesions. - **Nonendoscopic Tools:** Emerging technologies like Cytosponge, salivary markers, breath tests, and buccal DNA analysis show promise as scalable, noninvasive screening options. - **Lugol-Voiding Lesions:** Multiple Lugol-voiding lesions are biomarkers of field cancerization and future cancer risk, aiding in identifying high-risk individuals. - **Artificial Intelligence (AI):** AI-assisted endoscopy improves real-time lesion recognition and matches or exceeds expert diagnostic performance. - **EAC Screening:** - **Targeted Screening:** Routine population screening is not justified; instead, high-risk individuals (e.g., those with Barrett’s esophagus, GERD, obesity) are prioritized. - **Endoscopy:** Structured examination from the hypopharynx to the esophagogastric junction is essential for reducing missed lesions. - **Nonendoscopic Tools:** Swallowable devices combined with biomarker assays provide scalable alternatives to endoscopy for triaging EAC risk. - **Barrett’s Esophagus Role:** Screening strategies often center on detecting and monitoring Barrett’s esophagus, as it is the precursor lesion for EAC. #### **3. Regional Screening Importance:** Screening strategies must be tailored to regional disease patterns to maximize cost-effectiveness and outcomes. For example: - **High ESCC Regions:** Population-level endoscopic screening is critical for early detection. - **Western Countries:** Focus is on targeted screening for EAC based on individual risk factors like GERD and obesity. #### **4. Role of Risk Factor Stratification:** Accurate identification of high-risk populations is essential for optimizing screening yield and efficiency. Risk factors include: - **ESCC:** Tobacco, alcohol, poor diet, air pollution, and socioeconomic conditions. - **EAC:** GERD, Barrett’s esophagus, obesity, and Western lifestyle habits. #### **5. Emerging Technologies and Future Directions:** - **Nonendoscopic Screening:** Tools like Cytosponge and swallowable devices offer less invasive, scalable options for early detection. - **Artificial Intelligence:** AI integration into endoscopy enhances lesion recognition and reduces diagnostic errors. - **Biomarkers:** Salivary markers, breath tests, and buccal DNA analysis are under investigation for noninvasive screening, although liquid biopsy methods currently have limited sensitivity for early-stage esophageal cancer. - **Integrated Strategies:** Combining endoscopy, noninvasive tools, biomarkers, and AI allows for personalized, risk-based screening pathways. ### **6. Limitations:** - **Liquid Biopsy Challenges:** Current blood-based multicancer detection assays lack adequate sensitivity for early-stage esophageal cancer. - **Cost Considerations:** Endoscopic screening can be expensive and resource-intensive, making regional tailoring essential. ### **Conclusion:** Screening for esophageal cancer requires a nuanced approach based on subtype, regional incidence, and individual risk factors. While endoscopy remains the cornerstone for early detection, advances in noninvasive tools, biomarkers, and AI offer promising avenues for scalable and personalized screening strategies. In high-incidence regions, population-based ESCC screening is effective, whereas targeted screening for EAC is preferred in Western populations.

Glecirasib with or without Cetuximab in previously treated CRC with KRAS mutation - Lancet Gastroenterol Hepatol

The study published in *Lancet Gastroenterology & Hepatology* investigates the efficacy and safety of glecirasib (JAB-21822), a novel covalent small molecule KRASG12C inhibitor, as monotherapy or in combination with the anti-EGFR antibody cetuximab in patients with previously treated colorectal cancer (CRC) harboring KRASG12C mutations. Below is a detailed summary: ### Background: KRASG12C mutations are present in approximately 4% of patients with colorectal cancer and are associated with poor prognosis, reduced treatment response rates, and lower overall survival. Resistance to KRASG12C inhibitors has been linked to EGFR signaling, making combination therapies targeting KRASG12C and EGFR an area of interest for improving outcomes in these patients. ### Study Design: Two open-label, non-randomized trials were conducted: 1. **JAB-21822-1002**: Evaluating glecirasib monotherapy (phase 1 dose escalation and phase 2a expansion). 2. **JAB-21822-1007**: Evaluating glecirasib in combination with cetuximab (phase 1b dose escalation and phase 2 expansion). Participants were adults (≥18 years) with histologically or cytologically confirmed advanced or metastatic CRC harboring KRASG12C mutations. Patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and at least one measurable lesion per RECIST criteria. For phase 1, participants were required to have failed, been unsuitable for, or refused standard of care treatment. For phase 2, patients must have received at least first-line standard of care and experienced disease progression or intolerance. - **Monotherapy Trial**: Participants received oral glecirasib at 800 mg once daily in 21-day treatment cycles until disease progression, intolerable toxicity, or withdrawal. - **Combination Trial**: In addition to glecirasib (800 mg once daily), cetuximab was administered intravenously (initial loading dose of 400 mg/m² followed by either 250 mg/m² weekly or 500 mg/m² biweekly). ### Primary Endpoints: - **Monotherapy Trial**: - Phase 1: Safety (treatment-emergent adverse events, serious adverse events, dose-limiting toxicities, etc.). - Phase 2a: Objective response rate (ORR, defined as complete or partial response). - **Combination Trial**: - Phase 1b: Dose-limiting toxicities, maximum tolerated dose, and recommended phase 2 dose. - Phase 2: Objective response rate. ### Findings: #### Monotherapy Trial: - **Safety**: - Among 44 patients, treatment-emergent adverse events (TEAEs) occurred in 100% of patients, with 53% experiencing grade ≥3 TEAEs. - Treatment-related adverse events (TRAEs) were reported in 87% of patients, with 27% experiencing grade ≥3 TRAEs. - Serious TEAEs were observed in 33% of patients, but none were treatment-related. - No dose-limiting toxicities or clinically significant unexpected laboratory values of grade ≥3 were observed. - **Efficacy**: - Objective response rate was 23% (95% CI 11–38), with ten partial responses out of 44 patients. #### Combination Trial: - **Safety**: - Among 47 patients, TEAEs occurred in 100% of patients, with 19% experiencing grade 3 or 4 TRAEs. - The most common TRAEs included rash (83%), increased blood bilirubin (62%), increased conjugated bilirubin (36%), elevated alanine aminotransferase (34%), and anemia (32%). - Serious TRAEs occurred in 9% of patients and included interstitial lung disease, pleural effusion, pericardial effusion, pyrexia, and rash. No treatment-related deaths were reported. - **Efficacy**: - Objective response rate was 50% (95% CI 35–65), with 23 partial responses out of 46 patients. ### Interpretation: The study demonstrated that glecirasib monotherapy and its combination with cetuximab are promising treatment options for patients with advanced, refractory colorectal cancer harboring KRASG12C mutations. The combination therapy showed higher efficacy (50% ORR) compared to monotherapy (23% ORR), suggesting that simultaneous inhibition of KRASG12C and EGFR signaling pathways may overcome resistance mechanisms and enhance clinical outcomes. ### Safety Profile: Both monotherapy and combination therapy were generally well tolerated, with manageable adverse events. The incidence of grade 3 or 4 TRAEs was similar between the two trials (20% for monotherapy and 19% for combination therapy). Serious TRAEs were rare, and no treatment-related deaths were observed. ### Conclusion: Glecirasib, either as monotherapy or in combination with cetuximab, represents a promising therapeutic strategy for KRASG12C-mutated CRC. The results support further exploration of glecirasib-based combinations in earlier lines of treatment or in broader patient populations. The combination approach, in particular, warrants further investigation as it demonstrated enhanced efficacy compared to monotherapy. ### Future Directions: Further studies are needed to: 1. Optimize glecirasib-based combination regimens. 2. Evaluate treatment in earlier disease stages or lines of therapy. 3. Investigate mechanisms of resistance to KRASG12C inhibitors. 4. Explore biomarkers for predicting response to therapy. These trials are registered with ClinicalTrials.gov (NCT05009329 and NCT05194995) and remain active but are no longer recruiting participants.

New Drugs for hepatobiliary Cancers - J of Hepatology - Jan.26

The treatment of hepatobiliary cancers, including hepatocellular carcinoma (HCC) and biliary tract cancer (BTC), is undergoing significant advancements with the development of novel drugs and therapeutic strategies. These developments are primarily categorized into two key strategies: 1. **Immune System Targeting Beyond Conventional Checkpoints**: - Novel therapies are being developed to target immune checkpoints beyond the well-established ones like PD-1 and CTLA-4. This includes new antibodies aimed at alternative immune checkpoints and cytokines that regulate tumor immune responses. - Combinations of these antibodies with already approved immunotherapy regimens are being investigated in Phase II and III clinical trials. - Cellular therapies, such as chimeric antigen receptor (CAR)-T cells and tumor-infiltrating lymphocytes (TILs), are in early clinical testing for both HCC and BTC. - Advances in antibody engineering have enabled the development of bispecific T-cell engagers, which are designed to enhance immune responses against tumors. 2. **Targeting Traditionally Undruggable or Novel Pathways**: - New drugs are being developed to target pathways and molecules previously considered undruggable, such as PPAR-α, KRAS, histone deacetylase, and β-catenin. - Antibody-drug conjugates (ADCs) targeting HER2 or nectin-4, which have shown success in other cancers, are being explored for BTC. Additionally, these advances are influencing the treatment of less common liver cancer subtypes, such as sarcomatoid HCC and combined HCC-cholangiocarcinoma. Emerging genomic data and clinical experiences suggest that these rare cancers may be responsive to immune checkpoint inhibitors. Including these subtypes in clinical trials could accelerate the development of effective therapies. In conclusion, the ongoing innovations in immunotherapy, cellular therapies, and targeted drug development are reshaping the treatment landscape for hepatobiliary cancers, offering new hope for improved outcomes in these challenging malignancies.

Tumour Microenvironment in ICC

The tumor microenvironment (TME) in intrahepatic cholangiocarcinoma (iCCA) plays a pivotal role in tumor progression, immune evasion, and therapeutic resistance. iCCA is characterized by a highly complex and heterogeneous TME, comprising cancer cells, immune cells, stromal cells, extracellular matrix components, and signaling molecules. This intricate environment influences tumor growth, metastasis, and response to treatments. Key players in the TME include tumor-associated macrophages, particularly CD163hi M2-like macrophages, which promote immune suppression and tumor progression by impairing CD8+ T cell-mediated antitumor responses. Cancer-associated fibroblasts (CAFs) contribute to the formation of a fibrotic barrier, preventing immune cell infiltration and creating an immunosuppressive milieu. Granulocytes and other myeloid cells further exacerbate immune suppression. The TME in iCCA can be classified into distinct spatial subtypes, such as "immune hot," "immune suppressive," and "immune desert," which correlate with prognosis and treatment response. For example, immune hot TMEs, enriched in antitumor immune cells, are more responsive to immunotherapy, while immune desert TMEs, lacking immune cells, are associated with poor outcomes. By influencing immune evasion mechanisms and modulating therapy resistance, the TME is a critical determinant of iCCA progression. Targeting the TME through combination therapies, such as immunotherapy and antifibrotic agents, holds promise for improving patient outcomes.

Chines Expert Consensus of GIST

The Chinese Expert Consensus on Diagnosis and Treatment of Small Gastrointestinal Stromal Tumors (GISTs) is a comprehensive guideline developed by the CSCO Gastrointestinal Stromal Tumor Committee in collaboration with other professional associations. It aims to standardize the diagnosis, treatment, and management of small GISTs, defined as tumors measuring less than 2 cm in greatest dimension. Below is a detailed summary of the consensus: --- ### **Definition and Epidemiology** 1. **Definition**: Small GISTs are defined as tumors measuring <2 cm in greatest dimension. 2. **Common Locations**: The stomach is the most common site for small GISTs, followed by the small intestine, colon, and rectum. Esophageal GISTs are rare, and colonic GISTs are extremely rare with an incidence rate of ≤0.1%. 3. **Detection**: The detection rate of small GISTs has significantly increased in recent years due to advances in diagnostic tools like endoscopy and imaging techniques. --- ### **Biologic Behavior** 1. **Malignant Potential**: Small GISTs have varying malignant potential. Nongastric small GISTs (e.g., in the duodenum, small intestine, or rectum) exhibit worse behavior compared to gastric small GISTs. 2. **High-Risk Features**: Endoscopic ultrasonography (EUS) features such as hyperechoic foci, heterogeneity, irregular borders, and cystic changes are weak predictors of malignant potential. 3. **Aggressiveness**: While most small GISTs exhibit indolent behavior, some may show local progression or distant metastasis, particularly nongastric tumors. --- ### **Diagnosis** 1. **EUS as First-Line Tool**: EUS is considered the most effective diagnostic tool for small GISTs. It provides detailed information on tumor size, internal structure, and relationship with surrounding tissues. 2. **Role of CT**: Contrast-enhanced computed tomography (CT) is used to aid in localization and follow-up, especially for tumors between 1–2 cm in size. 3. **Limitations of Endoscopy**: Gastrointestinal endoscopy is widely used but has limited specificity in differentiating between intramural lesions and extramural compression. 4. **Tissue Sampling**: EUS-guided fine-needle aspiration or biopsy is recommended for definitive diagnosis when necessary. In some cases, endoscopic resection can be used for both diagnosis and treatment. --- ### **Differential Diagnosis** Small GISTs must be differentiated from other submucosal lesions, including: 1. **Leiomyomas**: Benign tumors originating from the muscularis mucosae or muscularis propria. 2. **Neuroendocrine Tumors**: Malignant tumors originating from chromaffin cells, often found in the rectum. 3. **Lipomas**: Benign fatty tumors, commonly found in the gastric antrum or colon. 4. **Ectopic Pancreas**: Submucosal lesions often located in the gastric antrum, with variable EUS appearances. 5. **Schwannomas**: Tumors originating from Schwann cells, most commonly found in the stomach. 6. **Others**: Duplication cysts, glomus tumors, metastatic cancers, and early-stage lymphomas. --- ### **Surgical Treatment** 1. **Gastric Small GISTs**: - High-risk gastric small GISTs require surgery. - Laparoscopic wedge resection is preferred for accessible lesions, but open surgery may be required for lesions in difficult locations like the esophagogastric junction. - Endoscopic resection is feasible but should be performed cautiously in experienced centers. 2. **Duodenal Small GISTs**: - Organ-sparing resection (e.g., wedge resection, segmental resection) is prioritized over pancreaticoduodenectomy. - Endoscopic resection is not recommended due to the high risk of complications and malignancy. 3. **Small Intestinal Small GISTs**: - Prompt resection is recommended due to the higher malignancy rate of small intestinal GISTs. - Laparoscopy may aid in tumor localization but is not yet a standard approach. 4. **Colonic Small GISTs**: - These are rare but should be resected upon detection. 5. **Rectal Small GISTs**: - Minimally invasive techniques, such as transanal or robotic surgery, are preferred to preserve rectal function while ensuring complete resection. --- ### **Endoscopic Treatment** 1. **Esophageal Small GISTs**: - Endoscopic resection (e.g., endoscopic submucosal dissection, submucosal tunneling endoscopic resection) is safe and effective for small esophageal GISTs (<2 cm). 2. **Gastric Small GISTs**: - Endoscopic submucosal dissection or endoscopic full-thickness resection is feasible for select cases. - Complications like bleeding and perforation are common but manageable with advanced techniques. 3. **Duodenal, Small Intestinal, and Colorectal Small GISTs**: - Endoscopic resection is not routinely recommended due to the thin walls of these organs and the higher malignancy risk of these tumors. --- ### **Pathologic Diagnosis** 1. **Histology**: Small GISTs are typically classified into spindle cell, epithelioid cell, or mixed types. They often arise from the muscularis propria and exhibit low mitotic activity. 2. **Immunohistochemistry**: Markers such as CD117, DOG1, CD34, and Ki-67 are critical for diagnosis. 3. **Genetic Testing**: Testing for KIT and PDGFRA mutations is recommended, especially for high-risk tumors with a mitotic index >5 per 5 mm². --- ### **Molecular-Targeted Therapy** 1. **Adjuvant Therapy**: Imatinib is recommended post-resection for tumors with a mitotic index >5 per 5 mm² or high-risk features. 2. **Genetic Testing**: Helps predict treatment efficacy and guides the use of targeted therapy. --- ### **Surveillance Strategy** 1. **Observation**: Observation is acceptable for asymptomatic gastric small GISTs with informed consent, but nongastric small GISTs require resection. 2. **High-Risk Features**: Surgery is indicated if high-risk features (e.g., irregular borders, cystic changes) are detected during surveillance. 3. **Monitoring Frequency**: - Tumors >1 cm: Monitor every 6–12 months. - Tumors <1 cm: Monitor at least once every 2 years. 4. **Combined Approach**: EUS and enhanced CT should be used together for follow-up to ensure accurate monitoring of tumor growth and behavior. --- ### **Key Takeaways** 1. Small GISTs are defined as tumors <2 cm in size, with the stomach being the most common location. 2. While most small GISTs exhibit benign behavior, nongastric tumors and those with high-risk features may have malignant potential. 3. EUS is the first-line diagnostic tool, with CT used for localization and follow-up. 4. Differential diagnosis is crucial to distinguish small GISTs from other submucosal tumors like leiomyomas, lipomas, and neuroendocrine tumors. 5. High-risk small GISTs require surgical resection, with minimally invasive techniques preferred for accessible lesions. 6. Endoscopic resection is feasible for select gastric and esophageal small GISTs but is not recommended for duodenal, small intestinal, or colorectal GISTs. 7. Pathologic diagnosis relies on immunohistochemistry (e.g., CD117, DOG1) and genetic testing (e.g., KIT, PDGFRA). 8. Adjuvant imatinib therapy is recommended for high-risk tumors. 9. Surveillance strategies depend on tumor size and location, with regular monitoring using EUS and CT. This consensus provides a detailed roadmap for clinicians managing small GISTs, emphasizing individualized treatment based on tumor characteristics and location. It also highlights the importance of early detection, accurate diagnosis, and appropriate treatment to improve patient outcomes.

Chemotherapy for Locally Advanced Pancreatic Cancer After NEOPAN: David vs Goliath

The title “Chemotherapy for Locally Advanced Pancreatic Cancer After NEOPAN: David vs Goliath” appears to metaphorically frame the debate between different treatment paradigms for locally advanced pancreatic cancer (LAPC) in light of the NEOPAN trial results. Here's a detailed breakdown of the key considerations and implications: ### 1. **NEOPAN Trial Overview** The NEOPAN trial was a phase III randomized study that compared modified FOLFIRINOX (a more intensive combination chemotherapy regimen) with gemcitabine monotherapy (a standard, less intensive option) in patients with LAPC. The trial aimed to address the lack of robust randomized data in this challenging disease setting. - **Findings:** NEOPAN showed that FOLFIRINOX offered a progression-related benefit, meaning it delayed disease progression compared to gemcitabine. However, this did not clearly translate into an overall survival (OS) advantage. - **Complexity in Interpretation:** The lack of OS benefit could be due to post-progression therapies and treatment crossover, which may have diluted the survival impact of first-line treatment. ### 2. **David vs Goliath Analogy** The metaphor likely represents the contrast between: - **"David" (Gemcitabine):** A simpler, less intensive, and more tolerable chemotherapy option that is often used in frail or elderly patients. - **"Goliath" (FOLFIRINOX):** A more aggressive, complex, and toxic regimen aimed at achieving better disease control in fitter patients. The analogy suggests a struggle between these two approaches, raising questions about which is more appropriate in different clinical scenarios. ### 3. **Key Considerations Post-NEOPAN** The NEOPAN trial sheds light on several critical aspects of treating LAPC, but also raises new questions: #### a. **Progression-Free Survival vs Overall Survival** - While FOLFIRINOX delayed progression, it did not clearly improve overall survival, which remains the gold standard for assessing treatment efficacy. - Post-progression therapies and treatment crossover may have confounded survival outcomes, highlighting the need for more nuanced analyses. #### b. **Surgical Resection Rates** - Surgical resection is the only curative option for pancreatic cancer, but resection rates remained low in both arms of the NEOPAN trial, reflecting the real-world challenges of achieving resectability in LAPC. - For patients who are not surgical candidates, the focus should shift to symptom management and minimizing treatment-related harm. #### c. **Toxicity and Quality of Life** - FOLFIRINOX is associated with significant toxicity, which may outweigh its benefits in some patients, particularly those who are older or frail. - Gemcitabine, while less effective in controlling disease progression, may be better tolerated and more suitable for patients with poor performance status. #### d. **Patient Selection and Personalization** - The trial highlights the importance of tailoring treatment to individual patient characteristics, such as age, performance status, and comorbidities. - There is a need for better molecular and transcriptomic stratification to identify subgroups of patients who might benefit most from intensified therapy. ### 4. **Future Directions** The NEOPAN trial underscores the need for continued research and innovation in LAPC treatment: - **Intensified Regimens:** Exploring modifications to FOLFIRINOX or combining it with other agents to improve outcomes without excessive toxicity. - **Targeted Therapies:** Incorporating molecularly targeted agents and immunotherapies to personalize treatment. - **Supportive Care:** Enhancing supportive care measures to mitigate toxicity and improve quality of life during treatment. - **Clinical Trial Design:** Designing trials that account for real-world patient populations, including older and frail individuals, to ensure broader applicability of findings. ### 5. **Clinical Implications** Until more advanced strategies are developed, the choice between "David" (gemcitabine) and "Goliath" (FOLFIRINOX) in LAPC must be guided by individualized clinical judgment. Factors to consider include: - Patient fitness and ability to tolerate aggressive therapy. - Goals of care (e.g., symptom control vs. disease control). - Potential for surgical resection and long-term survival. ### Conclusion The NEOPAN trial represents a pivotal step in addressing the evidence gap in LAPC, but it also highlights the ongoing challenges of balancing efficacy, toxicity, and quality of life. The "David vs Goliath" analogy aptly captures the tension between less intensive and more aggressive chemotherapy options, emphasizing the need for personalized treatment strategies in this complex disease setting.

Short-Course Radiotherapy for Older Patients With Locally Advanced Rectal Cancer (SOFT Study)

The Short-Course Radiotherapy (SCRT) for Older Patients With Locally Advanced Rectal Cancer (SOFT Study) is a multicenter investigation focused on evaluating the effectiveness and feasibility of SCRT followed by delayed surgery as a treatment strategy for older patients with stage II–III rectal adenocarcinoma who are unfit for chemotherapy. This patient population often faces challenges in tolerating conventional long-course chemoradiotherapy due to age-related frailty, comorbidities, and reduced physiological reserve. The SOFT study aimed to address these challenges by offering a potentially less burdensome yet effective therapeutic approach. ### Key Features of the SOFT Study: 1. **Patient Population**: - Older patients diagnosed with locally advanced rectal cancer (stage II–III rectal adenocarcinoma). - Patients deemed unfit for chemotherapy due to frailty, significant comorbidities, or other health-related limitations. 2. **Treatment Protocol**: - **Short-Course Radiotherapy (SCRT)**: Patients underwent a condensed schedule of radiotherapy, which is typically delivered over five consecutive days. - **Delayed Surgery**: After a planned interval following radiotherapy, patients proceeded to surgical resection of the tumor. 3. **Outcomes Assessed**: - **Tumor Response**: Both complete and partial tumor responses were observed, with evidence of tumor down-staging prior to surgery. - **Surgical Results**: High rates of complete tumor removal were achieved during surgery. - **Pathologic Tumor Eradication**: A subset of patients demonstrated complete tumor eradication, underscoring the biological effectiveness of SCRT. - **Survival Outcomes**: Long-term follow-up indicated encouraging disease control and survival rates. - **Safety and Tolerability**: Postoperative complications were deemed acceptable, and treatment-related mortality was low, highlighting the safety of the approach. ### Advantages of SCRT Followed by Delayed Surgery: - **Reduced Treatment Burden**: SCRT involves a shorter duration of radiotherapy compared to conventional chemoradiotherapy, making it more manageable for elderly patients. - **Oncologic Effectiveness**: The study demonstrated meaningful tumor control, with favorable rates of tumor down-staging and eradication. - **Improved Tolerability**: The approach was associated with limited toxicity and acceptable postoperative outcomes, making it a viable option for frail patients. - **Safety Profile**: Low treatment-related mortality and manageable side effects further support its feasibility in this vulnerable population. ### Conclusion: The SOFT study provides strong evidence that short-course radiotherapy followed by delayed surgery is a feasible, effective, and well-tolerated alternative to standard chemoradiotherapy for older patients with locally advanced rectal cancer who are unable to undergo chemotherapy. This approach offers meaningful tumor control, favorable safety, and improved tolerability, addressing the unique needs of this patient population. It represents an important advancement in the management of elderly patients with rectal cancer, helping to standardize care for those who may otherwise struggle with conventional treatment regimens.

Immune Checkpoint Inhibitor–Induced Diabetes in PD-1/PD-L1 Cancer Trials

Immune Checkpoint Inhibitor–Induced Diabetes (ICI-D) is a rare yet serious immune-related adverse event that can arise in patients undergoing cancer immunotherapy, specifically in clinical trials involving programmed cell death 1 protein (PD-1) or programmed cell death 1 ligand 1 (PD-L1) inhibitors. Below is a detailed overview of findings related to ICI-D based on the evaluation of patients enrolled in National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP) trials: ### Study Overview: - **Objective:** To assess the distribution, incidence, and clinical characteristics of ICI-D among cancer patients receiving PD-1/PD-L1 inhibitors. - **Data Source:** Adverse event reports from the NCI-CTEP database. - **Study Population:** 13,966 patients treated across 158 clinical trials between June 2015 and December 2022. - **Treatment Regimens:** Trials included PD-1/PD-L1 monotherapy and combination immunotherapy regimens. ### Key Findings: 1. **Incidence:** - **Overall Incidence:** The cumulative incidence of ICI-D was **0.52 per 100 treated patients**, indicating that it is a rare adverse event. - **Variation by Treatment Setting:** - **Lower Risk:** Patients receiving concurrent chemotherapy had significantly lower risk of developing ICI-D. - **Higher Risk:** Combination immunotherapy regimens were associated with a markedly higher incidence compared to PD-1 or PD-L1 monotherapy. 2. **Clinical Characteristics:** - **Hospitalization:** Most patients diagnosed with ICI-D required hospitalization. - **Intensive Care:** Nearly half of the patients required intensive care, highlighting the severity of the condition. - **Severe Hyperglycemia:** A key distinguishing feature of ICI-D was severe hyperglycemia, which set it apart from other causes of hyperglycemia such as pre-existing diabetes or metabolic disorders. 3. **Risk Factors:** - **Combination Immunotherapy:** Patients exposed to combination regimens involving multiple immune checkpoint inhibitors were at higher risk for ICI-D. - **Concurrent Chemotherapy:** Concurrent chemotherapy appeared to mitigate the risk of ICI-D compared to immunotherapy alone. 4. **Health Care Burden:** - Despite its rarity, ICI-D imposes a significant health care burden due to the need for extensive medical intervention, including hospitalizations and intensive care management. ### Clinical Implications: - **Recognition and Management:** Clinicians should be aware of ICI-D as a potential immune-related adverse event, especially when treating patients with combination immunotherapy regimens. - **Risk Assessment:** Identifying patients at higher risk based on treatment regimens can help guide monitoring strategies and improve clinical outcomes. - **Treatment Adjustments:** Concurrent chemotherapy may offer protective effects against ICI-D, suggesting potential avenues for optimizing treatment protocols. ### Conclusion: ICI-D is an uncommon but highly morbid adverse event associated with PD-1/PD-L1 cancer immunotherapy. The risk varies significantly depending on the type of immunotherapy regimen and concurrent treatments. While rare, its severe clinical presentation and substantial health care burden underscore the need for heightened awareness, early diagnosis, and effective management strategies in clinical practice.

SEOM Clinical Guidelines for Localized Rectal Cancer

The SEOM (Spanish Society of Medical Oncology) Clinical Guidelines for localized rectal cancer emphasize a comprehensive, multidisciplinary approach to ensure optimal treatment outcomes. Below is a detailed overview based on the context provided: --- ### **1. Accurate Staging Is Critical** - **Pelvic MRI** is the gold standard for staging localized rectal cancer. It provides detailed information on tumor depth, nodal involvement, circumferential resection margin (CRM) status, mesorectal fascia involvement, and extramural venous invasion (EMVI). - Accurate staging is essential for determining prognosis and guiding treatment strategies. --- ### **2. Multidisciplinary Management** - All cases of rectal cancer should be discussed in a **multidisciplinary tumor board**. This ensures coordinated input from oncologists, radiologists, surgeons, and pathologists, leading to individualized treatment plans and improved outcomes. --- ### **3. Universal MMR/MSI Testing** - **Mismatch repair (MMR) or microsatellite instability (MSI) testing** is mandatory for all newly diagnosed rectal cancer patients. Results are critical for assessing prognosis and determining eligibility for immunotherapy, especially in cases of deficient mismatch repair (dMMR). --- ### **4. Tumor Location and Classification** - Rectal cancers are classified based on their distance from the anal verge into **low**, **middle**, or **high** rectal tumors. - Tumor location impacts surgical options (e.g., sphincter preservation) and the feasibility of organ-preserving strategies. --- ### **5. Early-Stage Disease Management** - For **early-stage disease** (e.g., pT1 tumors with favorable histology), **local excision** or **endoscopic approaches** may be considered. However, a meticulous histopathologic risk assessment is required to ensure safe management. --- ### **6. Standard Surgical Approach: Total Mesorectal Excision (TME)** - **Total Mesorectal Excision (TME)** is the standard curative surgical technique for localized rectal cancer. When performed with high technical quality, TME minimizes local recurrence and optimizes oncologic outcomes. --- ### **7. Neoadjuvant Therapy Options** - **Total Neoadjuvant Therapy (TNT)** is increasingly used for locally advanced rectal cancer. It combines chemotherapy and radiation before surgery to: - Improve tumor response. - Reduce distant recurrence risk. - Enable organ preservation strategies in cases of complete clinical response. --- ### **8. Organ Preservation and Watch-and-Wait Strategies** - TNT can lead to **complete clinical response**, making **nonoperative management** a viable option for selected patients. This avoids surgery and preserves rectal function. - The **Watch-and-Wait approach** is considered safe for patients with documented complete response, with outcomes comparable to immediate surgery. Intensive surveillance protocols are required to monitor for regrowth. --- ### **9. Radiotherapy Personalization** - Radiotherapy options include **short-course** or **long-course regimens**, tailored to tumor risk and location. Care must be taken to avoid overtreatment in low-risk cases. --- ### **10. Chemotherapy Sequencing** - **Consolidation chemotherapy** after chemoradiation increases complete response rates and enhances the feasibility of organ preservation. --- ### **11. High-Risk Disease Management** - Patients with high-risk features (e.g., threatened margins, EMVI, or nodal involvement) benefit most from **TNT**. Risk-adapted treatment intensification improves disease control and reduces recurrence. --- ### **12. Limited Role of Adjuvant Chemotherapy** - After modern neoadjuvant therapy approaches, **adjuvant chemotherapy** offers modest benefits. Its use should be individualized based on patient risk factors and response to prior treatment. --- ### **13. Immunotherapy for dMMR Rectal Cancer** - **Checkpoint inhibitors** (e.g., PD-1/PD-L1 inhibitors) demonstrate dramatic responses in patients with dMMR rectal cancer. In selected cases, immunotherapy may replace chemoradiation. --- ### **14. Elderly and Frail Patients** - Treatment decisions for older or frail individuals should prioritize **quality of life**. A comprehensive geriatric assessment is recommended to tailor therapies to the patient's overall health and functional status. --- ### **15. Local Excision Post-Neoadjuvant Therapy** - For small residual tumors after neoadjuvant therapy, **local excision** may reduce morbidity compared to radical surgery. This approach is reserved for carefully selected patients. --- ### **16. Long-Term Survivorship Care** - Survivorship care should address: - **Recurrence surveillance**. - Management of functional outcomes and quality of life. - Lifestyle counseling and symptom management. --- ### **Key Takeaways** - **Personalized treatment** based on tumor staging, location, and risk factors is essential. - **TNT** and organ preservation strategies are revolutionizing rectal cancer management. - **Multidisciplinary care** and intensive surveillance protocols are critical for optimizing outcomes. - Emerging therapies like **immunotherapy** are transforming care for dMMR rectal cancer. The SEOM guidelines align with international standards, emphasizing evidence-based, patient-centered approaches to ensure the best oncologic and functional outcomes for localized rectal cancer patients.

Colorectal Cancer Incidence and Survival in the UK

Colorectal cancer (CRC) remains a significant public health concern in the United Kingdom, as it is a major cause of cancer-related mortality. A population-based cohort study examined trends in CRC incidence and survival over two decades using large, nationally representative primary care databases. The findings highlight both progress and challenges in CRC outcomes in the UK. ### **Incidence Trends:** 1. **Overall Incidence:** - CRC incidence initially increased during the early years of the study period. This was followed by a modest decline and then a plateau in incidence rates. - Despite the decline in overall incidence, CRC remains one of the most common cancers in the UK. 2. **Age-Specific Incidence:** - **Early-Onset CRC:** - A concerning trend was observed in younger adults, particularly those under the age of 60, where CRC incidence consistently rose over the study period. - This rise in early-onset CRC affected both men and women similarly, suggesting evolving lifestyle or environmental factors as potential contributors. - **Older Adults:** - Incidence remained highest among older adults, reflecting the well-established age-related nature of CRC risk. 3. **Potential Contributing Factors:** - The rise in early-onset CRC may be linked to lifestyle changes, including diet, obesity, physical inactivity, and other risk factors. - The introduction of population-based fecal screening in the mid-2000s may have contributed to the modest decline and plateau in overall incidence by improving early detection. --- ### **Survival Trends:** 1. **Overall Survival:** - Gradual improvements in survival outcomes were observed over time, particularly in short- and intermediate-term survival. - These improvements likely reflect advances in early detection, treatment, and cancer care delivery. 2. **Age- and Sex-Specific Survival:** - **Gender Differences:** - Women demonstrated better overall survival outcomes compared to men. - **Age Differences:** - Younger patients had significantly better survival rates compared to older individuals, likely due to better overall health and the ability to tolerate aggressive treatments. 3. **Long-Term Survival:** - While there were gains in short- and intermediate-term survival, long-term survival improvements were modest. - Progress in long-term survival was uneven across different age groups, with older adults facing greater challenges. --- ### **Persistent Challenges and Implications:** 1. **Early-Onset CRC:** - The rise in early-onset CRC is a major concern, as younger populations are traditionally considered to be at lower risk. This underscores the need for increased awareness, earlier diagnosis, and potentially updated screening guidelines for younger age groups. 2. **Survival Disparities:** - Despite improvements, survival disparities persist between age groups and sexes. Older adults, in particular, face poorer outcomes, highlighting the need for tailored interventions for this population. 3. **Prevention and Diagnosis:** - The findings emphasize the importance of improved prevention strategies, including lifestyle modifications, public health campaigns, and risk reduction efforts. - Timely diagnosis is critical, especially for younger patients who may be overlooked due to their lower perceived risk. 4. **Treatment and Survivorship Care:** - Continued advances in treatment and survivorship care are essential to improve long-term outcomes for CRC patients. --- ### **Conclusion:** While there has been progress in CRC survival outcomes in the UK over the past two decades, challenges remain, particularly with the rising incidence of early-onset CRC and the modest improvements in long-term survival. Addressing these issues requires a multifaceted approach, including enhanced prevention strategies, early detection efforts, and equitable access to advanced treatments. The findings highlight the need for continued research and public health initiatives to reduce the burden of CRC and improve outcomes for all affected populations.

Improving Access and Quality Care for Immune Checkpoint Inhibitor–Related Thyroid Dysfunction

Improving access and quality care for immune checkpoint inhibitor-related thyroid dysfunction (irTD) is a critical focus in the management of patients undergoing immunotherapy. Immune checkpoint inhibitors (ICIs), which are increasingly used in oncology, can lead to immune-related adverse events, including thyroid dysfunction. Addressing these complications effectively is essential to minimize symptom burden, optimize treatment outcomes, and improve the overall quality of life for affected patients. ### Key Strategies for Improvement: 1. **Dedicated Care Models**: - The establishment of specialized clinics, such as the Immuno-Oncology Toxicity (IOTOX) clinic described in the context, is a highly effective strategy. - These clinics focus specifically on the evaluation and management of irTD and other immune-related adverse events. - By utilizing advanced practice providers (APPs) working under evidence-based algorithms and endocrinologist oversight, these clinics can streamline care delivery and ensure consistent, high-quality management. 2. **Reducing Wait Times**: - One of the major barriers to effective care is the delay in accessing specialist consultations. - In the IOTOX clinic model, the median wait time for an initial consultation was reduced significantly from 21 days to 9 days. - Faster access to care enables earlier diagnosis and intervention, helping to alleviate symptoms and prevent further complications. 3. **Standardized Protocols**: - The use of standardized, evidence-based algorithms ensures that patients receive timely and appropriate care. - These protocols guide APPs in managing thyroid dysfunction, with endocrinologists providing support for complex cases. 4. **Improved Follow-Up and Monitoring**: - Regular follow-up is crucial for managing irTD, as thyroid dysfunction may require ongoing adjustments to treatment. - The IOTOX clinic reduced the median time to follow-up from 180 days to 58 days, ensuring that patients receive continuous care and monitoring. 5. **Accelerating Normalization of Thyroid Function**: - A key clinical goal in managing irTD is the normalization of thyroid function tests (TFTs), particularly thyroid-stimulating hormone (TSH) levels. - The dedicated clinic model significantly improved the median time to normalization of TSH levels, from 102 days to 38 days. - This improvement reflects the effectiveness of timely intervention and optimized treatment protocols. 6. **Efficient Resource Utilization**: - By leveraging APPs and implementing a streamlined referral system, the IOTOX clinic optimized the use of healthcare resources. - This approach allows endocrinologists to focus on more complex cases while ensuring that all patients receive high-quality care. ### Outcomes and Benefits: The introduction of a dedicated clinic model, such as the IOTOX clinic, has demonstrated significant improvements in access to care, efficiency, and clinical outcomes for patients with irTD. Key benefits include: - Reduced wait times for consultations and follow-ups. - Faster normalization of thyroid function, leading to improved symptom management and quality of life. - Consistent application of evidence-based care protocols. - Enhanced collaboration between APPs and endocrinologists, ensuring comprehensive care. ### Broader Implications: The success of this quality improvement initiative highlights the potential for similar models to be implemented in other institutions and for other immune-related adverse events. As the use of ICIs continues to grow, the need for innovative care delivery models will become increasingly important to address the associated complications effectively. In summary, improving access and quality care for irTD requires a multifaceted approach that prioritizes timely evaluation, standardized management, and efficient resource utilization. The IOTOX clinic model serves as a blueprint for achieving these goals, ultimately enhancing the care and outcomes for patients undergoing immunotherapy.

Comprehensive Genomic Profiling for Resectable Pancreatic Cancer

Comprehensive Genomic Profiling (CGP) for resectable pancreatic cancer is an evolving area of investigation, with its role and timing in the disease course still under debate. Below is a detailed discussion based on the context provided: ### Current Role of CGP: - **Advanced/Metastatic Pancreatic Cancer:** CGP is already a standard of care in advanced or metastatic pancreatic cancer cases. It identifies actionable mutations and informs the use of targeted therapies, which can significantly impact treatment outcomes. - **Resectable Pancreatic Cancer:** For early-stage, surgically resectable pancreatic cancer, the role of CGP is less clear. The current standard approach does not routinely involve CGP at this stage. ### Why Consider CGP Earlier in Resectable Disease? 1. **High Recurrence Rates After Surgery:** - Most patients undergoing curative-intent surgery for pancreatic cancer experience disease recurrence, often within a short period. - This underscores the aggressive nature of pancreatic cancer and the need for better post-surgical therapeutic strategies. 2. **Missed Opportunities for Personalized Treatment:** - A significant proportion of patients do not undergo CGP after recurrence, which limits access to personalized therapies and clinical trials. - Performing CGP earlier (before or shortly after surgery) ensures that molecular data is available when needed, especially at the time of relapse. 3. **Proactive Preparation for Targeted Therapies:** - Having CGP results early could prepare patients for emerging precision medicine approaches, including clinical trials and novel therapies targeting specific mutations. ### Challenges and Limitations of Early CGP: 1. **Limited Impact on First-Line Treatment After Recurrence:** - Retrospective analyses show that early CGP rarely influences the initial treatment decisions made after relapse. - This raises questions about the immediate utility of CGP in resectable disease. 2. **Unproven Survival Benefit:** - There is no clear evidence that earlier CGP improves overall survival or long-term outcomes for patients with resectable pancreatic cancer. - More research is needed to establish whether early CGP translates into meaningful clinical benefits. 3. **Cost-Effectiveness:** - The financial implications of performing CGP earlier in the disease course are uncertain, especially if it does not lead to improved survival or change in treatment strategy. 4. **Fragmented Care:** - Pancreatic cancer care is often fragmented, with surgery and oncology treatment occurring at different centers. - This fragmentation reduces the likelihood of CGP being performed or the results being accessible when needed. ### Future Outlook: - **Emerging Targeted Therapies:** - The development of new targeted therapies, such as RAS inhibitors (potentially applicable to most pancreatic cancers), could make CGP essential for all stages of the disease. - As these therapies become more widely available, early CGP could play a critical role in identifying patients who would benefit from them. - **Potential for Precision Medicine:** - Early CGP represents a proactive approach to prepare for the future of precision oncology. While currently unproven, it may become standard practice as the therapeutic landscape evolves. ### Conclusion: Comprehensive Genomic Profiling for resectable pancreatic cancer is a promising but still investigational strategy. While it offers the potential to improve access to personalized therapies and clinical trials, its impact on survival, cost-effectiveness, and treatment decisions remains uncertain. Emerging targeted therapies may soon make early CGP indispensable, but for now, it is a forward-looking approach awaiting further validation.

Irradiation vs Conventional Stents for Unresectable Malignant Hilar Biliary Obstruction

The study you referred to compares irradiation stents loaded with iodine-125 (¹²⁵I) seeds versus conventional uncovered self-expandable metal stents for the palliative treatment of unresectable malignant hilar biliary obstruction (MHBO). Below is a detailed analysis of the findings regarding both types of stents: ### 1. **Primary Outcome: Stent Patency** - **Irradiation Stents (¹²⁵I-loaded stents):** - Demonstrated significantly superior stent patency compared to conventional stents. - Restenosis (narrowing of the stent due to tumor ingrowth or tissue overgrowth) rates were markedly lower at 90, 180, and 360 days. - Median stent patency was not reached within the study period due to the low incidence of restenosis. - **Conventional Stents:** - Median stent patency was 254 days, significantly shorter compared to the irradiation stents. **Conclusion:** Irradiation stents significantly reduce the risk of stent restenosis and prolong the functional lifespan of biliary stents. --- ### 2. **Secondary Outcomes** - **Technical Success:** - Both irradiation and conventional stents achieved 100% technical success in placement. - **Jaundice Relief:** - Early relief of jaundice was comparable between the two groups, indicating both stents were effective in decompressing the biliary obstruction initially. - **Complications:** - Early complication rates, such as pancreatitis and cholangitis, were similar between the two groups. - Importantly, no radiation-related adverse events were observed in the irradiation stent group. - **Overall Survival:** - Median survival was numerically longer in the irradiation stent group but did not reach statistical significance. - Survival was more closely associated with tumor etiology and whether the patient received post-procedure chemotherapy, rather than the type of stent used. --- ### 3. **Key Findings** - **Advantages of Irradiation Stents:** - Prolong stent patency significantly. - Reduce the risk of restenosis over time. - Do not increase the risk of complications compared to conventional stents. - **Limitations of Irradiation Stents:** - Despite improved stent patency, irradiation stents did not confer a significant survival advantage. - Survival was influenced more by factors such as tumor type and post-procedure chemotherapy rather than the stent type. --- ### 4. **Clinical Implications** - **For Patients with MHBO:** - Irradiation stents are an effective palliative option, especially for patients at high risk of stent restenosis. - They provide longer-lasting relief from biliary obstruction without increasing complications. - **Survival Considerations:** - While the stent type improves patency, survival outcomes are more dependent on tumor biology and systemic therapies (e.g., chemotherapy). - **Future Directions:** - Larger prospective studies are needed to identify subgroups of patients who would benefit the most from irradiation stents. - Research should focus on combining irradiation stents with systemic therapies to potentially improve overall survival. --- ### 5. **Conclusion** Irradiation stents loaded with iodine-125 seeds offer a significant advantage in prolonging stent patency and reducing restenosis for patients with unresectable MHBO, making them an effective palliative treatment option. However, they do not provide a survival benefit over conventional stents. The decision to use irradiation stents should consider patient-specific factors, including tumor type, prognosis, and potential for systemic treatment.

Advancing IBD-Associated Colorectal Cancer Management Through Precision Medicine

Advancing the management of inflammatory bowel disease (IBD)-associated colorectal cancer (CRC) through precision medicine represents a transformative approach to mitigating one of the most serious complications of IBD. Precision medicine leverages a combination of advanced diagnostics, molecular profiling, and personalized therapeutic strategies to optimize patient outcomes. Below is a detailed breakdown of how precision medicine is reshaping IBD-associated CRC management: --- ### **1. Understanding the Unique Pathogenesis of IBD-Associated CRC** IBD-associated CRC develops through distinct inflammation-driven molecular pathways that differ fundamentally from sporadic colorectal cancer. Chronic inflammation in IBD leads to oxidative stress, DNA damage, and an inflammation–dysplasia–carcinoma sequence. Key features include: - **Early TP53 Alterations:** Loss of TP53 function occurs early in colitis-associated carcinogenesis, preceding dysplasia and setting it apart from sporadic CRC. - **Epigenetic Dysregulation:** DNA methylation, histone modification, and microRNA (miRNA) dysregulation play critical roles in the pathogenesis. - **Chromosomal Instability:** Aneuploidy and chromosomal instability correlate with dysplasia grade and are potential markers for early risk stratification. - **Molecular Changes Before Dysplasia:** Genetic and epigenetic alterations can be detected in nondysplastic mucosa, providing opportunities for preemptive interventions. Precision medicine aims to exploit these unique molecular features for early detection, risk stratification, and targeted intervention. --- ### **2. Advances in Endoscopic Surveillance** Endoscopic surveillance forms the cornerstone of early detection and management of IBD-associated CRC. Precision medicine has led to significant advancements in endoscopic technologies: - **High-Definition Endoscopy and Chromoendoscopy:** These techniques have improved the detection and characterization of dysplastic lesions. - **Ultra-High Magnification Endoscopy:** Methods like confocal laser endomicroscopy and endocytoscopy allow real-time optical biopsy, enabling precise differentiation between neoplastic and non-neoplastic lesions. - **Shift Toward Targeted Biopsies:** With advanced imaging, targeted biopsies are now preferred over random sampling, improving diagnostic accuracy and reducing unnecessary interventions. - **AI in Dysplasia Detection:** Artificial intelligence (AI) systems enhance lesion detection and characterization, aiding even nonexpert endoscopists in identifying early dysplastic changes. --- ### **3. Emerging Molecular Biomarkers** Molecular diagnostics are at the forefront of precision medicine, offering tools for noninvasive risk assessment and monitoring: - **Epigenetic and Genetic Biomarkers:** DNA methylation patterns, miRNAs, and circular RNAs are being explored as early indicators of CRC risk. - **Proteomic Markers:** Proteins associated with inflammation and tumorigenesis may serve as biomarkers for early detection. - **Immune-Related Biomarkers:** Immune profiling can provide insights into the inflammatory microenvironment and its role in tumor progression. - **Liquid Biopsy:** Circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) offer minimally invasive options for early detection, monitoring disease progression, and assessing treatment response. --- ### **4. Microbiome and Diet Interaction** The gut microbiome plays a pivotal role in IBD-associated CRC pathogenesis, influenced by diet and intestinal barrier dysfunction: - **Microbiome–Diet Interaction:** Diet-induced changes in the microbiome can modulate inflammation, barrier integrity, and tumorigenesis. - **Barrier Dysfunction:** Impaired intestinal barrier integrity promotes microbial translocation, chronic inflammation, and cancer progression. Precision medicine approaches aim to restore microbiome balance through dietary interventions, probiotics, and microbiome-targeted therapies. --- ### **5. Artificial Intelligence and Multi-Omics Integration** AI and multi-omics integration are revolutionizing precision medicine by enabling comprehensive risk stratification and personalized care: - **AI-Driven Analysis:** AI can integrate genomic, epigenetic, metabolomic, and microbiome data to identify high-risk patients and guide management decisions. - **Multi-Omics Integration:** Combining data from genomics, proteomics, epigenomics, and microbiomics allows for a holistic understanding of disease mechanisms and facilitates precision risk assessment. --- ### **6. Personalized Therapies** The ultimate goal of precision medicine is to tailor therapeutic strategies to the individual patient, considering their unique molecular and clinical profile: - **Targeted Therapies:** Drugs targeting specific molecular pathways involved in IBD-associated CRC are under development. - **Immune Modulation:** Immunotherapies aimed at modulating the inflammatory response may prevent or delay the progression to CRC. - **Chemoprevention:** Strategies such as anti-inflammatory agents and antioxidants are being explored to reduce cancer risk in high-risk individuals. --- ### **7. High-Risk Populations and Special Considerations** Certain IBD patients, such as those with primary sclerosing cholangitis (PSC), have a markedly increased risk of CRC. Precision medicine approaches can help: - Identify these high-risk individuals through molecular profiling. - Implement tailored surveillance and preventive strategies. - Develop therapies targeting the unique molecular features of PSC-associated CRC. --- ### **8. Future Precision Medicine Model** The future of IBD-related CRC management lies in the integration of advanced diagnostics, AI, and personalized therapies. Key elements include: - **Integrated Endoscopy:** High-definition imaging combined with AI and molecular diagnostics to improve detection and characterization of lesions. - **Molecular Diagnostics:** Noninvasive biomarker-based tools for early risk stratification and monitoring. - **Personalized Treatment Plans:** Tailored therapies based on individual molecular and clinical profiles. - **Preventive Strategies:** Proactive interventions to modify risk factors, such as microbiome-targeted therapies and dietary adjustments. --- ### **Conclusion** Precision medicine holds the promise of transforming the management of IBD-associated CRC by enabling early detection, accurate risk stratification, and personalized therapeutic interventions. By integrating molecular diagnostics, advanced endoscopic technologies, AI, and targeted therapies, precision medicine can significantly improve outcomes for patients with IBD, reducing the burden of CRC and enhancing quality of life.

Impact of Adenoma Detection Rate on Prevalent Colorectal Cancer Identification in a National Colonoscopy Registry

The study investigated the impact of adenoma detection rate (ADR), a key quality metric for colonoscopy, on the identification of prevalent colorectal cancer (CRC) during colonoscopy. While ADR is known to inversely correlate with post-colonoscopy CRC, its association with detecting existing CRC at the time of the procedure was less clear. Using data from a large national colonoscopy registry, the researchers analyzed both screening colonoscopies and those conducted after abnormal fecal test results. The primary aim was to assess the relationship between individual endoscopists' ADR and the likelihood of identifying CRC present during the procedure. Secondary analyses examined related quality indicators, such as detection of sessile serrated lesions and advanced precancerous lesions, while considering patient demographics, procedural factors, and endoscopist-specific variables. The findings revealed a strong positive association between higher ADR and increased detection of prevalent CRC in both screening and follow-up colonoscopies. Endoscopists with lower ADRs consistently missed more cancers, regardless of their ability to detect sessile serrated lesions. Detection of advanced precancerous lesions also mirrored ADR patterns, suggesting overlapping skills in identifying adenomas and invasive cancers. The study concluded that many post-colonoscopy CRCs might arise from cancers missed during the initial examination, not just from undetected precursor lesions progressing over time. These results underscore the importance of maintaining high ADRs and enhancing colonoscopy quality improvement initiatives. Improving ADR can lead to better recognition of early-stage cancers and subtle neoplastic lesions, ultimately reducing the burden of CRC.

Enfortumab vedotin for gastric and esophageal cancers

Enfortumab vedotin (EV), a Nectin-4–directed antibody–drug conjugate, has been evaluated for its antitumor activity and safety in patients with heavily pretreated gastric and esophageal cancers through the EV-202 study, a phase II, open-label, multicenter trial. Below is a detailed summary of the findings regarding its use in this context: ### Study Design & Patient Population - **Objective:** The study aimed to assess the efficacy and safety of EV in patients with advanced or metastatic gastroesophageal adenocarcinoma (GEA) and esophageal squamous cell carcinoma (ESCC) who had previously undergone platinum-based chemotherapy and immune checkpoint inhibitors. - **Dosing Regimen:** Patients received EV intravenously at a dose of 1.25 mg/kg on days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity. ### Primary and Secondary Endpoints - **Primary Endpoint:** The objective response rate (ORR) was evaluated per RECIST v1.1. - **Secondary Endpoints:** These included duration of response (DOR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety. ### Key Findings #### 1. **Efficacy Results** - **Gastroesophageal Adenocarcinoma (GEA) Cohort:** - ORR: 9.5% (4 out of 42 patients responded to treatment). - DCR: 47.6%. - Median DOR: 10.3 months. - Median PFS: 3.1 months. - Median OS: 8.3 months. - Predefined efficacy threshold (≥17.5% ORR) was **not met** in this cohort. - **Esophageal Squamous Cell Carcinoma (ESCC) Cohort:** - ORR: 18.2% (8 out of 44 patients responded to treatment). - DCR: 45.5%. - Median DOR: 3.9 months. - Median PFS: 2.1 months. - Median OS: 7.4 months. - Predefined efficacy threshold (≥17.5% ORR) was **met** in this cohort, indicating promising antitumor activity. #### 2. **Nectin-4 Expression** - High expression of Nectin-4, the target of EV, was observed in the majority of patients (93.9% in GEA and 97.6% in ESCC). - However, no clear correlation was identified between Nectin-4 expression levels and treatment response. #### 3. **Safety Profile** - Treatment-related adverse events (AEs) were common, occurring in 85.7% of GEA patients and 95.5% of ESCC patients. - Most AEs were manageable, with commonly reported mild AEs including pruritus, alopecia, dysgeusia, rash maculopapular, fatigue, and diarrhea. - Severe AEs (Grade ≥3) were reported in approximately 28% of patients in both cohorts, including rash, hyperglycemia, and neutropenia. - No treatment-related deaths were observed. - Dose interruptions (~33%) and reductions (~25%) were required in some patients to manage toxicity. #### 4. **Response Timing** - Median time to partial response was 1.7–1.8 months, suggesting early measurable effects in responders. #### 5. **Comparison with Other Treatments** - The ORR observed with EV (9.5% in GEA, 18.2% in ESCC) was modestly higher than that reported with anlotinib monotherapy (8.4%), demonstrating EV's activity even in heavily pretreated populations. #### 6. **Quality of Life** - Quality-of-life assessments (EQ-5D-5L and pain evaluations) indicated stable or slightly improved quality of life during EV treatment. ### Clinical Implications - **For ESCC:** EV demonstrated moderate efficacy and manageable safety, meeting the threshold for antitumor activity. This suggests that EV could serve as a potential salvage therapy for ESCC patients who have failed prior chemotherapy and immunotherapy. These results support further investigation of EV, particularly in combination regimens. - **For GEA:** The efficacy of EV in GEA was limited, as the predefined threshold for efficacy was not met. This indicates that EV may have less clinical relevance in this subgroup. ### Conclusion Enfortumab vedotin showed manageable safety and moderate efficacy in patients with heavily pretreated gastric and esophageal cancers. While its clinical relevance was limited in gastroesophageal adenocarcinoma, it demonstrated promising activity in esophageal squamous cell carcinoma, warranting further exploration, particularly in combination with other therapies.

VEGF bispecific fast lane

The term "VEGF bispecific fast lane" refers to the accelerated development and competitive landscape surrounding VEGF bispecific antibodies in oncology, particularly in the context of Pfizer's strategic initiatives and the broader industry trends. Here's a detailed breakdown of the concept: ### 1. **What is VEGF Bispecific Therapy?** VEGF bispecific antibodies are a class of immunotherapies that target two pathways simultaneously: - **PD-(L)1 blockade**: Enhancing immune activation by inhibiting the PD-(L)1 pathway, which tumors exploit to evade immune system attacks. - **VEGF inhibition**: Normalizing tumor vasculature and disrupting the blood supply tumors need to grow, leveraging anti-angiogenesis mechanisms. This dual-action approach has shown promise in preclinical and early clinical trials, offering a synergistic effect that could surpass the efficacy of single-pathway inhibitors like Keytruda (pembrolizumab). ### 2. **Why is it a "Fast Lane"?** The term "fast lane" reflects the urgency and rapid progress in developing VEGF bispecific therapies due to their potential to revolutionize cancer treatment. Key factors contributing to the fast lane include: #### a. **Intense Competition Among Global Players** - Pfizer's PF-08634404 is entering pivotal phase 3 trials for **non-small cell lung cancer (NSCLC)** and **colorectal cancer (CRC)**, directly competing with other VEGF bispecific candidates like: - **Ivonescimab** (Summit/Akeso): Already in phase 3 trials for NSCLC and CRC. - **Pumitamig** (BioNTech/Bristol Myers Squibb): Set to begin phase 3 trials in 2026. - The competition is fierce, with companies racing to achieve regulatory approval and market dominance in this emerging class. #### b. **High Confidence in the Molecule** - Pfizer is launching fully-fledged phase 3 trials for PF-08634404 from the outset, skipping adaptive phase 2/3 designs used by competitors. This signals strong confidence in the molecule's efficacy and safety profile, based on preliminary phase 2 data. #### c. **Strategic Timing** - Pfizer's first trial readouts are expected in late 2026 to early 2027, aligning with competitor milestones (e.g., Akeso's Harmoni-3 results in H2 2026 and H1 2027). This timing positions Pfizer to compete directly in the fast-evolving market. #### d. **Innovative Mechanistic Rationale** - The combination of PD-(L)1 and VEGF blockade represents the next major evolution in immuno-oncology, following checkpoint inhibitors. This innovative approach is driving rapid investment and trial launches. ### 3. **Pfizer’s Position in the Fast Lane** Pfizer has made significant moves to secure its position in the VEGF bispecific fast lane: - **$1.25 Billion Investment**: Pfizer licensed PF-08634404 (originally SSGJ-707) from China's 3SBio in May 2025, underscoring its commitment to oncology innovation as COVID-19 revenues decline. - **Global Phase 3 Trials**: - NSCLC: PF-08634404 + chemotherapy vs. Keytruda + chemotherapy, split by histology (squamous vs. non-squamous). - CRC: PF-08634404 vs. Avastin + chemotherapy in microsatellite-stable (MSS), non–BRAF-mutant patients—a challenging subgroup with low immunotherapy response rates. - **Mechanistic Validation**: Preclinical studies and early clinical data have shown strong anti-tumor activity and synergy between PD-(L)1 and VEGF blockade, although toxicity concerns remain. ### 4. **Challenges and Opportunities** #### Challenges: - **Toxicity Concerns**: Early phase 2 data from 3SBio highlighted potential safety issues, which will need to be addressed in phase 3 trials. - **Competitive Pressure**: Pfizer faces direct competition from Akeso, BioNTech/Bristol Myers Squibb, and other Asian biotech pioneers who have led the innovation in bispecific immuno-oncology. #### Opportunities: - **Market Impact**: Success in phase 3 trials could establish Pfizer as a top-tier player in bispecific immunotherapy, rivaling Merck's Keytruda dominance in lung and colorectal cancer markets. - **Innovation Leadership**: By advancing PF-08634404, Pfizer aims to close the innovation gap and position itself as a leader in the next generation of cancer treatments. ### 5. **Industry Context** VEGF bispecifics are considered the next frontier in oncology, combining immune activation and anti-angiogenesis to tackle difficult-to-treat cancers like MSS colorectal cancer and squamous NSCLC. The "fast lane" refers not only to the speed of development but also to the high stakes and intense competition among pharmaceutical giants and biotech innovators. ### 6. **Future Outlook** The success of VEGF bispecific therapies, including PF-08634404, will depend on: - Phase 3 trial outcomes (expected late 2026 to early 2027 for Pfizer). - Regulatory approval timelines. - Commercial adoption and market penetration. - Long-term safety and efficacy data. In summary, the VEGF bispecific fast lane represents a high-stakes race in oncology innovation, with Pfizer, Akeso, BioNTech/Bristol Myers Squibb, and others vying to lead the next wave of cancer treatment advancements.

Radiofrequency ablation for malignant biliary obstruction

Radiofrequency ablation (RFA) is a minimally invasive procedure that uses heat generated by high-frequency electrical currents to destroy abnormal or malignant tissue. In the context of malignant biliary obstruction (MBO), which occurs when cancer blocks the bile ducts and prevents bile from flowing properly, RFA has been studied as a potential adjunct therapy to biliary stenting. Biliary stenting is the standard treatment for MBO, as it helps restore bile flow and alleviate symptoms like jaundice and digestive issues. However, stents can become clogged over time due to tumor growth or bile sludge. Researchers have explored whether adding RFA to stenting could improve outcomes for patients with MBO. ### Role of RFA in Malignant Biliary Obstruction: 1. **Tumor Control**: RFA may help destroy malignant tissue within or near the bile ducts. This can potentially slow tumor progression, providing a local or systemic benefit that could improve survival outcomes. 2. **Survival Benefit**: Studies have shown that adding RFA to biliary stenting may improve short-term survival, particularly in patients with cholangiocarcinoma (a type of bile duct cancer). This suggests that RFA might offer some therapeutic advantage beyond simply relieving bile duct obstruction. 3. **Stent Patency**: Despite its tumor-destroying capabilities, RFA does not seem to prolong the functional lifespan of biliary stents. Stents still tend to clog or fail at similar rates whether RFA is used or not. 4. **Safety Considerations**: While RFA may offer survival benefits, it also comes with risks. One notable concern is an increased incidence of cholecystitis (inflammation of the gallbladder) in patients who undergo RFA. This highlights the importance of careful patient selection and close monitoring during and after the procedure. ### Summary: RFA is not a solution for improving stent functionality, but it may enhance survival in patients with malignant biliary obstruction, particularly those with cholangiocarcinoma. Its role appears to focus more on controlling tumor growth rather than directly addressing stent patency. However, its use requires caution due to potential complications like cholecystitis, emphasizing the need for individualized treatment planning.

Big Bang Moment

The "Big Bang" moment, as described in the context of bowel cancer research, refers to a defining early event in the development of the cancer that determines how the tumor will grow and interact with the immune system throughout its life. This moment is pivotal because it sets the stage for the tumor's characteristics and its ability to evade immune detection. Here’s a detailed breakdown of what happens during this "Big Bang" moment: 1. **Immune Escape**: At this early stage, cancer cells develop mechanisms to hide from the immune system. They disrupt genes that are essential for immune detection, preventing the immune system from recognizing and attacking the tumor. This immune evasion allows the cancer to grow unchecked. 2. **Reduction in Neoantigens**: Neoantigens are specific proteins on the surface of cancer cells that act as "red flags" for the immune system. During the "Big Bang," bowel cancer cells reduce the number of neoantigens displayed on their surface. With fewer neoantigens, the immune system struggles to identify the tumor as a threat. 3. **Epigenetic Changes**: The study revealed that epigenetic modifications—chemical changes that alter how DNA is read—play a significant role in this process. These changes contribute to the reduction of neoantigens and the immune escape mechanism. 4. **Long-Term Impact**: Once this immune escape occurs during the "Big Bang," the tumor’s interaction with the immune system remains largely consistent as it grows. This explains why many bowel cancers are resistant to immunotherapy, which relies on the immune system to attack the tumor. ### Implications of the "Big Bang" Moment: - **Resistance to Immunotherapy**: Since the immune escape happens early and remains stable, only about 15% of bowel cancers respond well to immunotherapy treatments. Most tumors remain hidden from immune cells due to the lack of neoantigens. - **Potential Treatment Strategies**: The research suggests that combining immunotherapy with drugs that modify epigenetics could help reverse the immune escape. By increasing neoantigen production, these drugs could make tumors visible again to the immune system, potentially improving the effectiveness of immunotherapy and vaccines for a larger group of patients. - **Personalized Medicine**: Understanding this "Big Bang" moment provides insights into the early stages of tumor development, enabling researchers to design more personalized treatments that target immune evasion before the cancer progresses. In summary, the "Big Bang" moment is a critical early event in bowel cancer development where the tumor gains the ability to evade immune detection, shaping its growth and resistance to treatments throughout its life. This discovery opens new avenues for therapeutic strategies aimed at reversing immune escape and improving outcomes for patients.

FDA grant Fast Track Designation to a new drug combination for metastatic CRC

Yes, the FDA has granted Fast Track Designation to a new drug combination for metastatic colorectal cancer (CRC). This combination includes **alnodesertib** (an ATR inhibitor) and **low-dose irinotecan**. The designation was given due to the promising results observed in patients with metastatic CRC whose tumors lack the **ATM DNA-repair protein**. The mechanism behind this drug combo is particularly innovative. Irinotecan works by damaging the DNA of cancer cells, while alnodesertib blocks the cancer cells' ability to repair that damage. Tumors that are **ATM-deficient** already have compromised DNA repair systems, making this dual approach especially effective. In clinical trials, many patients with ATM-deficient tumors experienced meaningful tumor shrinkage, offering hope to a group of patients who previously had limited treatment options. The Fast Track Designation is significant because it aims to accelerate the development, review, and availability of therapies that address unmet medical needs, particularly in high-need patient populations. This designation will help expedite the process of bringing this potentially transformative therapy to patients battling metastatic CRC.

Bemarituzumab in First-Line Gastric Cancer — FORTITUDE Trials

Bemarituzumab is a first-in-class monoclonal antibody that targets FGFR2b (fibroblast growth factor receptor 2b), a key driver in a subset of gastric cancers characterized by FGFR2b overexpression. The FORTITUDE clinical trial program explores the efficacy and safety of bemarituzumab in various settings, primarily focusing on its use in first-line treatment for gastric cancer. Below is a detailed breakdown of the FORTITUDE trials relevant to first-line gastric cancer: --- ### **1. FORTITUDE-101:** - **Objective:** Evaluated the combination of bemarituzumab with chemotherapy (mFOLFOX6) versus chemotherapy plus placebo in patients with FGFR2b-positive gastric cancer. - **Results:** - Bemarituzumab plus chemotherapy significantly **improved overall survival (OS)** compared to chemotherapy alone. - **Median OS:** - Bemarituzumab + mFOLFOX6: **17.9 months** - Placebo + mFOLFOX6: **12.5 months** - **Hazard Ratio (HR):** 0.61 (indicating a 39% reduction in the risk of death). - **Statistical Significance:** p = 0.005. - This trial demonstrates the potential benefit of bemarituzumab in improving survival for patients with FGFR2b-positive gastric cancer. --- ### **2. FORTITUDE-102:** - **Objective:** A Phase 1b/3 study designed to evaluate bemarituzumab in combination with chemotherapy and nivolumab versus chemotherapy and nivolumab alone in FGFR2b-positive first-line gastric cancer. - **Status:** This trial was **stopped**. The specific reasons for discontinuation are not provided in the context, but it is common for trials to be stopped due to various factors, including safety concerns, lack of efficacy, or strategic decisions. --- ### **3. FORTITUDE-103:** - **Objective:** A Phase 1b/2 study investigating bemarituzumab in combination with or without nivolumab across different oral chemotherapy regimens for first-line gastric cancer patients. - **Update:** The trial has successfully **completed patient enrollment**, indicating that the study is progressing as planned. Results from this study will provide further insights into the potential of bemarituzumab in combination with different therapeutic approaches. --- ### **Broader Development – FORTITUDE-30:** - While not limited to gastric cancer, the Phase 1b/2 **FORTITUDE-30 basket study** is exploring bemarituzumab as a monotherapy in patients with solid tumors that overexpress FGFR2b. This study could expand the use of bemarituzumab beyond gastric cancer to other FGFR2b-driven malignancies. --- ### **Conclusion:** The FORTITUDE clinical trial program underscores the promise of bemarituzumab as a targeted therapy for FGFR2b-positive gastric cancer, particularly in the first-line setting. The positive results from FORTITUDE-101 highlight its potential to improve overall survival when combined with chemotherapy. The ongoing FORTITUDE-103 study and the broader FORTITUDE-30 basket trial may further solidify bemarituzumab's role in treating FGFR2b-overexpressing tumors, while the discontinuation of FORTITUDE-102 highlights the challenges of combining multiple therapies. Future results from these studies will be crucial to defining bemarituzumab's place in the treatment landscape for gastric cancer and potentially other cancers.

Intratumoral heterogeneity and immunotherapy resistance

Intratumoral heterogeneity (ITH) plays a critical role in immunotherapy resistance, significantly influencing the success or failure of immune checkpoint inhibitor therapies. ITH refers to the genetic, epigenetic, and phenotypic diversity observed within individual tumors and across metastatic sites. This heterogeneity enables tumors to adapt to selective pressures exerted by the immune system and therapeutic interventions, creating challenges for achieving durable responses with immunotherapy. ### Key Factors Linking ITH to Immunotherapy Resistance 1. **Intrinsic ("Hardware") Mechanisms**: - **Genetic Diversity**: Tumors often contain subclonal populations with distinct genetic mutations. These mutations may confer resistance to immune checkpoint inhibitors by altering the expression of antigens or immune-related pathways, such as major histocompatibility complex (MHC) molecules, interferon signaling, or immune checkpoints like PD-L1. - **Epigenetic Modifications**: Epigenetic changes, such as DNA methylation or histone modifications, can regulate immune-related gene expression, leading to immune evasion. For example, silencing of tumor antigens or genes involved in immune recognition can reduce the effectiveness of immunotherapy. 2. **Extrinsic ("Software") Mechanisms**: - **Tumor Microenvironment (TME)**: The TME is composed of immune cells, stromal cells, and secreted factors that can vary significantly within different regions of the tumor. Certain areas may be immunosuppressive, with high levels of regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), or immunosuppressive cytokines like TGF-β and IL-10, shielding tumor cells from immune attack. - **Immune Editing**: Tumor cells and immune cells are engaged in a dynamic coevolution process, where immune pressure selects for tumor variants that are less immunogenic or better equipped to evade immune detection. This process results in the survival of resistant clones within the tumor. ### Mechanisms of Resistance Driven by ITH - **Innate Resistance**: Some tumor cells are inherently resistant to immunotherapy due to their genetic or epigenetic makeup. For example, tumors with low mutational burden or defective antigen presentation machinery may fail to elicit a robust immune response. - **Acquired Resistance**: Tumor cells can adapt to immunotherapy over time, often through mechanisms like upregulation of immune checkpoints (e.g., PD-L1), loss of tumor antigens, or recruitment of immunosuppressive cells to the TME. ### Therapeutic Implications of ITH in Immunotherapy Given the role of ITH in driving resistance, personalized therapeutic strategies are essential to improve immunotherapy outcomes. Key approaches include: 1. **ITH Profiling**: - Comprehensive analysis of tumor heterogeneity, using techniques like single-cell sequencing, spatial transcriptomics, and multi-region sampling, can identify specific subclonal populations and resistance mechanisms. - Biomarker-driven approaches can help predict which patients are likely to respond to specific immunotherapies. 2. **Combination Immunotherapy**: - Combining immune checkpoint inhibitors with other treatments, such as targeted therapies, chemotherapy, or radiation, may help address different resistance mechanisms simultaneously. - Pairing immunotherapy with agents that modulate the TME, such as inhibitors of Tregs, MDSCs, or TGF-β, may improve immune infiltration and efficacy. 3. **Targeting Tumor Evolution**: - Therapies aimed at preventing or reversing immune editing, such as adoptive cell therapies (e.g., TILs or CAR-T cells), can target resistant tumor clones directly. - Epigenetic therapies that restore antigen expression or enhance immune recognition may counteract immune evasion. 4. **Novel Immune Targets**: - Exploring immune checkpoints beyond PD-1/PD-L1, such as LAG-3, TIM-3, TIGIT, or VISTA, may provide alternative pathways to overcome resistance. - Vaccines targeting neoantigens derived from tumor-specific mutations could enhance immune responses against heterogeneous tumors. ### Conclusion Intratumoral heterogeneity represents a formidable barrier to effective immunotherapy, as it allows tumors to adapt and evade immune surveillance. Understanding the interplay between ITH and immunotherapy resistance through advanced profiling techniques and molecular analyses is critical for developing personalized and combinatorial treatment strategies. By addressing the diverse mechanisms of resistance driven by ITH, the next generation of immunotherapies has the potential to achieve more durable and complete responses in cancer patients.

Surveillance for Esophageal Cancer from SANO Trial

Surveillance for esophageal cancer, particularly in the context of patients treated with neoadjuvant chemoradiotherapy (nCRT), is a critical area of research and clinical practice. Active surveillance is an approach where patients are closely monitored after nCRT instead of proceeding directly to surgery. This strategy has been shown to be non-inferior to immediate surgery for select patients, but it comes with challenges, especially in identifying which patients are suitable for this approach. The SANO trial analyzed 750 esophageal or junctional cancer patients treated with the CROSS regimen of nCRT. It found that only 37% achieved a complete clinical response (CCR) 12 weeks after treatment, and of those who entered active surveillance (198 patients), only 25% maintained sustained CCR over a median follow-up of 54 months. This highlights the limited success of achieving and maintaining full remission with active surveillance. Key findings from the study include: - Patients with higher clinical nodal categories (cN2–3) had lower odds of achieving CCR and a twofold higher risk of recurrence, making them less suitable for active surveillance. - Tumor histology influenced outcomes, with squamous cell carcinoma showing better distant progression-free survival compared to adenocarcinoma. - Standard clinical factors like age, sex, tumor differentiation, and tumor size were not reliable predictors of CCR or sustained CCR. - Current diagnostic tools, such as PET-CT and endoscopic ultrasound, have limited accuracy in detecting residual disease. The study underscores the need for advanced biomarkers, such as radiomics, circulating tumor DNA (ctDNA), and FAPI PET-CT, to improve the prediction of treatment response and guide decisions about active surveillance versus surgery. This approach could help optimize treatment strategies and reduce unnecessary delays for high-risk patients.

Pembrolizumab in microsatellite-stable CRC

### Explanation of Key Terms: #### **Microsatellite-Stable (MSS) Colorectal Cancer (CRC):** Microsatellite stability refers to the genetic stability of certain DNA sequences called microsatellites, which are short, repetitive sequences scattered throughout the genome. In microsatellite-stable (MSS) colorectal cancer (CRC), these sequences remain intact, indicating that the tumor lacks defects in the mismatch repair (MMR) system. MSS tumors are characterized by low levels of mutations and are typically less responsive to immunotherapy compared to microsatellite instability-high (MSI-H) tumors, which have defective MMR and high mutation rates. #### **Tumor Mutational Burden-High (TMB-H):** Tumor mutational burden (TMB) measures the number of mutations per megabase (mut/Mb) of DNA within a tumor genome. TMB-H refers to tumors with a high mutation load, often defined as ≥10 mutations per megabase. High TMB is thought to generate more neoantigens, making tumors potentially more recognizable to the immune system. In certain cancers, TMB-H predicts better responses to immune checkpoint inhibitors (ICIs) like pembrolizumab. However, in MSS CRC, high TMB alone does not reliably predict immunotherapy efficacy. #### **Metastatic Colorectal Cancer (mCRC):** Metastatic colorectal cancer (mCRC) is an advanced stage of CRC where cancer has spread from the colon or rectum to other parts of the body, such as the liver, lungs, or lymph nodes. Treatment for mCRC often includes chemotherapy, targeted therapy, and, in some cases, immunotherapy depending on the tumor's genetic profile. #### **Pembrolizumab:** Pembrolizumab is an immune checkpoint inhibitor targeting the PD-1 receptor on T-cells. By blocking PD-1, pembrolizumab prevents cancer cells from evading immune detection, allowing the immune system to attack the tumor. It is FDA-approved for various cancers, including MSI-H CRC, but its effectiveness in MSS CRC is limited due to the immune-resistant nature of these tumors. --- ### **Summary of the Study:** This study focused on evaluating the real-world efficacy of pembrolizumab in patients with **microsatellite-stable (MSS), tumor mutational burden-high (TMB-H) metastatic colorectal cancer (mCRC)**. The researchers used data from Japan’s national C-CAT genomic database, which included 127 patients with TMB-H mCRC treated with pembrolizumab. Of these, 77 had MSS tumors, and 50 had MSI-H tumors. #### **Key Findings:** 1. **Poor Outcomes in MSS-TMB-H Subgroup:** - Patients with MSS-TMB-H mCRC had significantly worse outcomes compared to MSI-H-TMB-H patients. - Median overall survival (OS) for MSS-TMB-H was **4.5 months**, whereas MSI-H-TMB-H patients had a median OS of **33.6 months**. - Median time to treatment failure (TTF) was **2.0 months** for MSS-TMB-H versus **10.6 months** for MSI-H-TMB-H. 2. **Comparative Efficacy:** - Pembrolizumab demonstrated **shorter overall survival (OS)** and **time to treatment failure (TTF)** compared to standard later-line treatments like **trifluridine/tipiracil (FTD/TPI)** ± bevacizumab and regorafenib. - For MSS-TMB-H patients, pembrolizumab showed no survival advantage over regorafenib and performed worse than FTD/TPI ± bevacizumab. 3. **Limited Predictive Power of TMB:** - High TMB alone (≥10 muts/Mb) was not a reliable predictor of pembrolizumab response in MSS tumors. - MSI status was a stronger determinant of benefit, highlighting the importance of combining MSI and TMB profiling in treatment decisions. 4. **Genomic Insights:** - MSS-TMB-H tumors resembled MSS-TMB-L tumors genomically, explaining their poor response to pembrolizumab despite high TMB. - MSS-TMB-H CRCs were found to be "immune cold," with low T-cell infiltration and reduced immune activation. 5. **Rare Exceptions:** - Rare MSS-TMB-H cases with pathogenic **POLE mutations** (hypermutated subtype) showed exceptionally high TMB (>100 muts/Mb) and better outcomes with pembrolizumab. 6. **Predictive Biomarkers:** - Amplifications in **BCL2L1** and **SRC** (Chr20q11 region) correlated with longer progression-free survival (PFS) and overall survival (OS) under pembrolizumab treatment, suggesting these may serve as prognostic markers. --- ### **Clinical Implications:** 1. **Pembrolizumab Limitations:** - Pembrolizumab should **not be considered a standard later-line therapy** for MSS-TMB-H mCRC due to minimal efficacy in this subgroup. - MSI status remains the key biomarker for pembrolizumab eligibility. 2. **Alternative Therapies:** - Standard treatments like **FTD/TPI ± bevacizumab** and **regorafenib** demonstrated better survival outcomes in MSS-TMB-H mCRC and should remain the preferred options for later-line therapy. 3. **Biomarker Refinement:** - The study emphasizes the need for **refined biomarker-based therapy approvals**, recommending combined MSI and TMB profiling to guide immunotherapy decisions. 4. **Research Direction:** - Future studies should explore alternative strategies for treating MSS-TMB-H mCRC, including therapies targeting the tumor microenvironment or novel combinations of immunotherapy and other modalities. --- ### **Core Conclusion:** Pembrolizumab demonstrates **limited efficacy** in MSS-TMB-H metastatic colorectal cancer due to genomic and immunologic similarities to MSS-TMB-L disease, which is inherently resistant to immune checkpoint inhibitors. The study underscores the importance of alternative, non-immunotherapy strategies for this subgroup and highlights the need for improved biomarker-based treatment approaches.

Immunogenomics of Cholangiocarcinoma

The immunogenomics of cholangiocarcinoma (CCA) is a rapidly evolving field that explores the interplay between genetic and non-genetic alterations in tumor cells and immune cells, and their impact on antitumor immunity, tumor progression, and response to therapy. Below is a detailed overview of key aspects related to immunogenomics in CCA: ### 1. **Understanding Immunogenomics in CCA** - **Definition**: Immunogenomics investigates how mutations, chromosomal instability (CIN), and epigenetic changes in tumor cells or immune cells shape the immune microenvironment and influence the immune system's ability to recognize and attack tumors. - **Relevance**: In CCA, this approach is critical due to its highly heterogeneous nature, with distinct genetic profiles and immune landscapes in different anatomical subtypes (intrahepatic CCA [iCCA] and extrahepatic CCA [eCCA]). ### 2. **Genomic Alterations Influencing Immunity** - **Tumor Mutational Burden (TMB)**: High TMB is associated with increased production of neoantigens, which can enhance immune recognition. However, TMB is generally low in CCA, limiting its immunogenic potential. - **Microsatellite Instability-High (MSI-H) and DNA Mismatch Repair Deficiency (dMMR)**: These features are strong predictors of immune responsiveness in cancers. In CCA, MSI-H occurs in only 1–5% of cases, but when present, it can make tumors more susceptible to immunotherapies like immune checkpoint inhibitors. - **Chromosomal Instability (CIN)**: CIN activates the cGAS–STING pathway, leading to inflammation and the creation of a tumor-supportive microenvironment. This is mediated by IL-6, which promotes immune suppression and tumor progression. ### 3. **Driver Mutations and Neoantigens** - **Key Mutations**: Common oncogenic drivers in CCA include IDH1/2, FGFR2, KRAS, TP53, BAP1, and ARID1A. These mutations influence tumor biology and immune evasion differently across iCCA and eCCA subtypes. - **Stable Neoantigens**: Certain mutations, such as KRAS^G12D^, produce stable neoantigens that are less prone to immune editing, making them promising targets for immunotherapies like vaccines or engineered T cells. - **Alternative Neoantigens**: Aberrant expression of olfactory receptors or altered mucin glycosylation patterns can generate non-mutational neoantigens, which may be leveraged for personalized vaccine or CAR-T cell therapies. ### 4. **Immune Microenvironment in CCA** - **Immune Subtypes**: CCA can be classified into three immune microenvironment subtypes: - **Immune Desert**: Characterized by low immune cell infiltration, leading to poor immunotherapy response. - **Immune Excluded**: Immune cells are present but excluded from the tumor core, limiting their antitumor activity. - **Inflamed**: High immune cell infiltration, often associated with better immunotherapy response but also immune suppression due to chronic inflammation. - **T Cell Dysfunction**: Chronic antigen exposure or infection leads to T cell exhaustion, reducing their ability to fight tumors. This is particularly evident in KRAS-mutant inflammatory iCCA. - **Cytokine Crosstalk**: Tumor-associated macrophages (TAMs) release cytokines like IL-10 and TGF-β, promoting epithelial–mesenchymal transition (EMT), immune suppression, and tumor progression. ### 5. **BRCA Mutations and Immunogenicity** - **BRCA1/2 Alterations**: These mutations are rare in CCA (~3.6%) but increase DNA damage and inflammatory signaling. They are associated with higher TMB and enhanced immunogenic potential, making BRCA-mutant tumors more likely to respond to immune-based therapies. ### 6. **Immune Checkpoints and Therapeutic Targets** - **Checkpoint Overexpression**: Immune checkpoints such as PD-1, CTLA-4, and GITR are often overexpressed in tumor-infiltrating lymphocytes in CCA, making them key targets for immune checkpoint blockade therapies. - **Combination Therapies**: Combining immune checkpoint inhibitors (e.g., anti–PD-1/PD-L1) with IL-6R or VEGFR inhibitors shows promise in enhancing immune responses by targeting multiple steps in the cancer-immunity cycle. ### 7. **Emerging Immunotherapeutic Strategies** - **Personalized Vaccines**: A case study demonstrated long-term remission in metastatic iCCA using a personalized peptide vaccine targeting expressed, non-mutated tumor peptides. - **Adoptive Cell Therapies**: CAR-T cells and TCR-engineered T cells targeting tumor-specific or non-genetic antigens are being developed as strategies for resistant CCA subtypes. - **Alternative Targets**: Aberrant mucin glycosylation and olfactory receptor expression may provide novel targets for vaccine or CAR-T development. ### 8. **Challenges in Immunogenomic Research** - **Modeling Immune Evolution**: Studying immune dynamics in vivo is challenging due to species differences and the complexity of immune subpopulations. - **Integration of Human Data**: Leveraging ex vivo human data is crucial to better understand immune evolution and improve therapeutic strategies. ### 9. **Clinical Implications** - **Patient Stratification**: Immune-based stratification is expected to become a standard approach in CCA management, enabling tailored immunotherapeutic interventions based on genomic and immune profiles. - **Future Directions**: Combining immunogenomics with genomic-guided therapies holds promise for improving survival outcomes in CCA patients. ### Conclusion The immunogenomics of cholangiocarcinoma highlights the complex interplay between tumor genetics, immune microenvironment, and therapeutic response. By understanding these interactions, researchers and clinicians can develop more effective, personalized immunotherapies that address the unique challenges posed by this heterogeneous cancer type.

Lenvatinib Disappoints in Metastatic Esophageal Cancer Trial (LEAP -041)

The LEAP-014 trial investigated the efficacy of adding lenvatinib to pembrolizumab and chemotherapy in patients with metastatic esophageal squamous cell carcinoma (ESCC). Unfortunately, the results were disappointing, as the combination failed to demonstrate any survival benefit or meaningful clinical advantage. Here are the key findings and implications of the trial: ### Trial Outcomes: 1. **No Survival Benefit**: - The addition of lenvatinib did not improve overall survival (OS). The median OS was nearly identical between the two groups: - **Lenvatinib Group**: 17.6 months - **Control Group (Pembrolizumab + Chemotherapy)**: 15.5 months - The difference was statistically non-significant (Hazard Ratio [HR] = 0.92; P = .185). 2. **Progression-Free Survival (PFS) Unchanged**: - The median PFS was also similar between the groups: - **Lenvatinib Group**: 7.2 months - **Control Group**: 6.9 months - Again, the difference was not statistically significant (HR = 0.89; P = .075), confirming no meaningful clinical advantage in delaying disease progression. 3. **Adverse Events Comparable**: - Grade 3 or higher treatment-related adverse events occurred at similar rates: - **Lenvatinib Group**: 81.2% - **Control Group**: 79.1% - Common side effects included decreased neutrophil counts, nausea, diarrhea, and anemia, consistent with the known safety profiles of the drugs. 4. **Trial Halted Early**: - The study was stopped prematurely due to futility. Interim analyses showed it was unlikely that lenvatinib would achieve statistical significance for improving survival outcomes. ### Key Observations: 1. **Lenvatinib's Lack of Efficacy**: - Despite lenvatinib's success in other cancers, such as renal cell carcinoma and endometrial carcinoma, it did not produce similar benefits in metastatic ESCC. This highlights the importance of tailoring therapies to specific cancer types. 2. **Missed Opportunity for Biomarker Analysis**: - The study did not evaluate predictive biomarkers for lenvatinib response, which could have provided valuable insights into patient selection for targeted therapies. Experts believe this omission limits the ability to refine future strategies for ESCC treatment. 3. **Expert Consensus**: - Leading oncologists, including Dr. Jaffer Ajani, concluded that lenvatinib does not currently have a therapeutic role in metastatic esophageal cancer based on the trial results. ### Implications for Esophageal Cancer Treatment: - **No Role for Lenvatinib in ESCC**: The findings indicate that lenvatinib should not be pursued further for metastatic esophageal squamous cell carcinoma. - **Focus on Other Approaches**: Researchers may need to explore alternative combinations or novel therapies, potentially guided by biomarker analyses, to improve outcomes for patients with ESCC. ### Transparency and Funding: - The study was funded by Merck Sharp & Dohme LLC, with investigators disclosing financial associations with the company. This ensures transparency in reporting and highlights the industry's involvement in advancing cancer research. ### Conclusion: The LEAP-014 trial underscores the challenges of extending successful therapies from one cancer type to another. While lenvatinib has shown promise in other malignancies, it failed to deliver survival benefits in metastatic esophageal squamous cell carcinoma. Moving forward, researchers and clinicians must focus on identifying more effective, personalized treatments for this aggressive disease.

Oncology and Molecular Medicine

**Oncology and Molecular Medicine** is a highly specialized and interdisciplinary field of science and medicine that focuses on understanding, diagnosing, and treating cancer at the molecular and cellular level. This field combines the principles of oncology, which deals with the study and treatment of cancer, and molecular medicine, which focuses on understanding diseases at the molecular and genetic levels. Below is a detailed explanation of the key aspects of this domain: --- ## **1. Oncology: The Study of Cancer** Oncology is the branch of medicine dedicated to the prevention, diagnosis, treatment, and research of cancer. Cancer is a complex disease caused by genetic mutations and epigenetic changes that lead to uncontrolled cell growth, invasion of surrounding tissues, and metastasis to distant organs. ### **Key Subfields of Oncology**: 1. **Medical Oncology**: - Focuses on systemic treatments, such as chemotherapy, targeted therapy, immunotherapy, and hormone therapy. - Aims to treat cancer throughout the body by targeting cancer cells wherever they may be. 2. **Surgical Oncology**: - Involves the surgical removal of tumors, affected tissues, and sometimes nearby lymph nodes. - Often combined with other treatments like radiation or chemotherapy. 3. **Radiation Oncology**: - Uses high-energy radiation to kill cancer cells or shrink tumors. - Often used in combination with surgery or chemotherapy. 4. **Pediatric Oncology**: - Focuses on cancers that occur in children, such as leukemia, neuroblastoma, and Wilms tumor. 5. **Preventive Oncology**: - Aims to prevent cancer through lifestyle changes, risk factor management, vaccination (e.g., HPV vaccine), and early detection through screening programs (e.g., mammograms, colonoscopies). --- ## **2. Molecular Medicine: Understanding Cancer at the Molecular Level** Molecular medicine applies molecular biology, genetics, and biotechnology to understand the mechanisms of diseases, including cancer. It has revolutionized oncology by enabling the identification of specific molecular alterations in cancer cells and the development of targeted therapies. ### **Key Concepts in Molecular Medicine**: 1. **Genomics**: - Studies the entire genome to identify mutations, alterations, or variations that drive cancer. - Example: BRCA1 and BRCA2 mutations linked to breast and ovarian cancers. 2. **Transcriptomics**: - Focuses on RNA expression patterns to understand which genes are active or inactive in cancer cells. 3. **Proteomics**: - Examines proteins, their structures, functions, and interactions, as proteins are the functional molecules in cells. - Example: Overexpression of HER2 protein in certain breast cancers. 4. **Epigenomics**: - Studies changes in gene expression caused by mechanisms other than changes in the DNA sequence, such as DNA methylation and histone modifications. 5. **Metabolomics**: - Investigates metabolic changes in cancer cells, such as the Warburg effect, where cancer cells rely on glycolysis for energy even in the presence of oxygen. --- ## **3. Molecular Mechanisms of Cancer** Cancer arises due to a combination of genetic mutations and epigenetic changes. These changes disrupt the normal regulation of cell growth, division, and death. The key players in cancer development include: ### **a. Oncogenes**: - Mutated or overexpressed versions of normal genes (proto-oncogenes) that promote cell growth and division. - Examples: HER2, KRAS, BRAF, MYC. ### **b. Tumor Suppressor Genes**: - Genes that normally act as "brakes" to prevent uncontrolled cell growth. When these genes are inactivated or mutated, cancer can develop. - Examples: TP53 (p53), RB1, BRCA1, BRCA2. ### **c. DNA Repair Genes**: - These genes repair DNA damage. Mutations in these genes lead to genomic instability and increase the risk of cancer. - Examples: MLH1, MSH2 (associated with Lynch syndrome), BRCA1/2. ### **d. Epigenetic Modifications**: - Alterations in DNA methylation, histone modification, and chromatin structure can silence tumor suppressor genes or activate oncogenes. --- ## **4. Molecular Diagnostics in Oncology** The integration of molecular medicine into oncology has led to the development of advanced diagnostic tools, enabling early detection, personalized treatment, and monitoring of cancer progression. ### **Key Molecular Diagnostic Tools**: 1. **Next-Generation Sequencing (NGS)**: - Provides comprehensive genomic profiling of tumors to identify mutations, amplifications, and translocations. - Example: Detecting EGFR mutations in non-small cell lung cancer (NSCLC). 2. **Polymerase Chain Reaction (PCR)**: - Amplifies specific DNA sequences, allowing for the detection of mutations or gene rearrangements. - Example: BCR-ABL fusion gene in chronic myeloid leukemia (CML). 3. **Fluorescence In Situ Hybridization (FISH)**: - Identifies chromosomal abnormalities or gene amplifications. - Example: HER2 amplification in breast cancer. 4. **Immunohistochemistry (IHC)**: - Detects specific protein expression in tumor tissues. - Example: PD-L1 expression for eligibility for immune checkpoint inhibitors. 5. **Liquid Biopsies**: - Non-invasive tests that analyze circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs) in the blood. - Used for early detection, monitoring, and identifying resistance mutations. --- ## **5. Targeted Therapies and Precision Medicine** The advent of molecular medicine has led to the development of targeted therapies, which aim to inhibit specific molecular pathways involved in cancer progression. These therapies are a cornerstone of precision medicine, which tailors treatment to the individual patient based on their tumor's molecular profile. ### **Examples of Targeted Therapies**: 1. **Tyrosine Kinase Inhibitors (TKIs)**: - Block specific enzymes (tyrosine kinases) involved in cell signaling and growth. - Example: Imatinib for BCR-ABL-positive CML, Erlotinib for EGFR-mutant NSCLC. 2. **Monoclonal Antibodies**: - Target specific proteins on cancer cells, either blocking their function or marking them for destruction by the immune system. - Example: Trastuzumab for HER2-positive breast cancer. 3. **Immune Checkpoint Inhibitors**: - Block immune checkpoints (e.g., PD-1/PD-L1, CTLA-4), allowing the immune system to attack cancer cells. - Example: Pembrolizumab for PD-L1-positive cancers. 4. **PARP Inhibitors**: - Target DNA repair enzymes, particularly effective in cancers with BRCA mutations. - Example: Olaparib for BRCA-mutant ovarian and breast cancers. 5. **Angiogenesis Inhibitors**: - Block the formation of new blood vessels (angiogenesis) that tumors need to grow. - Example: Bevacizumab for colorectal and lung cancers. --- ## **6. Emerging Therapies in Molecular Oncology** ### **a. CAR-T Cell Therapy**: - Involves engineering a patient’s T-cells to express chimeric antigen receptors (CARs) that can specifically target and kill cancer cells. - Example: Approved for certain blood cancers like acute lymphoblastic leukemia (ALL). ### **b. Cancer Vaccines**: - Personalized vaccines that stimulate the immune system to target tumor-specific antigens. - Example: Vaccines targeting neoantigens are currently in clinical trials. ### **c. Gene Editing**: - Techniques like CRISPR-Cas9 are being explored to correct genetic mutations or silence oncogenes in cancer cells. ### **d. Epigenetic Therapy**: - Drugs targeting epigenetic changes, such as DNA methyltransferase inhibitors and histone deacetylase inhibitors. - Example: Azacitidine for myelodysplastic syndromes. --- ## **7. Challenges in Oncology and Molecular Medicine** Despite the significant advancements, there are challenges that need to be addressed: 1. **Tumor Heterogeneity**: Tumors often consist of diverse cell populations, making treatment more complex. 2. **Acquired Resistance**: Cancer cells can adapt and develop resistance to therapies, requiring new treatment strategies. 3. **Cost and Accessibility**: Advanced diagnostics and targeted therapies are expensive, limiting their availability to patients in low-resource settings. 4. **Data Overload**: The vast amount of data generated by molecular diagnostic tools requires advanced computational tools for analysis. --- ## **8. Future Directions** The future of oncology and molecular medicine lies in the following areas: 1. **Artificial Intelligence (AI)**: - AI can analyze large-scale genomic data, identify patterns, and predict treatment outcomes. 2. **Combination Therapies**: - Combining immunotherapy, targeted therapy, and other modalities to overcome resistance. 3. **Personalized Medicine**: - Developing treatment plans tailored to individual patients’ genetic and molecular profiles. 4. **Early Detection**: - Identifying novel biomarkers and using non-invasive methods like liquid biopsies for early cancer diagnosis. 5. **Gene-Based Therapies**: - Advances in gene editing and RNA-based therapies to correct genetic mutations or silence cancer-driving genes. --- ### **Conclusion** Oncology and molecular medicine represent a transformative approach to understanding and treating cancer. By unraveling the molecular mechanisms of cancer and leveraging advanced diagnostic tools and targeted therapies, this field has paved the way for personalized and more effective cancer treatments. While challenges like tumor heterogeneity and treatment resistance persist, ongoing research and technological advancements hold great promise for improving cancer care and patient outcomes in the future.

Non-Coding RNA (ncRNA)

Non-Coding RNA (ncRNA) refers to RNA molecules that are transcribed from DNA but do not encode proteins. Unlike messenger RNA (mRNA), which serves as a template for protein synthesis, ncRNAs perform a variety of regulatory, structural, and catalytic roles in the cell. They are essential for numerous biological processes, including gene expression regulation, RNA processing, chromatin remodeling, and maintaining genome stability. Despite their lack of protein-coding ability, ncRNAs have emerged as key players in cellular function and disease mechanisms. --- ### **Types of Non-Coding RNA** Non-coding RNAs are broadly categorized based on their size and function: #### **1. Small Non-Coding RNAs (sncRNAs)**: These are short RNA molecules typically less than 200 nucleotides in length. Key types include: - **MicroRNAs (miRNAs)**: - Length: ~19–25 nucleotides. - Function: Regulate gene expression post-transcriptionally by binding to complementary sequences in the 3' untranslated regions (3' UTRs) of target mRNAs. This results in mRNA degradation or inhibition of translation. - Clinical Importance: miRNAs are involved in cellular processes like differentiation, proliferation, apoptosis, and stress responses. Dysregulation is linked to diseases like cancer (e.g., miR-21 in colorectal and pancreatic cancer), cardiovascular diseases, and neurodegenerative disorders. - **Small interfering RNAs (siRNAs)**: - Length: ~20–25 nucleotides. - Function: Silence gene expression by degrading target mRNA via RNA interference (RNAi). siRNAs are widely used in research and therapeutic applications. - **Piwi-interacting RNAs (piRNAs)**: - Length: ~26–31 nucleotides. - Function: Interact with PIWI proteins to silence transposable elements in germline cells, thereby maintaining genome stability. #### **2. Long Non-Coding RNAs (lncRNAs)**: - Length: More than 200 nucleotides. - Function: Regulate gene expression at transcriptional, post-transcriptional, and epigenetic levels. They can act as scaffolds for protein complexes, decoys for transcription factors, or guides for chromatin-modifying enzymes. - Clinical Importance: LncRNAs are implicated in cancer (e.g., HOTAIR in breast cancer), cardiovascular diseases, and other disorders. They are being explored as potential biomarkers and therapeutic targets. #### **Other Types of ncRNAs**: - **Ribosomal RNA (rRNA)**: Structural and functional components of ribosomes, essential for protein synthesis. - **Transfer RNA (tRNA)**: Transfers amino acids to ribosomes during protein synthesis. - **Small Nuclear RNA (snRNA)**: Involved in RNA splicing as part of the spliceosome. - **Small Nucleolar RNA (snoRNA)**: Guides chemical modifications of rRNA and other RNA molecules. - **Circular RNA (circRNA)**: Covalently closed RNA molecules that can act as miRNA sponges or regulators of gene expression. --- ### **Functions of Non-Coding RNAs** Non-coding RNAs are involved in diverse cellular processes, including: 1. **Regulation of Gene Expression**: - miRNAs and lncRNAs modulate mRNA stability, translation, or chromatin structure. - Example: miR-21 acts as an oncogene in multiple cancers by downregulating tumor suppressor genes. 2. **Chromatin Remodeling and Epigenetic Regulation**: - LncRNAs like **XIST** and **HOTAIR** are involved in histone modification and DNA methylation, regulating gene expression. 3. **RNA Splicing and Processing**: - snRNAs and snoRNAs play essential roles in the splicing of pre-mRNA and chemical modification of rRNA. 4. **Genome Stability**: - piRNAs silence transposable elements in the germline to maintain genomic integrity. 5. **Cellular Signaling**: - Certain ncRNAs act as molecular sponges, binding to signaling molecules or other RNAs to regulate signaling pathways. 6. **Structural Roles**: - rRNAs and snRNAs form the structural framework for ribosomes and spliceosomes, respectively. --- ### **Non-Coding RNAs in Disease** Dysregulated ncRNAs are increasingly recognized as key contributors to various diseases: #### **1. Cancer**: - **miRNAs**: - Oncogenic miRNAs (oncomiRs), such as **miR-21**, promote tumor growth by inhibiting tumor suppressor genes. - Tumor-suppressive miRNAs like **let-7** are often downregulated in cancers, leading to uncontrolled cell proliferation. - **lncRNAs**: - **HOTAIR**: Overexpressed in breast and colorectal cancers; promotes metastasis by altering chromatin structure. - **MALAT1**: Implicated in lung cancer progression. #### **2. Neurological Disorders**: - **miRNAs**: Dysregulated miRNAs (e.g., miR-9, miR-124) are associated with neurodegenerative diseases like Alzheimer's and Parkinson's disease. - **lncRNAs**: Abnormal expression of lncRNAs like **BACE1-AS** has been linked to Alzheimer's disease. #### **3. Cardiovascular Diseases**: - **miRNAs**: miR-126 regulates vascular integrity and angiogenesis, while miR-21 is involved in cardiac hypertrophy and fibrosis. - **lncRNAs**: LncRNA **ANRIL** is associated with atherosclerosis. --- ### **Clinical Applications of Non-Coding RNAs** Non-coding RNAs have significant potential in diagnostics and therapeutics: 1. **Biomarkers**: - Circulating ncRNAs (e.g., miRNAs) in blood, plasma, or other body fluids can serve as non-invasive biomarkers for early diagnosis, prognosis, and treatment monitoring in cancers and other diseases. 2. **Therapeutic Targets**: - **Antisense Oligonucleotides (ASOs)**: Synthetic oligonucleotides designed to inhibit specific ncRNAs are being developed for therapeutic purposes. For example, **miR-122 inhibitors** are being explored for hepatitis C virus (HCV) treatment. - **miRNA Mimics**: Synthetic miRNAs can restore the function of tumor-suppressive miRNAs. 3. **Gene Editing**: - CRISPR/Cas9 technology is being used to target ncRNAs involved in disease processes, offering potential for gene therapy. 4. **Drug Resistance**: - ncRNAs play a role in mediating resistance to chemotherapy and targeted therapies. For instance, certain miRNAs can modulate the expression of drug transporters or apoptosis-related proteins. --- ### **Take-Home Points** - Non-coding RNAs are crucial for regulating gene expression, chromatin remodeling, RNA processing, and maintaining genome stability. - There are various types of ncRNAs, including **miRNAs**, **lncRNAs**, **siRNAs**, **piRNAs**, **rRNAs**, **tRNAs**, **snRNAs**, **snoRNAs**, and **circRNAs**. - Dysregulation of ncRNAs is linked to diverse diseases, including cancer, neurodegenerative disorders, cardiovascular diseases, and autoimmune conditions. - ncRNAs are promising **biomarkers** for disease detection and prognosis, as well as potential **therapeutic targets** in precision medicine. - Research into ncRNAs is revolutionizing our understanding of gene regulation and disease mechanisms, paving the way for innovative diagnostics and treatments.

Oncogenes: Definition, Mechanism, and Clinical Relevance

### **Oncogenes: Definition, Mechanism, and Clinical Relevance** --- ### **Definition**: Oncogenes are mutated or abnormally expressed versions of normal cellular genes known as *proto-oncogenes*. Proto-oncogenes encode proteins that regulate essential cellular processes such as growth, proliferation, differentiation, and survival. These genes are vital for maintaining normal cellular function. However, when proto-oncogenes undergo mutations, amplifications, or chromosomal rearrangements, they transform into oncogenes, which promote uncontrolled cellular proliferation and tumor formation. Oncogenes are critical drivers in the development of cancer. --- ### **Mechanism of Action** 1. **Proto-oncogene Activation**: Proto-oncogenes can be converted into oncogenes through the following mechanisms: - **Point Mutations**: A single base change in the DNA sequence can activate proto-oncogenes. For example: - Mutations in the **KRAS** gene, particularly at codons 12, 13, or 61, lead to a constitutively active protein that drives uncontrolled cell division. This is commonly seen in colorectal, pancreatic, and lung cancers. - **Gene Amplification**: An increase in the number of copies of a proto-oncogene results in overproduction of its protein product. For instance: - Amplification of the **HER2/ERBB2** gene in breast and gastric cancers leads to excessive signaling for cell growth. - **Chromosomal Translocations**: Rearrangements of chromosomes can fuse a proto-oncogene with another gene, creating a hybrid protein with oncogenic properties. For example: - The **BCR-ABL** translocation (Philadelphia chromosome) in chronic myeloid leukemia (CML) produces a constitutively active tyrosine kinase. - **Insertional Mutagenesis**: Viral integration near a proto-oncogene can lead to its overexpression, resulting in excessive production of oncogenic proteins. 2. **Function of Oncogenes in Tumorigenesis**: Oncogenes encode proteins that disrupt normal cellular regulation and promote cancer development through: - **Uncontrolled Cell Division**: Oncogenes bypass normal cell cycle checkpoints, leading to unregulated cell proliferation. - **Inhibition of Apoptosis**: Oncogenes prevent programmed cell death, allowing damaged or abnormal cells to persist and multiply. - **Angiogenesis**: Oncogenes stimulate the formation of new blood vessels to supply nutrients to the tumor, enabling its growth. - **Invasion and Metastasis**: Oncogenes enable cancer cells to invade nearby tissues and spread to distant organs. --- ### **Examples of Oncogenes** | **Oncogene** | **Protein Product** | **Cancer Types** | **Mechanism of Activation** | |-----------------------|-------------------------------------|------------------------------------------------|--------------------------------| | **KRAS** | GTPase | Colorectal, pancreatic, lung cancers | Point mutation | | **HER2 (ERBB2)** | Receptor tyrosine kinase | Breast, gastric cancers | Gene amplification | | **BCR-ABL** | Fusion protein (tyrosine kinase) | Chronic myeloid leukemia (CML) | Chromosomal translocation | | **MYC** | Transcription factor | Burkitt lymphoma, neuroblastoma | Gene amplification | | **EGFR** | Epidermal growth factor receptor | Non-small cell lung cancer, glioblastoma | Point mutation, amplification | | **ALK** | Tyrosine kinase receptor | Lung adenocarcinoma, anaplastic large cell lymphoma | Gene fusion | | **BRAF** | Serine/threonine kinase | Melanoma, colorectal cancer, thyroid cancer | Point mutation | --- ### **Clinical Relevance** 1. **Role in Cancer Development**: Oncogenes are among the "driver mutations" that initiate and promote cancer progression. Their activation leads to dysregulated cell signaling pathways, such as the **RAS-RAF-MEK-ERK** and **PI3K-AKT-mTOR** pathways, which are critical for cell proliferation, survival, and growth. These pathways are often hyperactivated in cancer, contributing to the aggressive nature of the disease. 2. **Therapeutic Implications**: Oncogenes are essential targets for cancer therapy. Their role in driving tumorigenesis has made them valuable for developing targeted therapies that specifically inhibit their activity. Examples include: - **Tyrosine Kinase Inhibitors (TKIs)**: Drugs like **imatinib** target the **BCR-ABL** fusion protein in CML, effectively reducing tumor growth. - **Monoclonal Antibodies**: Drugs like **trastuzumab** target HER2-overexpressing breast and gastric cancers, blocking the excessive signaling caused by HER2 amplification. - **Small Molecule Inhibitors**: Drugs like **vemurafenib** target **BRAF V600E** mutations in melanoma, reducing cancer cell proliferation. 3. **Biomarkers for Diagnosis and Prognosis**: Oncogene mutations are used as diagnostic markers to identify specific cancer types. For example: - **BCR-ABL** translocation is diagnostic for CML. - **KRAS** mutations in colorectal cancer can indicate poor response to EGFR inhibitors, serving as a prognostic marker. 4. **Companion Diagnostics for Personalized Medicine**: Molecular testing for oncogene mutations (e.g., **EGFR**, **ALK**, **ROS1**) is critical for identifying patients who may benefit from targeted therapies. This approach ensures personalized treatment plans tailored to the genetic makeup of the patient's tumor, improving outcomes and minimizing unnecessary treatments. --- ### **Take-Home Points** - **Oncogenes** are mutated proto-oncogenes that are key drivers of cancer development by promoting uncontrolled cell growth, survival, and metastasis. - Examples of oncogenes include **KRAS, HER2, BCR-ABL, EGFR, MYC**, and **BRAF**. - They are activated through mutations, gene amplifications, chromosomal translocations, or insertional mutagenesis. - Oncogenes are central to cancer progression and serve as critical targets for precision therapies, including **TKIs**, **monoclonal antibodies**, and **small molecule inhibitors**. - Molecular testing for oncogene alterations plays a pivotal role in cancer diagnosis, prognosis, and therapy selection, enabling personalized cancer treatment strategies. Understanding oncogenes is fundamental to advancing cancer research, improving diagnostic accuracy, and developing novel and effective therapeutic approaches.

Microvascular invasion and postoperative recurrence in HCC

Microvascular invasion (MVI) is a critical pathological feature in hepatocellular carcinoma (HCC) that significantly influences prognosis and postoperative recurrence patterns, particularly aggressive recurrence, following hepatectomy. Here's a detailed explanation of its role, implications, and effects in the context of HCC: ### **What is Microvascular Invasion (MVI)?** Microvascular invasion refers to the microscopic spread of tumor cells into the small intrahepatic blood vessels surrounding the primary tumor. It is considered an early manifestation of metastatic potential, as it indicates the ability of the tumor to disseminate through the vascular system. MVI is not visible on imaging or during surgery and can only be identified through histopathological examination of the resected liver tissue. ### **MVI and Prognosis in HCC** 1. **Aggressive Tumor Biology**: MVI is regarded as a marker of aggressive tumor behavior. Even in early-stage HCC, the presence of MVI suggests a higher likelihood of recurrence and poorer overall survival. 2. **Independent Risk Factor**: MVI has been identified as an independent risk factor for both aggressive recurrence and mortality in patients with HCC. It is more predictive of early recurrence compared to other factors such as tumor size or satellite nodules. 3. **Prognostic Implications**: Patients with MVI exhibit a significantly higher risk of developing aggressive recurrence that exceeds the Milan criteria, which are used to determine eligibility for liver transplantation. This underscores its importance in guiding treatment decisions and surveillance strategies. ### **Post-Hepatectomy Microvascular Invasion and Recurrence** 1. **Early Recurrence**: Studies have shown that nearly half of HCC patients with MVI experience recurrence within six months of hepatectomy. This recurrence is often intrahepatic and reflects the tumor's early metastatic potential. 2. **Aggressive Recurrence**: Aggressive recurrence refers to the development of HCC that exceeds the Milan criteria (e.g., multiple tumors, large tumor size) at the first relapse. MVI is strongly associated with this type of recurrence, making it a crucial factor in postoperative risk stratification. 3. **Impact on Survival**: The presence of MVI significantly reduces survival rates, as patients with MVI are more likely to experience rapid and widespread recurrence, limiting the effectiveness of subsequent treatments. ### **Challenges in Diagnosing MVI** 1. **Histopathological Variability**: Diagnostic criteria for MVI vary across studies and pathology labs, leading to inconsistencies in its identification and grading. This heterogeneity limits reproducibility and clinical standardization. 2. **Grading Systems**: The Chinese Liver Cancer Pathology Group uses a three-tiered grading system (M0, M1, M2), which provides more predictive accuracy than the binary "yes/no" classification used in some studies. This highlights the need for standardized grading protocols to improve prognostic assessment. 3. **Sampling Adequacy**: Proper tissue sampling from the tumor margin and adjacent liver tissue is essential for accurate detection of MVI. Insufficient sampling can lead to underdiagnosis, affecting risk stratification and postoperative management. ### **Clinical Implications of MVI** 1. **Adjuvant Therapy**: Recognizing MVI as a high-risk marker supports the use of adjuvant therapies, such as immunotherapy or transarterial chemoembolization (TACE), to reduce the risk of early recurrence post-hepatectomy. 2. **Preoperative Biomarkers**: There is an urgent need for molecular or imaging biomarkers that can predict MVI preoperatively, enabling better surgical planning and patient stratification. 3. **Postoperative Surveillance**: Patients with MVI require closer postoperative monitoring due to their elevated risk of aggressive recurrence. Surveillance strategies should be tailored to detect recurrence at an early stage. ### **Key Conclusion** Microvascular invasion is a pivotal determinant of aggressive recurrence in early-stage HCC after hepatectomy. Accurate identification and grading of MVI are essential for refining recurrence prediction, guiding adjuvant therapy, and improving survival outcomes. Future studies should focus on standardizing diagnostic criteria, differentiating MVI from satellite nodules, and developing predictive biomarkers to enhance clinical management of HCC patients.

CT-derived extracellular volume (ECV) fraction for hepatocellular adenoma and FNH

Hepatocellular adenoma (HCA) and focal nodular hyperplasia (FNH) are two types of benign liver lesions that can sometimes be difficult to differentiate based on imaging studies due to overlapping features. CT-derived extracellular volume (ECV) fraction has emerged as a valuable quantitative imaging biomarker to distinguish between these two entities more accurately and noninvasively. ### **What is Hepatocellular Adenoma (HCA)?** Hepatocellular adenoma is a rare benign liver tumor that predominantly occurs in women, often associated with hormonal factors such as oral contraceptive use or anabolic steroid use. HCA carries a risk of complications, including hemorrhage and malignant transformation, making accurate diagnosis critical for appropriate management. ### **What is Focal Nodular Hyperplasia (FNH)?** Focal nodular hyperplasia is another benign liver lesion that is more common than HCA and typically occurs in women of reproductive age. It is considered a hyperplastic response to abnormal vascular flow rather than a true neoplasm. FNH is generally asymptomatic and has no risk of malignant transformation, making it less concerning from a clinical perspective compared to HCA. ### **Differentiating Features of HCA and FNH** Differentiating HCA from FNH can be challenging due to overlapping imaging characteristics on conventional modalities such as ultrasound, CT, or MRI. However, there are some distinguishing features: - **HCA**: Typically appears as a well-circumscribed, homogenous lesion on imaging. It lacks a central scar and may show hemorrhage or fat deposition. - **FNH**: Often presents with a central stellate scar and radiating fibrous septa. It may display a "spoke-wheel" pattern of enhancement due to its vascular nature. ### **Role of CT-Derived Extracellular Volume (ECV) Fraction** The extracellular volume fraction is a quantitative imaging parameter derived from unenhanced and equilibrium phase CT images. It reflects the proportion of extracellular space within a tissue and has shown promise in distinguishing between HCA and FNH. #### **Study Findings on ECV Fraction** 1. **ECV Fraction in FNH vs. HCA**: - The mean ECV fraction was significantly higher in FNH (37.7% ± 8.8%) compared to HCA (26.7%, interquartile range 22.5%–31%). - This difference was statistically significant (P = .001). 2. **Optimal Cutoff Value**: - A cutoff value of 32.25% was determined to differentiate FNH from HCA. - Sensitivity: 76.5% - Specificity: 78.9% - Area under the ROC curve (AUC): 0.824 (95% CI: 0.675–0.972, P = .001), indicating strong diagnostic accuracy. 3. **Reproducibility**: - The interobserver agreement for ECV fraction measurements was excellent, with intraclass correlation coefficients of 0.884 for HCA and 0.915 for FNH. #### **Clinical Implications** - **High Diagnostic Accuracy**: The ECV fraction provides strong performance metrics for distinguishing between HCA and FNH, reducing diagnostic uncertainty. - **Noninvasive Biomarker**: The technique is noninvasive, which can minimize the need for liver biopsies and invasive procedures. - **Improved Diagnostic Confidence**: ECV fraction analysis can improve diagnostic confidence for radiologists and clinicians, aiding in appropriate patient management. ### **Conclusion** CT-derived ECV fraction is a promising imaging biomarker for differentiating hepatocellular adenoma (HCA) from focal nodular hyperplasia (FNH). With high accuracy, reproducibility, and diagnostic reliability, it offers a noninvasive alternative to invasive procedures like biopsies. The quantitative approach of ECV fraction measurement enhances the ability to make precise diagnoses, ultimately improving patient care and reducing unnecessary interventions.

Recurrent non-malignant ampullary neoplasms

Recurrent non-malignant ampullary neoplasms, primarily adenomas, are benign tumors located at the ampulla of Vater, a critical junction where the bile duct and pancreatic duct meet and empty into the small intestine. These neoplasms can recur following initial treatment, such as endoscopic papillectomy, with recurrence rates reported between 5% and 40%. Even when the initial resection appears complete, recurrence remains a significant clinical challenge due to the complex anatomy and microscopic residual tissue that may persist. ### Management Options for Recurrent Non-Malignant Ampullary Neoplasms: 1. **Endoscopic Mucosal Resection (EMR):** - EMR is the preferred approach for managing localized residual or recurrent lesions. - It is minimally invasive and allows for the precise removal of tumor tissue while preserving surrounding structures. - EMR is particularly effective for small, well-defined lesions. 2. **Endoscopic Ablation Therapies:** - **Argon Plasma Coagulation (APC):** - APC is commonly used either as a standalone therapy or in combination with EMR. - It uses ionized argon gas to coagulate and destroy residual tumor tissue. - APC is effective for small, flat residual lesions and is relatively safe. - **Radiofrequency Ablation (RFA):** - RFA has gained attention as a promising technique for intraductal residual or recurrent neoplasms. - It uses focused thermal energy to ablate tumor tissue within the bile or pancreatic ducts. - Clinical studies have shown a success rate of approximately 75.7% for RFA in controlling recurrent ampullary adenomas. - Repeat RFA can be performed in cases of recurrence, maintaining disease control without the need for surgical intervention. - While RFA shows promising results, further studies are required to establish its long-term efficacy and safety. 3. **Periodic Surveillance:** - After treatment, patients require regular follow-up with endoscopic examinations to monitor for recurrence. - Surveillance intervals are typically determined based on the risk profile of the patient and the completeness of the initial resection. 4. **Surgical Intervention (Rare):** - In cases where endoscopic therapies fail or the recurrence is extensive, surgical options such as pancreaticoduodenectomy (Whipple procedure) may be considered. - Surgery is generally reserved for cases where malignancy is suspected or endoscopic methods are insufficient. ### Challenges and Considerations: - **Complex Anatomy:** The ampulla of Vater’s anatomical location makes complete resection challenging, especially for intraductal components. - **Recurrence Risk:** Even with advanced techniques like EMR or RFA, recurrence can occur due to microscopic residual tissue. - **Safety of Ablation Techniques:** While APC and RFA are minimally invasive, they carry potential risks such as thermal injury to surrounding tissues or ducts. - **Need for Long-Term Data:** Despite promising results with RFA, prospective studies are needed to validate its role and standardize its use in this clinical setting. ### Conclusion: Recurrent non-malignant ampullary neoplasms are effectively managed with minimally invasive techniques such as EMR, APC, and RFA. Among these, RFA represents a novel and promising approach for intraductal lesions, offering high success rates and the potential to avoid surgery. However, long-term surveillance and further clinical research are essential to optimize treatment strategies and confirm the safety and efficacy of these modalities.

FIT versus colonoscopy in Korea’s national colorectal cancer screening program

In South Korea's national colorectal cancer (CRC) screening program, the fecal immunochemical test (FIT) and colonoscopy are two key approaches, each with distinct advantages and limitations. Here's a detailed comparison of FIT versus colonoscopy in the context of Korea's CRC screening program: ### **Fecal Immunochemical Test (FIT)** #### **Advantages:** 1. **Simplicity and Noninvasiveness**: - FIT is a stool-based test that detects hidden blood in feces, which may indicate the presence of colorectal cancer or advanced adenomas. - It is noninvasive, making it more acceptable to the general population compared to colonoscopy. 2. **Cost-Effectiveness**: - FIT is relatively inexpensive, which makes it suitable for large-scale implementation as part of a national screening program. 3. **Ease of Administration**: - The test is easy to perform at home and does not require specialized equipment or trained medical personnel for the initial sample collection. 4. **High Participation Rates**: - Its simplicity and affordability encourage broader public participation, which is critical for the success of mass screening programs. #### **Limitations:** 1. **Lower Diagnostic Accuracy**: - FIT has limited sensitivity for detecting advanced adenomas or early-stage colorectal cancer. It is more effective at identifying cancers that are already bleeding but may miss precancerous lesions. 2. **Reliance on Consistent Participation**: - FIT needs to be performed annually or biennially to maintain effectiveness, requiring consistent public adherence to the screening schedule. 3. **No Therapeutic Capability**: - FIT is purely a diagnostic tool. If the test result is positive, a follow-up colonoscopy is required to confirm the diagnosis and remove any precancerous lesions. --- ### **Colonoscopy** #### **Advantages:** 1. **High Diagnostic Accuracy**: - Colonoscopy allows direct visualization of the entire colon and rectum, making it highly accurate for detecting colorectal cancer and advanced adenomas. 2. **Dual Diagnostic and Therapeutic Capability**: - During the same procedure, precancerous lesions (e.g., adenomas or polyps) can be removed immediately, reducing the risk of cancer development. 3. **Longer Screening Interval**: - Unlike FIT, colonoscopy does not need to be repeated annually. If the results are normal, the next screening may be recommended after 5 or 10 years, depending on individual risk factors. 4. **Stronger Protection Against CRC Development**: - By directly removing precancerous lesions, colonoscopy offers stronger prevention of colorectal cancer and lowers mortality rates. #### **Limitations:** 1. **Invasive Nature**: - Colonoscopy is an invasive procedure, which can cause discomfort and anxiety among patients. It also carries a small risk of complications, such as bleeding or perforation. 2. **Higher Cost**: - Colonoscopy is significantly more expensive than FIT, making it less feasible for widespread implementation in a national screening program. 3. **Resource Demands**: - Colonoscopy requires specialized equipment, trained medical personnel, and healthcare infrastructure, which may strain resources in large-scale programs. 4. **Lower Participation Rates**: - The invasive nature and higher cost of colonoscopy can deter some individuals from undergoing the procedure, potentially reducing overall participation rates. --- ### **Current Status in Korea** - **FIT as the Primary Screening Tool**: - FIT remains the cornerstone of Korea’s national CRC screening program due to its affordability, simplicity, and ability to reach a large population. - It is particularly suited for large-scale public health initiatives in a country with universal healthcare coverage. - **Colonoscopy as a Follow-Up Tool**: - Individuals with positive FIT results are referred for colonoscopy to confirm the diagnosis and remove precancerous lesions. - Colonoscopy is also used as a first-line screening tool for individuals at higher risk of CRC, such as those with a family history of the disease or other risk factors. --- ### **Challenges and Future Directions** 1. **Improving FIT Adherence**: - Public education campaigns and reminders can help ensure consistent participation in FIT screening, enhancing its effectiveness. 2. **Enhancing Colonoscopy Quality**: - Training healthcare professionals and ensuring high-quality colonoscopy practices will be essential for accurate diagnosis and safe therapeutic interventions. 3. **Personalized Screening Strategies**: - Tailoring screening approaches based on individual risk profiles (e.g., age, family history, lifestyle factors) could optimize resource allocation and improve outcomes. 4. **Balancing Cost and Effectiveness**: - Developing evidence-based policies that balance the clinical benefits of colonoscopy with its economic and resource constraints will be crucial for sustainable implementation. 5. **Continuous Evaluation**: - Regular assessment of the screening program’s effectiveness, participation rates, and diagnostic accuracy will help refine national strategies over time. --- ### **Conclusion** In Korea, FIT and colonoscopy complement each other in the national colorectal cancer screening program. FIT serves as the primary tool for mass screening, offering simplicity and cost-effectiveness, while colonoscopy provides higher diagnostic accuracy and therapeutic benefits, making it indispensable for follow-up and high-risk populations. The optimal strategy will involve leveraging the strengths of both approaches, improving public adherence, and tailoring screening protocols to individual needs, all while ensuring economic sustainability and high-quality healthcare delivery.

HCC - Alcohol versus other etioloiges

Hepatocellular carcinoma (HCC), the most common type of primary liver cancer, can develop due to various etiologies. Alcohol-related liver disease (ALD) is a significant contributor to HCC, alongside other causes such as viral hepatitis (Hepatitis B Virus [HBV] and Hepatitis C Virus [HCV]) and metabolic dysfunction-associated steatotic liver disease (MASLD). Below is a detailed comparison of alcohol-related HCC versus HCC due to other etiologies: --- ### **Alcohol-related Liver Disease (ALD) and HCC** 1. **Definition of ALD:** ALD refers to liver damage caused by excessive alcohol consumption, which can progress to cirrhosis (advanced scarring of the liver) and eventually lead to HCC. Chronic alcohol use leads to oxidative stress, inflammation, and lipid metabolism dysregulation, which are key contributors to carcinogenesis. 2. **Epidemiological Role:** - ALD is the **third leading cause** of HCC globally and the **leading cause in Europe**, accounting for approximately **19% of liver cancer deaths**. - Central and Eastern Europe have the highest mortality rates from ALD-related HCC due to socioeconomic factors and high alcohol consumption rates. 3. **Delayed Diagnosis:** - HCC in ALD patients is often diagnosed **late or incidentally**, primarily due to the lack of structured surveillance programs and socioeconomic barriers. - Many patients with ALD-related cirrhosis are underdiagnosed, and active alcohol use often prevents regular medical follow-ups. 4. **Clinical Presentation:** - ALD-HCC patients frequently present with **poorer general health**, **impaired liver function**, and **comorbidities** such as cardiovascular disease and malnutrition. - This results in worse clinical outcomes compared to other HCC etiologies. 5. **Molecular Characteristics:** - ALD-HCC is associated with specific **genetic polymorphisms** such as PNPLA3, TM6SF2, HSD17B13, and MBOAT7, which influence lipid metabolism and carcinogenesis. - Somatic mutations affecting the **TERT promoter**, **CTNNB1 (β-catenin)**, **TP53**, and **ARID1A** drive tumor progression through mechanisms like oxidative stress, chromatin remodeling, and Wnt/β-catenin pathway activation. 6. **Surveillance and Screening Challenges:** - ALD patients face significant barriers to HCC surveillance, including cost, transportation issues, stigma, and poor scheduling. Active alcohol use correlates with reduced surveillance orders from healthcare providers. - Standard ultrasound-based screening is less sensitive in ALD patients due to obesity, fibrosis heterogeneity, and technical limitations, necessitating enhanced imaging methods or biomarker-based approaches. 7. **Treatment Inequalities:** - Historically, ALD-HCC patients faced stigma and reduced access to curative therapies like liver transplantation. While attitudes are improving, disparities in access to treatment persist internationally. 8. **Prognostic Factors:** - The etiology of cirrhosis (alcoholic vs. viral) does not independently determine prognosis. Instead, survival depends on liver function, tumor burden, and overall health. - Early detection through surveillance can improve survival outcomes, making them comparable to virus-related HCC. --- ### **Non-Alcoholic Etiologies of HCC** 1. **Viral Hepatitis (HBV and HCV):** - HBV and HCV are major global causes of HCC, especially in Asia and Africa. - Chronic viral hepatitis leads to liver inflammation, fibrosis, and cirrhosis, which increase the risk of HCC. - HCV-related HCC has slightly higher cumulative incidence rates compared to ALD (e.g., 1% at 1 year, 3-5% at 5 years, and 10-15% at 10 years in cirrhosis patients). 2. **Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD):** - Formerly known as non-alcoholic fatty liver disease (NAFLD), MASLD is caused by metabolic risk factors such as obesity, diabetes, and dyslipidemia. - MASLD-related HCC can occur even in the absence of cirrhosis, making surveillance crucial. - A new classification, **Metabolic Dysfunction-Associated Steatotic Liver Disease with Increased Alcohol Intake (MetALD)**, identifies patients with moderate alcohol use and metabolic risk factors who have distinct HCC risk profiles. 3. **Cumulative Incidence Rates:** - MASLD-related cirrhosis has slightly higher HCC incidence rates compared to ALD-related cirrhosis (e.g., 2% at 1 year, 5% at 5 years, and 13% at 10 years). 4. **Molecular Pathways:** - Viral hepatitis HCC is often driven by viral integration into the host genome, inflammation, and activation of oncogenic pathways. - MASLD-HCC involves metabolic dysfunction, lipid accumulation, and insulin resistance, contributing to tumorigenesis. 5. **Surveillance and Prognosis:** - Structured surveillance programs improve early-stage detection and survival outcomes for both viral and MASLD-related HCC. - MASLD patients often face barriers to surveillance due to underdiagnosis of liver disease in non-cirrhotic stages. --- ### **Alcohol versus Non-Alcohol Etiologies: Key Differences** | **Aspect** | **Alcohol-Related HCC (ALD)** | **Non-Alcohol-Related HCC (Viral/MASLD)** | |-------------------------------|--------------------------------------------------|------------------------------------------------| | **Primary Cause** | Excessive alcohol consumption | Chronic viral hepatitis, obesity, diabetes | | **Global Impact** | Third leading cause of HCC globally | HBV is dominant in Asia/Africa; MASLD rising | | **Risk Factors** | Alcohol abuse, socioeconomic deprivation | Viral infection, metabolic syndrome | | **Surveillance Challenges** | Poor access, stigma, active alcohol use | Underdiagnosis in non-cirrhotic MASLD | | **Prognosis** | Worse outcomes due to comorbidities | Better outcomes with early detection | | **Molecular Pathways** | Lipid metabolism genes (PNPLA3, TM6SF2, etc.) | Viral integration (HBV), metabolic dysfunction | | **Treatment Access** | Historically limited due to stigma | Better access, though disparities exist | --- ### **Public Health Implications** - **Alcohol-related HCC** is largely preventable through public health measures aimed at reducing alcohol consumption. Modeling predicts that reducing alcohol use by **3.5% annually** could cut ALD-HCC incidence by **30%** by 2040. - Enhanced surveillance programs, improved access to care, and integration of molecular diagnostics are essential for reducing mortality across all HCC etiologies. In conclusion, while alcohol-related HCC presents unique challenges such as delayed diagnosis, socioeconomic barriers, and molecular differences, structured surveillance and prevention strategies can significantly improve outcomes and reduce its global burden.

Serum Tyrosine, HCC and mortality

**Serum Tyrosine, Hepatocellular Carcinoma (HCC), and Mortality: Detailed Explanation** ### **What is Serum Tyrosine?** Serum tyrosine is an aromatic amino acid (AAA) that plays a critical role in protein synthesis and various metabolic pathways, including neurotransmitter production. In normal physiological conditions, tyrosine levels remain balanced as part of the body's amino acid profile. However, in chronic liver disease (CLD), an imbalance in amino acids often occurs, characterized by elevated tyrosine levels and decreased branched-chain amino acids (BCAAs). This imbalance is linked to complications such as hepatic encephalopathy, malnutrition, and metabolic disturbances. ### **The Role of Serum Tyrosine in Hepatocellular Carcinoma (HCC):** 1. **Independent Risk Factor for HCC Development:** - The study identified serum tyrosine as an **independent predictor** of HCC development in patients with chronic liver disease (CLD). Elevated tyrosine levels were significantly associated with higher HCC risk after adjusting for confounding factors such as age, sex, liver disease etiology, and liver function metrics. - Multivariable analysis showed that for every unit increase in serum tyrosine, the risk of developing HCC increased (subdistribution hazard ratio [HR] 1.01; 95% confidence interval [CI] 1.00–1.02; p = 0.004). 2. **Mechanistic Explanation:** - Elevated serum tyrosine may promote hepatocarcinogenesis through several mechanisms: - **Insulin Resistance:** Tyrosine levels were found to correlate strongly with insulin resistance, which is a known contributor to liver cancer development. Insulin resistance leads to metabolic dysregulation, chronic inflammation, and cellular proliferation, all of which increase HCC risk. - **mTOR Activation:** Tyrosine can activate the mammalian target of rapamycin (mTOR) pathway, which regulates cell growth and proliferation. Dysregulated mTOR signaling is implicated in cancer progression, including HCC. - **Impaired Amino Acid Catabolism:** In cirrhotic livers, amino acid metabolism is disrupted, leading to elevated tyrosine levels, which may further exacerbate liver dysfunction and promote carcinogenesis. 3. **Cumulative Incidence of HCC:** - Patients with high serum tyrosine levels had a significantly higher 5-year cumulative incidence of HCC (20%) compared to those with normal tyrosine levels (11%; p = 0.002). This highlights the prognostic importance of tyrosine in identifying patients at higher risk of developing liver cancer. ### **Serum Tyrosine and Mortality:** 1. **Independent Predictor of Mortality:** - Elevated serum tyrosine was also identified as an **independent predictor of all-cause mortality** in CLD patients. For every unit increase in serum tyrosine, the risk of mortality increased (HR 1.01; 95% CI 1.01–1.02; p < 0.001). - This association remained robust even when competing risks, such as mortality from causes other than HCC, were considered. 2. **Effect of HCC on Mortality:** - Once HCC developed, it significantly increased the risk of mortality (HR 2.91; 95% CI 1.75–4.81). This underscores the importance of early identification and prevention of HCC in reducing overall mortality in CLD patients. 3. **Mechanistic Link to Mortality:** - Elevated serum tyrosine contributes to metabolic dysregulation, insulin resistance, and impaired liver function, all of which increase the likelihood of liver failure and death. Tyrosine's role in promoting HCC further compounds its impact on mortality. ### **BCAA and BTR (Branched-Chain-to-Tyrosine Ratio):** - Unlike tyrosine, serum BCAA levels and the branched-chain-to-tyrosine ratio (BTR) were **not independently associated with HCC risk** after adjustment for confounders. This suggests that elevated tyrosine is the more critical prognostic indicator in CLD patients. - However, BCAA supplementation has been shown to improve amino acid balance by increasing BCAA levels and lowering tyrosine. This intervention may help reduce HCC risk and improve overall outcomes in high-risk patients. ### **Clinical Implications:** 1. **Tyrosine as a Biomarker:** - Measuring serum tyrosine levels provides a simple, cost-effective biomarker for identifying CLD patients at high risk of developing HCC and experiencing increased mortality. Patients with elevated tyrosine levels may benefit from closer monitoring and early interventions. 2. **Potential Interventions:** - **BCAA Supplementation:** Supplementing with BCAAs can restore amino acid balance by lowering tyrosine levels and improving metabolic function. This may reduce the risk of HCC and improve survival in CLD patients. - **HCC Surveillance:** High-risk patients with elevated tyrosine levels should undergo more frequent HCC screening (e.g., imaging and alpha-fetoprotein testing) to enable early detection and treatment. 3. **Guidance for Risk Stratification:** - Serum tyrosine levels can be incorporated into risk stratification models to guide preventive strategies and optimize clinical management for CLD patients. ### **Limitations and Future Directions:** - The study was retrospective and limited to Japanese patients, which may restrict generalizability to other populations. Further research is needed to validate these findings internationally and explore cutoff thresholds for tyrosine levels. - Data on other aromatic amino acids (AAAs) were not included, leaving room for investigation into their potential roles in HCC and mortality. ### **Conclusion:** Elevated serum tyrosine is an independent risk factor for both HCC development and all-cause mortality in chronic liver disease. Its role in metabolic dysregulation, insulin resistance, and hepatocarcinogenesis underscores its clinical significance. Measuring serum tyrosine levels offers a valuable tool for early risk stratification, guiding preventive interventions like BCAA supplementation, and improving outcomes in CLD patients.

CEACAM6, HOXA-AS3 and miR-29a in colorectal cancer

CEACAM6, HOXA-AS3, and miR-29a are molecular components that play significant roles in colorectal cancer (CRC) progression, diagnosis, prognosis, and potential therapeutic strategies. Below is a detailed explanation of their individual roles and their combined impact on CRC: --- ### **1. CEACAM6 (Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6):** - **What is CEACAM6?** CEACAM6 is a glycoprotein that belongs to the carcinoembryonic antigen (CEA) family. It functions primarily as a cell adhesion molecule and is known for its tumor-promoting properties. - **Role in Tumor Progression:** - CEACAM6 is **overexpressed** in CRC tumor tissues compared to adjacent normal tissues (4.7-fold increase, p < 0.05). - Its elevated expression correlates with advanced TNM stage and poor tumor differentiation, making it a marker of aggressive disease. - CEACAM6 promotes tumor invasion, immune evasion, and metastasis by activating oncogenic pathways such as **STAT3 signaling** and facilitating **epithelial–mesenchymal transition (EMT)**. - It also interacts with inflammatory cytokines like IL-6, further driving tumor progression. - **Clinical Impact:** - CEACAM6 serves as a prognostic biomarker, indicating worse outcomes in poorly differentiated and advanced-stage CRC. - Its overexpression is not limited to CRC; it is also observed in other cancers like breast, cervical, lung, pancreatic, rectal, and stomach malignancies, suggesting a broad oncogenic function. --- ### **2. HOXA-AS3 (Homeobox A Antisense RNA 3):** - **What is HOXA-AS3?** HOXA-AS3 is a long non-coding RNA (lncRNA) associated with the HOXA gene cluster. It has dual roles in cancer, acting as either an oncogene or a tumor suppressor depending on the cancer type. - **Role in Tumor Progression:** - In CRC, HOXA-AS3 is **downregulated** in tumor tissues compared to normal tissues, indicating a potential tumor-suppressive role. - Unlike CEACAM6, HOXA-AS3 expression does not correlate significantly with tumor differentiation or clinical stage, but its reduced levels suggest an association with tumorigenesis. - **Molecular Interactions:** - Bioinformatics analyses show that HOXA-AS3 interacts directly with CEACAM6 and IL-6 mRNAs, potentially regulating inflammatory and oncogenic pathways. - These interactions may influence key processes like immune evasion, tumor invasion, and metastasis. - **Clinical Impact:** - HOXA-AS3 could be explored as a therapeutic target to counteract tumor-promoting pathways in CRC. - Its role in regulating CEACAM6 and IL-6 further highlights its importance in CRC biology. --- ### **3. miR-29a (MicroRNA-29a):** - **What is miR-29a?** miR-29a is a small non-coding RNA molecule that regulates gene expression post-transcriptionally. It is involved in various cellular processes, including apoptosis, metastasis, and immune evasion. - **Role in Tumor Progression:** - miR-29a is **upregulated** in CRC tumor tissues and patient serum (p < 0.05), indicating its dysregulation in CRC. - Elevated miR-29a levels are linked to less aggressive disease, as serum miR-29a levels are lower in patients with lymphovascular invasion (p = 0.028) and advanced-stage disease (p = 0.043). - It suppresses oncogenesis by targeting critical pathways such as **PTEN/Akt/GSK3β** and **Wnt/β-catenin**, which are involved in cell proliferation and metastasis. - **Clinical Impact:** - miR-29a shows strong promise as a **non-invasive diagnostic biomarker** due to its consistent elevation in both tissue and serum. ROC curve analysis yielded an AUC of 0.918, indicating high sensitivity and specificity for distinguishing CRC patients from healthy individuals. - Its tissue–serum correlation (p = 0.038*) further supports its utility in liquid biopsy applications for early detection and disease monitoring. --- ### **Combined Impact in CRC:** - **Biomarker Network:** - The coordinated dysregulation of CEACAM6, HOXA-AS3, and miR-29a forms a potential biomarker network for CRC diagnosis and prognosis. - CEACAM6 and miR-29a are particularly promising for diagnostic purposes, with CEACAM6 indicating tumor aggressiveness and miR-29a offering non-invasive detection capabilities. - **Molecular Interactions:** - CEACAM6 and IL-6 are upregulated in CRC and appear to cooperate in promoting tumor progression via inflammatory and oncogenic pathways. - HOXA-AS3 interacts with CEACAM6 and IL-6, potentially modulating their effects on tumor biology. - miR-29a counteracts oncogenic pathways like PTEN/Akt/GSK3β and Wnt/β-catenin, suggesting therapeutic potential. - **Therapeutic Insights:** - Targeting CEACAM6 and IL-6 signaling pathways could inhibit tumor invasion and immune evasion. - Modulating miR-29a expression or restoring HOXA-AS3 levels may counteract tumor-promoting mechanisms, offering novel CRC treatment strategies. --- ### **Conclusion:** The study highlights the coordinated dysregulation of CEACAM6, HOXA-AS3, and miR-29a in CRC, emphasizing their diagnostic and prognostic significance. CEACAM6 is a marker of tumor aggressiveness, HOXA-AS3 may act as a tumor suppressor, and miR-29a shows promise for non-invasive early detection and disease monitoring. Together, these molecules provide a comprehensive framework for understanding CRC biology and developing innovative diagnostic and therapeutic approaches.

CD47 expression on survival of colorectal cancer

CD47 expression plays a significant role in determining the survival outcomes of colorectal cancer (CRC) patients. Here's a detailed explanation of its impact: ### **What is CD47?** CD47 is a transmembrane glycoprotein often referred to as the "don't eat me" signal. It interacts with signal regulatory protein alpha (SIRPα) on macrophages and other immune cells, suppressing their phagocytic activity. This mechanism allows tumor cells to evade immune system destruction, promoting cancer progression, angiogenesis, and survival. --- ### **CD47 Expression in CRC** 1. **Frequency of Expression:** - In the study cohort of 98 CRC patients, CD47 positivity was observed in 56.1% of patients, while 43.9% were CD47-negative, indicating frequent overexpression of CD47 in colorectal cancer. 2. **Clinicopathologic Correlation:** - CD47-positive tumors were associated with more aggressive clinical features, including significantly higher lymph node involvement (p = 0.005). 3. **Prognostic Impact:** - CD47 expression correlated with poorer survival outcomes: - **Overall Survival (OS):** Median OS for patients with CD47-positive tumors was significantly shorter (39.3 months) compared to CD47-negative tumors (median OS not reached; p = 0.001). - **Stage-Specific Outcomes:** - Metastatic CRC: CD47-positive patients had a median OS of 52.6 months, compared to "not reached" for CD47-negative patients (p = 0.015). - Non-metastatic CRC: CD47-positive patients had a median OS of 37 months, compared to 58.5 months for CD47-negative patients (p = 0.05). --- ### **Mechanism of Prognostic Impact** CD47’s overexpression contributes to tumor progression and poor survival outcomes through several mechanisms: 1. **Immune Evasion:** - By binding to SIRPα on macrophages, CD47 suppresses phagocytosis, allowing tumor cells to evade immune-mediated destruction. 2. **Angiogenesis and Tumor Survival:** - CD47 overexpression promotes angiogenesis (formation of new blood vessels), which supports tumor growth and metastasis. 3. **Resistance to Apoptosis:** - It may also enhance tumor cell resistance to programmed cell death, further contributing to disease progression. --- ### **Independent Prognostic Role** Multivariate analysis identified CD47 expression as an independent prognostic factor for overall survival in CRC patients: - **Hazard Ratio (HR):** 2.142 (p = 0.006), indicating that CD47-positive patients had more than twice the risk of death compared to CD47-negative patients. - Other independent factors included tumor differentiation (HR: 2.622) and tumor stage (HR: 1.817). --- ### **Comparison with Prior Studies** - While some earlier studies did not find a significant link between CD47 and survival, this study demonstrated its clear prognostic role. This discrepancy may be due to differences in tumor stage, microsatellite status, or study design. - The cohort in this study consisted exclusively of microsatellite-stable (MSS) tumors, which are known to rely heavily on CD47-mediated immune evasion. MSS tumors typically respond poorly to immune checkpoint inhibitors, further highlighting the importance of CD47 in CRC prognosis. --- ### **Therapeutic Implications** Given its role in immune evasion and cancer progression, CD47 is emerging as a promising therapeutic target: 1. **Anti-CD47 Therapies:** - Development of anti-CD47 monoclonal antibodies and bispecific inhibitors (e.g., PD-1/CD47) is underway to block the CD47-SIRPα signaling axis. 2. **Combination Therapies:** - Combining CD47 inhibitors with other immune-based therapies could enhance macrophage-mediated phagocytosis and boost both innate and adaptive anti-tumor immunity. 3. **Potential in MSS Tumors:** - CD47-targeted therapies may be particularly beneficial for MSS CRC patients who typically have limited responses to current immunotherapies. --- ### **Limitations and Future Research** 1. **Study Limitations:** - The retrospective design, single-institution setting, and small sample size may limit generalizability. - Lack of macrophage density data constrained analysis of the immune microenvironment. 2. **Future Directions:** - Larger, multicenter studies are needed to validate findings. - Inclusion of microsatellite instability-high (MSI-H) tumors could clarify the predictive value of CD47 expression for immunotherapy response. --- ### **Conclusion** CD47 expression serves as an independent negative prognostic biomarker in colorectal cancer, associated with reduced survival and advanced disease. Its immunosuppressive role highlights its potential as a therapeutic target, particularly in MSS CRC patients. Blocking CD47-SIRPα signaling could improve survival outcomes by enhancing immune-mediated tumor destruction.

AFP-L3 or DCP expression is associated with poor outcomes in unresectable HCC

Yes, the expression of AFP-L3 or DCP is strongly associated with poor outcomes in patients with unresectable hepatocellular carcinoma (HCC), as demonstrated by the study you referenced. Here's a detailed explanation of why these biomarkers are significant and how their expression correlates with prognosis: ### What is AFP-L3 and How is it Different from AFP? - **AFP (Alpha-fetoprotein):** AFP is a glycoprotein produced primarily by the fetal liver and yolk sac during development. In adults, elevated AFP levels are commonly associated with liver diseases such as hepatitis, cirrhosis, and HCC. However, AFP alone has limitations as a biomarker because up to half of early-stage HCC patients have normal AFP levels, making it insufficient for accurate risk stratification. - **AFP-L3 (Lens culinaris agglutinin-reactive AFP):** AFP-L3 is a specific isoform of AFP that is bound to a lectin called Lens culinaris agglutinin. Unlike total AFP, AFP-L3 is more specific to malignant hepatocytes and is considered a highly sensitive marker for HCC. It is especially useful in detecting aggressive and invasive tumor phenotypes. Elevated AFP-L3 levels have been associated with poorer prognosis, higher recurrence rates, and greater likelihood of vascular invasion. ### What is DCP (Des-gamma-carboxyprothrombin)? - **DCP:** DCP, also known as PIVKA-II (Protein Induced by Vitamin K Absence or Antagonist-II), is an abnormal form of prothrombin that arises due to defective post-translational carboxylation in malignant hepatocytes. It is a well-recognized biomarker for HCC and is associated with tumor progression, angiogenesis, and metastasis. DCP is particularly useful in detecting HCC in patients with normal AFP levels and in predicting poor outcomes. ### Why Are AFP-L3 and DCP Helpful for Prognosis in Unresectable HCC? - **Detection of Aggressive Tumor Biology:** Persistent AFP-L3 and DCP expression after liver-directed therapy (LDT) indicates the presence of viable, aggressive tumor tissue that may not be detectable through imaging. These biomarkers are associated with more invasive and advanced disease phenotypes. - **Prognostic Value Beyond Imaging:** While imaging techniques like CT or MRI are critical for assessing tumor response, they may not capture microscopic or indeterminate residual disease. Biomarkers like AFP-L3 and DCP provide additional, independent prognostic information about the biological activity of the tumor. - **Risk Stratification:** Patients with AFP-L3 and/or DCP positivity have a significantly higher risk of disease progression and worse survival outcomes compared to those with negative biomarker profiles. This allows for early identification of high-risk patients who may require more aggressive or alternative treatment strategies. ### Association of AFP-L3/DCP Expression with Poor Outcomes in Unresectable HCC 1. **Incomplete Response to LDT:** - Patients with persistent AFP-L3 or DCP positivity after LDT (e.g., Yttrium-90 radioembolization, microwave ablation, or chemoembolization) are less likely to achieve a complete radiographic response. Only 29% of biomarker-positive patients achieved a complete response compared to 64% of triple-negative patients (AFP, AFP-L3, and DCP all negative). 2. **Higher Risk of Disease Progression:** - Persistent AFP-L3/DCP positivity was associated with dramatically increased rates of disease progression: - 1-year progression rate: 39% in biomarker-positive patients vs. 8% in biomarker-negative patients. - 2-year progression rate: 66% in biomarker-positive patients vs. 10% in biomarker-negative patients. - Median time-to-progression (TTP) was only 18 months in biomarker-positive patients, whereas it was not reached in biomarker responders (triple-negative patients). 3. **Poor Overall Survival (OS):** - Two-year OS was significantly worse in biomarker-positive patients (62%) compared to biomarker-negative patients (81%). - Patients with AFP-L3+/DCP+ phenotypes had the worst outcomes, with a 10.8-fold higher progression risk compared to triple-negative or AFP-only groups, even after adjusting for competing risks. 4. **Phenotypic Subgroups and Survival:** - The AFP+ AFP-L3+/DCP+ subgroup had the poorest outcomes, with a 2-year OS of only 36%, which is similar to survival rates seen in advanced HCC (BCLC-C stage), despite their earlier clinical stage (BCLC A–B). - In contrast, patients with only AFP positivity but negative AFP-L3 and DCP had outcomes comparable to triple-negative patients, highlighting the importance of distinguishing isolated AFP elevation from multi-biomarker positivity. 5. **Shorter Time-to-Progression in Incomplete Responders:** - Among patients with incomplete radiographic response to LDT, those with AFP-L3+/DCP+ expression had a median TTP of only 9 months, compared to 63 months in patients with AFP-only or triple-negative profiles. ### Biological Interpretation - Persistent AFP-L3 and/or DCP positivity likely reflects residual tumor activity that is not fully eradicated by LDT. These biomarkers may signify the presence of viable but radiographically indeterminate tumor tissue, which could explain the higher rates of progression and poorer survival outcomes. - The inferior outcomes associated with AFP-L3/DCP expression were independent of liver function parameters, such as Child–Pugh score, bilirubin, or albumin levels, suggesting that these biomarkers provide prognostic information beyond hepatic reserve or liver dysfunction. ### Clinical Implications 1. **Routine Multi-Biomarker Testing:** - Incorporating AFP-L3 and DCP testing alongside AFP into routine clinical practice can improve risk stratification, identify high-risk residual disease, and guide treatment decisions after LDT. 2. **Therapeutic Considerations:** - Patients with persistent AFP-L3+/DCP+ expression may benefit from earlier transition to systemic therapy or combination regimens, such as LDT with immunotherapy, as suggested by ongoing trials like EMERALD-01 and LEAP-012. - Intensified surveillance and more aggressive retreatment strategies may be warranted for biomarker-positive patients to prevent early progression. 3. **Personalized Treatment:** - Distinguishing between biomarker profiles (e.g., triple-negative, AFP-only, AFP-L3+/DCP+) can help tailor therapy to individual patient risk, optimizing outcomes and avoiding unnecessary interventions in lower-risk patients. ### Conclusion The study conclusively demonstrates that persistent AFP-L3 or DCP expression following LDT is a robust predictor of incomplete tumor response, rapid disease progression, and poor survival in unresectable HCC. These biomarkers provide critical prognostic information that complements imaging and liver function tests, offering a powerful tool for early risk stratification and personalized therapy planning.

MIER2 as a prognostic marker in colon adenocarcinoma

**MIER2 as a Prognostic Marker in Colon Adenocarcinoma (COAD)** **What is MIER2?** Mesoderm Induction Early Response 2 (MIER2) is a gene that has been identified to play a significant role in various biological processes, including cell signaling, immune modulation, and transcriptional regulation. In the context of colon adenocarcinoma (COAD), MIER2 has been discovered to act as an oncogenic regulator, meaning it promotes tumor progression and aggressiveness. It is significantly overexpressed in COAD tissues compared to normal tissues and has shown similar upregulation in other cancer types such as liver, stomach, and rectal adenocarcinoma. **Importance of Prognostic Markers in Colon Cancer** Prognostic markers are biological factors that help predict the likely course or outcome of a disease, such as cancer, independent of treatment. They are crucial in colon cancer for several reasons: 1. **Risk Stratification**: Prognostic markers help categorize patients into different risk groups, enabling personalized treatment strategies. 2. **Predicting Survival Outcomes**: They provide insights into overall survival (OS), disease-specific survival (DSS), and progression-free intervals (PFI), helping clinicians and patients understand the likely disease trajectory. 3. **Therapeutic Targeting**: Identifying novel biomarkers enables the development of targeted therapies, improving treatment efficacy and minimizing side effects. 4. **Improved Diagnosis**: Biomarkers can assist in early detection and diagnosis, which is critical for improving survival rates in highly malignant cancers like COAD. **How MIER2 Serves as a Prognostic Marker in COAD** 1. **Overexpression in COAD**: MIER2 is significantly upregulated in COAD tissues compared to normal tissues. This consistent overexpression across multiple datasets and cancer types highlights its potential as a robust biomarker. 2. **Correlation with Survival Outcomes**: High MIER2 expression is associated with significantly worse outcomes in COAD patients. Kaplan-Meier survival analysis revealed that patients with elevated MIER2 levels had reduced overall survival (OS), disease-specific survival (DSS), and progression-free intervals (PFI). 3. **Independent Prognostic Factor**: Multivariate Cox regression analysis confirmed that MIER2 is an independent predictor of poor prognosis in COAD, even after adjusting for other clinical factors like TNM stage, age, and sex. The adjusted hazard ratio (HR = 2.52, p < 0.001) underscores the strong prognostic value of MIER2. 4. **Nomogram Integration**: A prognostic nomogram was developed by integrating MIER2 expression with clinical variables (e.g., TNM stage). This tool accurately predicted 1-, 2-, and 3-year survival probabilities, with a high calibration accuracy (C-index = 0.754), further validating MIER2's utility in prognostication. 5. **Functional Role in Tumor Progression**: Functional studies demonstrated that MIER2 promotes tumor cell proliferation and migration in vitro. Knockdown of MIER2 in COAD cell lines (e.g., SW480) resulted in a 30–40% reduction in cell proliferation and migration, confirming its oncogenic role. **Comparison to Other Prognostic Markers** While other prognostic markers in COAD, such as KRAS, BRAF, and microsatellite instability (MSI) status, have been widely studied, MIER2 offers several unique advantages: 1. **Independent Prognostic Value**: Unlike some existing markers that depend on clinical stage or other factors, MIER2 independently predicts patient outcomes, making it a reliable standalone biomarker. 2. **Immune Modulation**: MIER2 is associated with significant changes in the tumor microenvironment, including increased CD8⁺ T cells and Tregs, and decreased CD4⁺ T cells, monocytes, and dendritic cells. This suggests that MIER2 not only affects tumor growth but also influences immune responses, providing a dual role as both a prognostic and immunological marker. 3. **Pathway Involvement**: MIER2 is linked to critical signaling pathways, such as the Notch and HIF-1 pathways, which are involved in tumor growth, immune evasion, and angiogenesis. This makes MIER2 a potential target for therapies aimed at these pathways. 4. **Potential for Therapeutic Targeting**: Unlike many traditional markers that are primarily diagnostic or prognostic, MIER2 appears to play a direct role in tumor biology. Silencing MIER2 not only reduces tumor aggressiveness but also triggers transcriptional reprogramming, including the activation of apoptosis and ER stress response pathways. This suggests that targeting MIER2 could have therapeutic benefits in addition to its prognostic utility. **Conclusion** MIER2 emerges as a promising prognostic marker in colon adenocarcinoma, with significant implications for patient stratification, survival prediction, and therapeutic targeting. Its ability to independently predict poor prognosis, along with its role in tumor progression and immune modulation, sets it apart from traditional prognostic markers in COAD. The findings from this study highlight the potential of MIER2 as a novel biomarker and therapeutic target, paving the way for improved diagnosis, prognostication, and personalized treatment strategies in colon cancer management.

Ferroptosis and enhances immunotherapy in pancreatic cancer

Ferroptosis, an iron-dependent form of regulated cell death characterized by lipid peroxidation and oxidative damage, has emerged as a potential mechanism to overcome the resistance of pancreatic ductal adenocarcinoma (PDAC) to immunotherapy. PDAC tumors are typically immune-cold, exhibiting poor CD8+ T-cell infiltration and resistance to immune checkpoint blockade (ICB), such as anti-PD-1 therapy. However, inducing ferroptosis can enhance tumor immunogenicity and sensitize PDAC to immunotherapy. Recent research has revealed that epigenetic regulation of the Nrf2–Slc40a1 axis plays a critical role in driving ferroptosis and improving immunotherapy outcomes in PDAC. The study utilized a patient-derived organoid (PDO) and autologous T-cell co-culture platform to identify compounds that synergize with anti-PD-1 therapy. Among 177 screened epigenetic modifiers, the histone demethylase inhibitor JIB04 emerged as the most effective agent, demonstrating the ability to enhance T-cell-mediated killing of PDAC cells. Mechanistically, JIB04 suppresses nuclear factor erythroid 2-related factor 2 (Nrf2), reducing chromatin accessibility of its downstream gene Slc40a1, which regulates iron efflux. This leads to intracellular iron accumulation, oxidative lipid damage, and ferroptosis. Ferroptotic cells exhibit markers such as malondialdehyde (MDA), reactive oxygen species (ROS), and lipid peroxidation, and release immunogenic signals (HMGB1, ATP, calreticulin) that activate dendritic cells and prime T-cells. In vivo studies confirmed that JIB04 enhances CD8+ T-cell infiltration, converts immune-cold PDAC tumors to immune-hot phenotypes, and improves anti-PD-1 efficacy without systemic toxicity. This ferroptosis-based epigenetic strategy represents a promising therapeutic avenue for sensitizing PDAC to immunotherapy and improving patient outcomes.

MATTERHORN Trial

The MATTERHORN trial was a global, Phase 3 study that investigated the addition of Durvalumab (an immunotherapy drug) to the standard FLOT chemotherapy regimen in patients with resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma. The trial aimed to evaluate whether this combination could improve survival outcomes and pathological responses. Participants were randomized into two groups: one received Durvalumab (1500 mg) combined with FLOT chemotherapy, while the other received a placebo with FLOT. FLOT chemotherapy was administered every two weeks for 4 cycles before surgery (neoadjuvant) and 2 cycles after surgery (adjuvant). After surgery, patients continued with Durvalumab or placebo every 4 weeks for up to 10 additional cycles, extending the immunotherapy treatment. The primary endpoint of the trial was Event-Free Survival (EFS), while secondary endpoints included pathological complete response (pCR), major pathological response (MPR), and Overall Survival (OS). PD-L1 expression (a biomarker) was also analyzed to assess its impact on treatment outcomes. Results showed that the combination of Durvalumab + FLOT significantly improved OS, with a 22% reduction in the risk of death compared to placebo + FLOT. EFS also improved, particularly in patients achieving a pathological response. Additionally, nodal downstaging (reduction in cancer spread to lymph nodes) was more frequent in the Durvalumab group (58.2% vs 44.8%). Importantly, the survival benefits were consistent across both high and low PD-L1 expression groups. The study concluded that Durvalumab + FLOT chemotherapy provides a meaningful survival benefit and may set a new standard of care for resectable gastric and GEJ adenocarcinomas.

Top 10 GI Oncology Studies at ESMO 2025

Based on the context provided, here are the top 10 gastrointestinal (GI) oncology studies that could be highlighted at ESMO 2025 based on their significant findings, clinical implications, and advancements in treatment strategies: --- ### **1. CheckMate-8HW (mCRC, 1L, MSI-H/dMMR)** - **Study Design:** Comparison of nivolumab + ipilimumab versus nivolumab alone in first-line microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC). - **Key Findings:** - Significantly better progression-free survival (PFS) with dual-checkpoint blockade (HR ≈ 0.69). - Higher overall response rate (ORR) compared to nivolumab alone. - **Clinical Impact:** Confirms the advantage of dual immunotherapy in MSI-H/dMMR mCRC upfront, setting a new standard for first-line treatment in this subgroup. --- ### **2. STELLAR-303 (mCRC, previously treated, non-MSI-H)** - **Study Design:** Zanzalintinib (VEGFR/MET/AXL TKI) + atezolizumab versus regorafenib in previously treated non-MSI-H mCRC. - **Key Findings:** - Improved overall survival (OS) compared to regorafenib standard-of-care. - Demonstrates activity of VEGFR/MET/AXL-targeted therapy combined with PD-L1 blockade in proficient mismatch repair (pMMR) mCRC. - **Clinical Impact:** Signals potential for targeted therapy and immunotherapy combinations in later-line non-MSI-H mCRC treatment. --- ### **3. MATTERHORN (Resectable Gastric/GEJ Adenocarcinoma)** - **Study Design:** Peri-operative durvalumab + FLOT chemotherapy versus FLOT alone. - **Key Findings:** - Improved overall survival (OS) with the addition of durvalumab. - **Clinical Impact:** Supports integrating PD-L1 blockade into peri-operative FLOT for fit patients with resectable gastric and gastroesophageal junction (GEJ) adenocarcinoma. --- ### **4. CASANDRA (Resectable/Borderline-Resectable Pancreatic Cancer)** - **Study Design:** Short-course PAXG regimen versus long-course modified FOLFIRINOX (mFOLFIRINOX). - **Key Findings:** - Event-free survival (EFS) improved with short-course nab-paclitaxel–based PAXG regimen. - **Clinical Impact:** Demonstrates that a shorter and more tolerable regimen can rival and outperform long-course mFOLFIRINOX for peri-operative control in pancreatic cancer. --- ### **5. GFH375X1201 (KRAS G12D-Mutant Pancreatic Cancer, Previously Treated)** - **Study Design:** KRAS-G12D inhibitor monotherapy. - **Key Findings:** - Objective response rate (ORR) ≈ 41%. - Median progression-free survival (PFS) ≈ 5.5 months. - **Clinical Impact:** Represents one of the strongest signals for a single-agent KRAS-targeted therapy in KRAS-G12D-mutant pancreatic ductal adenocarcinoma (PDAC). --- ### **6. KC-WISE (HER2+ Gastric/GEJ Cancer, Post-Trastuzumab)** - **Study Design:** Abemintamab (bispecific anti-HER2) + chemotherapy versus chemotherapy alone. - **Key Findings:** - Improved progression-free survival (PFS) and overall survival (OS). - **Clinical Impact:** Suggests durable benefit for next-generation HER2 bispecifics in HER2+ gastric/GEJ cancer after trastuzumab. --- ### **7. ZSAB-neoGOLP (Resectable High-Risk Intrahepatic Cholangiocarcinoma)** - **Study Design:** Neoadjuvant toripalimab (PD-1 inhibitor) + lenvatinib (VEGFR inhibitor) + GEMOX (gemcitabine + oxaliplatin) versus upfront surgery. - **Key Findings:** - Median event-free survival (EFS) of 18.0 months versus 8.7 months with upfront surgery. - **Clinical Impact:** Strengthens the case for integrating immunotherapy, targeted therapy, and chemotherapy in neoadjuvant settings for high-risk intrahepatic cholangiocarcinoma (iCCA). --- ### **8. FORTITUDE-101 (FGFR2b-Overexpressing Gastric/GEJ Cancer)** - **Study Design:** Bemarituzumab (anti-FGFR2b) + mFOLFOX6 chemotherapy in biomarker-selected patients. - **Key Findings:** - Statistically significant overall survival (OS) benefit at primary analysis. - **Clinical Impact:** Reinforces FGFR2b as a validated therapeutic target in gastric/GEJ cancer, particularly in biomarker-selected patients. --- ### **9. ABC-HCC (Intermediate-Stage, Unresectable Hepatocellular Carcinoma [HCC])** - **Study Design:** Atezolizumab (PD-L1 inhibitor) + bevacizumab (VEGF inhibitor) versus transarterial chemoembolization (TACE). - **Key Findings:** - Improved time-to-treatment failure (~14.6 months vs 9.5 months). - **Clinical Impact:** Positions immune-oncology (IO)-VEGF combinations as a potential alternative to TACE in intermediate-stage HCC (BCLC-B patients). --- ### **10. CITRIC (Chemorefractory RAS/BRAF Wild-Type mCRC)** - **Study Design:** Circulating tumor DNA (ctDNA)-guided anti-EGFR "re-challenge" strategy versus standard options. - **Key Findings:** - Improved progression-free survival (PFS) and overall survival (OS) in RAS/BRAF wild-type mCRC. - **Clinical Impact:** Validates liquid-biopsy–guided re-challenge with anti-EGFR therapy as an effective strategy in chemorefractory mCRC. --- ### Summary: These landmark studies represent significant advancements in GI oncology, spanning colorectal, gastric, pancreatic, cholangiocarcinoma, and hepatocellular cancers. They highlight the importance of personalized medicine, targeted therapies, novel combinations of immunotherapy, and the role of biomarkers in guiding treatment decisions. These findings are poised to reshape treatment paradigms and improve outcomes for patients across various GI malignancies. Let me know if you'd like me to prepare a one-page handout or slide summarizing this update for your meeting!

Prognostic and Predictive Impact of HER2 Alterations in mCRC Treated with Chemotherapy–Bevacizumab vs Anti-EGFR Therapy

The prognostic and predictive impact of HER2 alterations (amplification or mutation) in metastatic colorectal cancer (mCRC) was evaluated through a pooled analysis of eight major randomized clinical trials, involving 1,604 patients with RAS/BRAF wild-type, microsatellite-stable tumors. The key findings are as follows: ### Prognostic Impact: 1. **Prevalence of HER2 Alterations**: Approximately 5% of patients had HER2 amplification or overexpression, while about 2% harbored activating HER2 mutations. 2. **Worse Survival Outcomes**: Patients with HER2-positive tumors had significantly worse outcomes compared to HER2-negative patients: - **Progression-Free Survival (PFS)**: HER2-positive patients had a shorter PFS (9.8 months) compared to HER2-negative patients (12.2 months). - **Overall Survival (OS)**: HER2-positive patients had a reduced OS (28.0 months) compared to HER2-negative patients (34.9 months). 3. **HER2 Positivity as a Negative Prognostic Factor**: These survival differences persisted even after adjusting for covariates, confirming that HER2 positivity is an independent negative prognostic factor in mCRC. ### Predictive Impact: 1. **Objective Response Rates (ORR)**: The ORR was similar between HER2-positive and HER2-negative groups, indicating that HER2 status does not influence the initial response to treatment. 2. **Efficacy of Biologic Therapies**: - No significant interaction was observed between HER2 status and the efficacy of biologic therapies. - Patients with HER2 alterations derived comparable benefit from chemotherapy combined with either bevacizumab (anti-VEGF) or anti-EGFR agents. 3. **HER2-Mutant Tumors**: These tumors also demonstrated worse overall survival but did not show a differential response to biologic therapies. ### Conclusion: HER2 amplification or mutation is associated with poorer prognosis in mCRC but does not alter the efficacy of standard targeted therapies, such as chemotherapy with bevacizumab or anti-EGFR agents. These findings highlight the need for HER2-directed treatment strategies to improve outcomes in this subset of patients.

HCC outcome at the age of 80 and beyond with RF Ablation

The study conducted at Musashino Red Cross Hospital in Tokyo evaluated the effectiveness and safety of radiofrequency ablation (RFA) for treating hepatocellular carcinoma (HCC) in patients aged 80 years and older. The analysis included 518 patients, of which 136 were elderly (≥80 years) and 382 were younger (<80 years). All patients had tumors ≤3 cm and ≤3 nodules within the Milan criteria. Key findings for elderly patients (≥80 years) include: 1. **Overall Survival (OS)**: Median OS for elderly patients was 80 months, significantly shorter than the 123 months observed in younger patients (p=0.021). However, age itself did not significantly affect liver disease-related mortality. 2. **Recurrence-Free Survival (RFS)**: Median RFS was shorter for elderly patients (17 months) compared to younger patients (27 months), with a statistically significant difference (p=0.017). Elderly age was identified as a risk factor for recurrence. 3. **Prognostic Factors**: Poor survival and recurrence were associated with higher ALBI grade, elevated DCP levels (≥40 mAU/mL), persistent HCV infection, and nonviral liver disease. 4. **Safety and Complications**: RFA demonstrated acceptable safety with only 3.9% of patients experiencing complications (e.g., bleeding, pneumothorax, renal dysfunction), and no treatment-related deaths were reported. 5. **Clinical Implication**: Despite slightly shorter survival, RFA remains a viable, safe, and effective treatment for elderly HCC patients. Age ≥80 years did not significantly impact liver disease-specific mortality, indicating effective post-recurrence management.

Neoadjuvant immunotherapy Versus Surgery +/− Chemotherapy in High Resectable Gastroesophageal Adenocarcinoma

This study focused on comparing neoadjuvant immunotherapy using immune checkpoint inhibitors (ICIs) with surgery and/or chemotherapy in patients with deficient mismatch repair (dMMR)/microsatellite instability-high (MSI-H) resectable gastroesophageal adenocarcinoma (GEA). These tumors are known to respond poorly to chemotherapy but are highly immunogenic, making immunotherapy a promising approach. The analysis included 197 patients divided into four groups: ICIs (49 patients), FLOT chemotherapy (27 patients), surgery alone (33 patients), and older chemotherapy regimens (88 patients). The study primarily assessed pathologic complete response (pCR) and major pathologic response (MPR) rates, alongside event-free survival (EFS) and overall survival (OS). Key findings showed that neoadjuvant ICIs resulted in significantly better tumor responses compared to chemotherapy. Patients treated with ICIs achieved a pCR rate of 61.9% versus 3.7% with FLOT chemotherapy, and an MPR rate of 78.6% versus 10%. Additionally, ICIs reduced residual nodal disease (ypN+) to 14.3% compared to 37% with chemotherapy, indicating superior tumor downstaging. Despite these impressive pathologic responses, survival outcomes (EFS and OS) were comparable between ICIs and surgery ± chemotherapy groups. At 36 months, EFS was 70.4% for ICIs versus 80.6% for surgery, and OS was 72.7% versus 90.4%. Patients with residual nodal disease (ypN+), advanced tumor stage (ypT4), or lack of pathologic response had worse survival outcomes. This study highlights neoadjuvant immunotherapy as a highly effective strategy for dMMR/MSI-H GEA, offering profound tumor regression and reduced reliance on chemotherapy. These findings support the potential for organ-sparing or non-surgical treatment approaches, paving the way for immunotherapy-centered management in this patient subgroup.

Anti-EGFRs and CRC

Anti-EGFR (epidermal growth factor receptor) therapies are a cornerstone of treatment for metastatic colorectal cancer (mCRC), particularly in patients with RAS/BRAF wild-type tumors. EGFR is a transmembrane receptor involved in cell growth, proliferation, and survival, and its dysregulation is a common feature in colorectal cancer. Below is a detailed explanation of how anti-EGFRs relate to colorectal cancer, focusing on their mechanisms, patient selection criteria, efficacy, and limitations: --- ### **Mechanism of Action** Anti-EGFR therapies target the EGFR receptor, blocking its activation by ligands such as EGF and TGF-alpha. This inhibition prevents downstream signaling through pathways like RAS-RAF-MAPK and PI3K-AKT, which are critical for tumor cell proliferation, survival, and metastasis. Common anti-EGFR monoclonal antibodies used in mCRC include: - **Cetuximab**: A chimeric monoclonal antibody. - **Panitumumab**: A fully human monoclonal antibody. --- ### **Patient Selection** Anti-EGFR therapies are only effective in certain subgroups of mCRC patients. Key criteria for their use include: 1. **RAS/BRAF Wild-Type Status**: - Patients with mutations in RAS (KRAS or NRAS) or BRAF genes are resistant to anti-EGFR therapy. Therefore, RAS/BRAF testing is mandatory before initiating treatment. - RAS mutations activate downstream signaling independent of EGFR, rendering anti-EGFR therapies ineffective. 2. **Tumor Sidedness**: - Tumor location (left-sided vs. right-sided) influences the efficacy of anti-EGFRs. Left-sided tumors (originating in the descending colon, sigmoid colon, or rectum) are generally more responsive to anti-EGFR therapy. Right-sided tumors (from the ascending colon or cecum) show poorer outcomes with these agents. 3. **Microsatellite Stability (MSS)/Mismatch Repair Proficiency (pMMR)**: - Anti-EGFR therapies are typically used in MSS/pMMR tumors, as microsatellite instability-high (MSI-H) tumors are more likely to benefit from immunotherapy. 4. **HER2 Status**: - HER2-positive tumors were historically thought to be resistant to anti-EGFR therapy. However, recent findings suggest HER2 status does not predict response to anti-EGFRs, although HER2-positive tumors are associated with worse prognosis overall. --- ### **Efficacy** Anti-EGFR therapies have shown significant benefits in terms of tumor shrinkage and survival in appropriately selected patients: - **Objective Response Rates (ORR)**: For RAS/BRAF wild-type left-sided tumors, ORR with anti-EGFR therapy can reach up to 60-70%. - **Progression-Free Survival (PFS)**: Anti-EGFR therapies improve PFS when combined with chemotherapy, such as FOLFIRI (5-FU, leucovorin, and irinotecan) or FOLFOX (5-FU, leucovorin, and oxaliplatin). - **Overall Survival (OS)**: Studies have shown improved OS in RAS/BRAF wild-type patients treated with anti-EGFRs compared to non-targeted therapies. --- ### **Limitations** Despite their benefits, anti-EGFR therapies have notable limitations: 1. **Resistance Mechanisms**: - Primary resistance occurs in patients with RAS/BRAF mutations or other alterations like HER2 amplification, PIK3CA mutations, or EGFR extracellular domain mutations. - Acquired resistance can develop during treatment due to clonal evolution, often involving secondary mutations in the EGFR pathway. 2. **Side Effects**: - Common adverse effects include skin toxicity (rash), hypomagnesemia, and infusion-related reactions. 3. **Limited Efficacy in Right-Sided Tumors**: - Right-sided mCRC tumors generally have worse outcomes with anti-EGFR therapy, likely due to distinct biological characteristics. 4. **Cost**: - Anti-EGFR therapies are expensive and may not be accessible in all healthcare settings. --- ### **Clinical Trials and Recent Findings** Recent studies have explored the role of anti-EGFR therapies in combination or sequential therapy settings: - **TRIBE2 Trial**: Demonstrated that bevacizumab-based therapies may be preferred for certain patients, but anti-EGFRs remain effective in RAS/BRAF wild-type left-sided tumors. - **PARADIGM Trial**: Highlighted the importance of tumor sidedness in guiding the choice between anti-EGFR and bevacizumab. - **CALGB/SWOG80405 Trial**: Compared anti-EGFRs and bevacizumab in first-line settings, showing similar efficacy overall but better outcomes with anti-EGFRs for left-sided tumors. --- ### **Future Directions** Anti-EGFR therapies remain an integral part of mCRC treatment, but ongoing research aims to refine their use: 1. **Biomarker Development**: - Identification of additional biomarkers (e.g., HER2, EGFR mutations, ctDNA profiling) to predict response and resistance. 2. **Combination Therapies**: - Combining anti-EGFRs with other targeted agents, such as HER2 inhibitors or immune checkpoint inhibitors, for specific molecular subgroups. 3. **Personalized Medicine**: - Leveraging next-generation sequencing (NGS) to tailor therapies based on individual tumor profiles. --- ### **Conclusion** Anti-EGFR therapies are highly effective in RAS/BRAF wild-type, left-sided mCRC, offering significant survival benefits. However, their efficacy is influenced by tumor biology, sidedness, and molecular alterations. While HER2 status does not predict benefit from anti-EGFR therapy, HER2-positive tumors represent a poor-prognosis subgroup that may benefit from HER2-targeted approaches in the future. Continued research and clinical trials are essential to optimize anti-EGFR use and improve outcomes for mCRC patients.

Pancreatic Cancer and mRNA Vaccines

Pancreatic cancer is one of the deadliest cancers, with a five-year survival rate of only 13% due to its aggressive nature and high recurrence rates even after surgery. Traditional treatments like chemotherapy, radiation, and immunotherapy have limited success because of the tumor's dense microenvironment and low visibility to the immune system. To address these challenges, researchers at Memorial Sloan Kettering (MSK) developed a personalized mRNA vaccine, autogene cevumeran, designed to train the immune system to recognize tumor-specific mutations (neoantigens). In a Phase I trial, 16 patients with surgically removed pancreatic cancer received a custom mRNA vaccine along with checkpoint inhibitor atezolizumab and chemotherapy. Tumor DNA was sequenced to identify neoantigens, which were encoded into an mRNA molecule and delivered via lipid nanoparticles. This vaccine successfully triggered T-cell responses in half the patients. Among responders, six out of eight remained cancer-free after three years, while non-responders experienced earlier recurrence, showing a strong link between immune activation and clinical outcomes. The vaccine-induced T cells demonstrated long-term memory, essential for sustained cancer control. The process was rapid, with vaccine production taking an average of nine weeks. However, patients without spleens showed reduced immune responses, highlighting the spleen's role in vaccine efficacy. This personalized approach showed safety, tolerability, and promise for treating not just pancreatic cancer but other resistant cancers like glioblastoma. Ongoing Phase II trials aim to validate these findings, offering hope for durable, individualized cancer treatments and advancing the future of precision medicine.

HCC and liver-related events in HDV infection

Hepatocellular carcinoma (HCC) and liver-related events (such as decompensation and cirrhosis progression) are significant complications in individuals with hepatitis D virus (HDV) infection. HDV infection is known to cause the most severe form of viral hepatitis, with a high risk of early-onset cirrhosis and HCC. The study summarized in the context provides valuable insights into the predictors, risk factors, and clinical tools for managing these outcomes in anti-HDV–positive individuals. ### Key Findings on HCC and Liver-Related Events in HDV Infection: #### **Incidence of HCC and Liver-Related Events:** - The 5-year cumulative incidence of HCC in anti-HDV–positive individuals was **3.8%**, while the incidence of liver-related events was **15.6%**. - Patients with **cirrhosis** had a markedly higher risk: - 5-year HCC incidence: **12%**. - 5-year liver-related event rate: **41.3%**. - Non-cirrhotic patients had negligible risks: - 5-year HCC incidence: **0%**. - 5-year liver-related event rate: **0.9%**. #### **Risk Stratification Using PAGE-B and FIB-4 Scores:** - **PAGE-B** and **FIB-4** scores were validated as effective tools for predicting both HCC and liver-related outcomes in HDV-infected individuals. - **Low-risk groups** (PAGE-B <10 or FIB-4 <1.45): - HCC incidence: **0%**. - Liver-related event rate: **0.9%–2.1%**. - **High-risk groups** (PAGE-B >17 or FIB-4 >3.25): - 5-year HCC incidence: **25%** and **21%**, respectively. - Liver-related event rate: **~45%–63%**. #### **Independent Predictors of HCC and Liver-Related Events:** - **Age** and **platelet count** were independently associated with both HCC and liver-related outcomes in multivariate analyses. - Detectable **HDV RNA** doubled the risk of liver-related events (adjusted hazard ratio [aHR]: **2.6**; 95% confidence interval [CI]: 1.3–5.0). #### **Diagnostic and Predictive Tools:** - **Liver stiffness measurement (LSM):** - LSM ≥10 kPa: 100% sensitivity for detecting cirrhosis. - LSM ≥12 kPa: 100% specificity for confirming cirrhosis. - **FIB-4:** - FIB-4 >3.25 had a high positive predictive value (PPV) of **91.7%** for advanced fibrosis but poor sensitivity (**36.7%**). #### **Comparative Risk:** - Anti-HDV–positive patients had: - **4.2-fold higher HCC risk** compared to HBV mono-infected controls. - **7.8-fold higher risk** of liver-related events compared to HBV mono-infected controls. #### **Antiviral Therapy and Novel Treatments:** - Only **15.2%** of patients received pegylated interferon, reflecting its limited efficacy and tolerability in clinical practice. - **Bulevirtide**, an HBV entry inhibitor, represents a promising new therapy for HDV but is costly and requires parenteral administration. --- ### Clinical Implications for Management: 1. **Risk Stratification:** - **PAGE-B and FIB-4 scoring systems** allow simple, noninvasive, and cost-effective assessment of HCC and liver-related event risk in HDV-infected individuals. - These tools can guide personalized care and surveillance strategies. 2. **Surveillance Recommendations:** - **Low-risk patients** (e.g., PAGE-B <10 or FIB-4 <1.45): May require less frequent imaging follow-up due to negligible HCC and minimal liver-related event risk. - **High-risk patients** (e.g., PAGE-B >17 or FIB-4 >3.25): Require intensified surveillance, including frequent imaging, strict HCC monitoring, and prioritization for novel antiviral treatments. 3. **Therapeutic Considerations:** - The limited use of pegylated interferon highlights the need for more effective and tolerable therapies. - Bulevirtide offers a new treatment option, but its cost and administration challenges must be considered. 4. **Validation Needs:** - The study authors recommend external validation of PAGE-B and FIB-4 scores in **bulevirtide-treated** and **ethnically diverse HDV populations** to confirm their utility in broader clinical settings. --- ### Conclusion: HCC and liver-related events are significant risks in HDV-infected individuals, particularly in those with cirrhosis or high-risk scores (PAGE-B >17, FIB-4 >3.25). The use of noninvasive scoring tools like PAGE-B and FIB-4 enables early identification of at-risk patients, guiding surveillance intensity and treatment prioritization. While novel therapies like bulevirtide offer hope, addressing their accessibility and efficacy in diverse populations remains a key challenge.

MAPK Signaling and Gastrointestinal Disorders

**MAPK Signaling and Gastrointestinal Disorders** Mitogen-Activated Protein Kinase (MAPK) signaling is an essential pathway regulating cell processes like proliferation, differentiation, apoptosis, inflammation, and stress responses. Dysregulation of this pathway is a key factor in the development of gastrointestinal (GI) disorders, including inflammatory bowel disease (IBD), colorectal cancer (CRC), gastric cancer, and pancreatitis. ### **Overview of MAPK Pathways** MAPK signaling involves three tiers of kinases: 1. **MAPKKKs (e.g., Raf, MEKK)**: Upstream activators. 2. **MAPKKs (e.g., MEK1/2)**: Intermediate kinases. 3. **MAPKs (e.g., ERK, JNK, p38 MAPK)**: Terminal effectors. Key MAPK pathways include: - **ERK (Extracellular Signal-Regulated Kinase)**: Promotes cell proliferation; its overactivation is linked to cancer. - **JNK (c-Jun N-terminal Kinase)**: Regulates inflammation, apoptosis, and stress; overactivation causes tissue damage. - **p38 MAPK**: Responds to stress and inflammation; drives inflammatory diseases and fibrosis. --- ### **Role in GI Disorders** 1. **Inflammatory Bowel Disease (IBD)**: - **Pathogenesis**: Overactivation of JNK and p38 MAPK increases pro-inflammatory cytokines (e.g., TNF-α, IL-6) and epithelial cell apoptosis. - **Therapeutics**: JNK and p38 MAPK inhibitors (e.g., SB203580) are being explored to reduce inflammation. 2. **Colorectal Cancer (CRC)**: - **Pathogenesis**: Dysregulated ERK signaling (due to KRAS/BRAF mutations) promotes tumor growth, survival, and angiogenesis. - **Therapeutics**: MEK inhibitors (e.g., trametinib) target ERK signaling, often in combination with immunotherapy. 3. **Gastric Cancer**: - **Pathogenesis**: Chronic *Helicobacter pylori* infection activates ERK, p38, and JNK pathways, leading to inflammation, genomic instability, and tumorigenesis. - **Therapeutics**: ERK inhibitors are being studied for advanced gastric cancer. 4. **Pancreatitis**: - **Pathogenesis**: Acute pancreatitis activates JNK and p38 MAPK, causing inflammation and acinar cell injury. Chronic activation leads to fibrosis. - **Therapeutics**: MAPK inhibitors may reduce inflammation and fibrosis. 5. **GI Fibrosis**: - p38 MAPK and JNK drive fibroblast activation and extracellular matrix deposition, contributing to fibrosis in IBD and pancreatitis. --- ### **Therapeutic Potential** Targeting MAPK pathways offers promising treatments for GI disorders: - **p38 MAPK inhibitors**: Reduce inflammation (e.g., IBD, pancreatitis). - **JNK inhibitors**: Suppress apoptosis and cytokine production. - **ERK inhibitors**: Treat cancers like CRC and gastric cancer. **Challenges** include off-target effects, resistance, and the need for combination therapies. Future research aims to optimize these therapies and personalize treatment strategies. In summary, MAPK signaling plays a central role in the pathogenesis of GI disorders, and therapeutic targeting of these pathways holds great potential for improving patient outcomes.

VEGF and Liver Tumor

Vascular Endothelial Growth Factor (VEGF) is a key protein involved in the development and progression of liver tumors, especially **hepatocellular carcinoma (HCC)**, which is the most common type of primary liver cancer. VEGF promotes **angiogenesis**, the formation of new blood vessels, which is critical for tumor growth, invasion, and metastasis. It binds to specific receptors, such as VEGFR-2, to stimulate endothelial cell proliferation, vascular remodeling, and increased vascular permeability. This process provides oxygen and nutrients to the tumor, enabling its rapid growth. In liver tumors like HCC, VEGF is often overexpressed, especially under **hypoxic conditions** (low oxygen), which are common in growing tumors. Hypoxia triggers the release of VEGF through the activation of **Hypoxia-Inducible Factor-1α (HIF-1α)**. VEGF also contributes to **portal vein tumor thrombosis (PVTT)**, a severe complication in HCC, and promotes the spread of secondary liver tumors (metastases) by enhancing vascularization. VEGF is not only a marker of poor prognosis, as its high levels correlate with larger tumors, vascular invasion, and metastasis, but it also serves as a major therapeutic target. Anti-VEGF therapies have transformed the treatment of advanced liver tumors. Examples include **bevacizumab**, a monoclonal antibody targeting VEGF-A, and **tyrosine kinase inhibitors (TKIs)** like **sorafenib** and **lenvatinib**, which block VEGF receptors and other angiogenic pathways. Combination therapies, such as **atezolizumab (anti-PD-L1) and bevacizumab**, have shown superior efficacy in managing advanced HCC by combining VEGF inhibition with immune checkpoint blockade. Despite their benefits, VEGF-targeted therapies face challenges like **resistance** (activation of alternative angiogenic pathways) and **toxicity** (e.g., hypertension, bleeding). Future directions focus on developing predictive biomarkers to select the right patients, combining VEGF inhibitors with other treatments, and personalizing therapies based on tumor profiles. In summary, VEGF plays a central role in liver tumor biology, and targeting it has become a cornerstone of treatment, particularly for advanced HCC. However, ongoing research aims to address resistance and improve outcomes through innovative strategies.

KRASG12D Mutantation and Adult Pancreas

KRASG12D mutation plays a pivotal role in pancreatic tumorigenesis, particularly in the context of the adult pancreas, which is characterized by unique biological features and challenges. Below is a detailed exploration of the relationship between KRASG12D mutants and the adult pancreas: --- ### **1. Prevalence of KRAS Mutations in PDAC** - KRAS mutations are present in over 90% of pancreatic ductal adenocarcinomas (PDAC), underscoring their central role in driving pancreatic cancer. - KRASG12D is one of the most common oncogenic variants, and its presence is strongly associated with tumor initiation and progression. --- ### **2. Challenges in the Adult Pancreas** - **Slow-Cycling Nature:** The adult pancreas has a slow turnover rate, meaning that its epithelial cells do not proliferate rapidly. This slow-cycling nature contrasts with tissues that have defined stem cell compartments, making mutant cell persistence more likely. - **Lack of Stem Cell Compartments:** Unlike other organs, the pancreas does not have well-defined stem cell niches, which limits the regenerative capacity and provides a unique environment for mutant cells to evade elimination. - **Homeostatic Defense Mechanisms:** Normal epithelial tissues are equipped with mechanisms to eliminate mutant cells via apoptosis, extrusion, or differentiation. However, KRASG12D-mutant cells can evade these defenses in the adult pancreas. --- ### **3. Persistence of KRASG12D Mutant Cells** - **Evasion of Elimination:** Despite the homeostatic mechanisms, a subset of KRASG12D-mutant cells can survive long-term. This survival is rare, with only about 10% of KRASG12D cells persisting in the adult pancreas over 70 days, as demonstrated by cell fate tracking using RFP fluorescence imaging. - **Dormancy Features:** Persistent KRASG12D cells exhibit dormancy traits, including: - **Ki-67 negativity:** Indicating a lack of proliferation. - **Upregulation of p27:** A marker of G1 arrest. - **Enhanced oxidative phosphorylation and hypoxia-related signaling:** Suggesting metabolic adaptation. - **Stem/Progenitor Reprogramming:** These cells express early stem/progenitor markers such as Nkx6-1, Prom1, and Hnf1b, indicating dedifferentiation toward a progenitor-like state. --- ### **4. Role of KRASG12D in Tumorigenesis** - **Oncogenic Signaling Activation:** KRASG12D-mutant cells activate pro-survival and tumorigenic pathways, including epithelial-to-mesenchymal transition (EMT), NF-κB, Notch, and Wnt signaling pathways. - **Transcriptomic Profiling:** Persisting KRASG12D cells show deregulated KRAS, MAPK, and p53 signaling, which alters their cell fate and stress response mechanisms. - **Early PanIN Formation:** When KRASG12D is co-expressed with TRP53R172H (a p53 mutation), mutant cell elimination is abolished, leading to stable retention and formation of precancerous PanIN lesions. --- ### **5. Wnt Signaling and Mutant Cell Retention** - **Wnt5a-Ror Pathway:** Persistent KRASG12D cells upregulate β-catenin-independent Wnt5a-Ror signaling, which enhances cell adhesion at mutant–normal interfaces through E-cadherin and β-catenin stabilization. - **Inhibition of Extrusion:** Wnt5a reduces RasV12 cell extrusion by stabilizing E-cadherin junctions and blocking caveolin-1–mediated endocytosis. - **Restoration via Wnt Inhibition:** Pharmacologic inhibition of Wnt signaling using WNT-974 or Frizzled receptor blockade (OMP-18R5) restores extrusion and reduces mutant cell retention both in vitro and in vivo. --- ### **6. Clinical Implications** - **Human Pancreatic Cancer Data:** Elevated expression of WNT5A, DVL2, and FZD7 is observed in PanIN and PDAC, correlating with advanced tumor grade and poor survival outcomes. - **Therapeutic Potential:** Targeting Wnt5a-driven signaling or dormancy-associated pathways could eliminate non-proliferating, premalignant KRASG12D-mutant cells before tumor initiation, offering a preventive strategy against PDAC. - **Safety Profile:** Genetic and pharmacologic interventions targeting Wnt signaling were well tolerated in vivo, with no adverse histological or systemic effects. --- ### **7. Mechanistic Insights** - KRASG12D-mutant cells evade elimination by leveraging Wnt5a-driven signaling, which creates a cohesive and adherent cellular environment. This prevents extrusion and allows the mutant cells to persist in the adult pancreas. - Dormancy-associated survival mechanisms, including metabolic adaptation and stem/progenitor reprogramming, further support the persistence and potential tumorigenic progression of KRASG12D cells. --- ### **Conclusion** The adult pancreas provides a unique environment where KRASG12D-mutant cells can evade homeostatic defense mechanisms and persist long-term. These cells exhibit dormancy features, metabolic adaptation, and stem-like reprogramming, which set the stage for tumor initiation. Targeting Wnt signaling and other dormancy-associated pathways offers a promising therapeutic approach to eliminate KRASG12D-mutant cells before they progress to pancreatic cancer.

High FIT results in CRC patients and 1-year mortality outcomes

High fecal immunochemical test (FIT) results in colorectal cancer (CRC) patients are strongly associated with significantly worse 1-year mortality outcomes, according to the study. Below is a detailed breakdown of the key findings related to high FIT results and 1-year mortality outcomes: ### 1. **Mortality Rates in High-FIT Group (FIT ≥ 10 µg Hb/g) vs Low-FIT Group (FIT < 10 µg Hb/g):** - **All-cause mortality:** - Elevated FIT group: 8.3% mortality within 1 year. - Lower FIT group: 2.8% mortality within 1 year. - This represents a **nearly threefold increase** in 1-year mortality in the elevated FIT group compared to the lower FIT group. - **All-cause mortality rate:** - Elevated FIT group: 87.21 deaths per 1000 person-years. - Lower FIT group: 28.41 deaths per 1000 person-years. - **Non-CRC mortality:** - Elevated FIT group: 92.4% of all deaths in this group were non-CRC related. - Non-CRC mortality rate: 74.79 per 1000 person-years in the elevated FIT group vs 27.72 per 1000 person-years in the lower FIT group. - **CRC-specific mortality:** While mortality due to CRC increased with higher FIT levels, the majority of excess deaths in the elevated FIT group were attributed to **non-CRC causes**. --- ### 2. **Adjusted Risk of Mortality (High FIT vs Low FIT):** - After adjusting for factors such as age, sex, and year, patients with elevated FIT results (≥ 10 µg Hb/g) had: - **Nearly double the risk of all-cause mortality** (adjusted hazard ratio [aHR]: 1.96). - **1.7 times higher risk of non-CRC mortality** (aHR: 1.70). - These findings indicate that high FIT results are predictive of a systemic vulnerability to death beyond CRC alone. --- ### 3. **Standardized Mortality Ratios (SMRs):** - For patients with FIT ≥ 10 µg Hb/g: - SMR for **all-cause mortality**: 2.12 (indicating a more than twofold excess risk compared to the general population). - SMR for **non-CRC mortality**: 1.86 (indicating significantly higher risk of non-CRC-related deaths). --- ### 4. **Demographic and Subgroup Insights:** - **Age:** Younger symptomatic patients with elevated FIT results showed particularly pronounced relative increases in mortality risk, highlighting that high FIT is worrisome even in traditionally lower-risk age groups. - **Sex differences:** Women with elevated FIT results demonstrated a greater relative risk of mortality compared to men, suggesting potential biological or diagnostic differences. --- ### 5. **Possible Mechanisms for Elevated Mortality in High-FIT Patients:** - Elevated FIT results may signal underlying systemic health issues beyond CRC, such as: - **Cardiovascular disease.** - **Other malignancies.** - **Inflammatory conditions** or other comorbidities. - These conditions may contribute to the significantly higher non-CRC mortality observed in the elevated FIT group. --- ### 6. **Clinical and Public Health Implications:** - **Red flag for overall mortality risk:** A positive FIT result in symptomatic patients should not be viewed solely as a marker of CRC risk but as an indicator of **increased overall mortality risk**. - **Comprehensive evaluation required:** High-FIT patients should undergo urgent diagnostic workup and closer surveillance for both CRC and non-CRC conditions. - **Prognostic utility:** FIT may serve as a biomarker of systemic disease burden, providing prognostic insights beyond its traditional role in CRC detection. --- ### 7. **Limitations of the Study:** - The study was retrospective and conducted within a single regional healthcare system (Nottingham University Hospitals), which may limit generalizability to other populations. However, the large cohort size (49,889 adults) strengthens the robustness of the findings. --- ### Summary: High FIT results (≥ 10 µg Hb/g) in CRC patients are associated with significantly worse 1-year mortality outcomes, driven by both CRC-specific and non-CRC-related causes. The findings underscore the importance of interpreting elevated FIT results as a **broad clinical red flag** requiring comprehensive evaluation and management, not only for CRC but also for other underlying health risks.

Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer

The combination of **encorafenib, cetuximab, and mFOLFOX6** has been studied as a first-line treatment for patients with **BRAF V600E–mutated metastatic colorectal cancer (mCRC)**, a particularly aggressive cancer subtype associated with poor prognosis. This evaluation was conducted in a **phase 3 clinical trial**, comparing this regimen to standard-of-care treatments. Below are the key findings and details from the study: --- ### **Background** - **BRAF V600E mutation**: This is a specific genetic alteration in colorectal cancer that drives tumor growth and is associated with worse outcomes compared to non-mutated cases. - **Encorafenib**: A BRAF inhibitor that targets the mutated BRAF protein. - **Cetuximab**: An anti-EGFR monoclonal antibody that helps block tumor growth. - **mFOLFOX6**: A chemotherapy regimen consisting of oxaliplatin, leucovorin, and fluorouracil (5-FU), commonly used in colorectal cancer treatment. --- ### **Study Design** - The trial compared the combination of **encorafenib + cetuximab + mFOLFOX6** (EC+mFOLFOX6) to standard-of-care treatments in patients with **previously untreated BRAF V600E-mutated metastatic colorectal cancer**. --- ### **Key Results** 1. **Progression-Free Survival (PFS)**: - EC+mFOLFOX6 significantly improved **PFS** compared to standard care. - **Median PFS**: - EC+mFOLFOX6: **12.8 months** - Standard care: **7.1 months** - **Hazard Ratio (HR)**: **0.53**, indicating a 47% reduction in the risk of disease progression or death with EC+mFOLFOX6. 2. **Overall Survival (OS)**: - EC+mFOLFOX6 also significantly improved **OS**. - **Median OS**: - EC+mFOLFOX6: **30.3 months** - Standard care: **15.1 months** - **HR**: **0.49**, suggesting a 51% reduction in the risk of death. 3. **Objective Response Rate (ORR)**: - While not detailed in the context, earlier studies had shown improved ORR with this regimen, which supported its **accelerated FDA approval** prior to the phase 3 trial. 4. **Safety Profile**: - The safety profile of EC+mFOLFOX6 was consistent with the known side effects of the individual agents. - However, **serious adverse events (SAEs)** were more frequent with EC+mFOLFOX6: - **46.1%** in the EC+mFOLFOX6 group - **38.9%** in the standard care group. --- ### **Conclusion** - The combination of **encorafenib, cetuximab, and mFOLFOX6** demonstrated **superior clinical outcomes** compared to standard care in patients with untreated **BRAF V600E-mutated metastatic colorectal cancer**. - This regimen significantly improved both **progression-free survival (12.8 vs. 7.1 months)** and **overall survival (30.3 vs. 15.1 months)**. - Despite a higher rate of serious adverse events, the benefits in survival make EC+mFOLFOX6 a **more effective first-line treatment** option for this patient population. --- ### **Clinical Implications** - These findings establish EC+mFOLFOX6 as a **new standard of care** for patients with **BRAF V600E-mutated metastatic colorectal cancer**. - Oncologists should weigh the improved survival benefits against the potential for increased serious adverse events when considering this treatment for their patients.

Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer

The international, randomized phase 3 clinical trial compared **trastuzumab deruxtecan** with **ramucirumab plus paclitaxel** as second-line treatment options for patients with **HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma** who had previously progressed on trastuzumab-based therapy. Below are the key findings and details from the study: ### **Efficacy Outcomes** 1. **Overall Survival (OS):** - **Trastuzumab deruxtecan** demonstrated significantly longer overall survival compared to ramucirumab plus paclitaxel: - **14.7 months vs. 11.4 months**. - **Hazard Ratio (HR):** 0.70, indicating a 30% reduction in the risk of death with trastuzumab deruxtecan. 2. **Progression-Free Survival (PFS):** - Trastuzumab deruxtecan also showed improvements in progression-free survival, though specific numbers were not provided in the context. 3. **Objective Response Rate (ORR):** - Trastuzumab deruxtecan achieved a higher objective response rate compared to ramucirumab plus paclitaxel: - **44.3% vs. 29.1%**. ### **Safety and Adverse Events** 1. **Adverse Events:** - Both treatment groups experienced common adverse events, with high-grade toxicities occurring in approximately **50% of patients**. 2. **Drug-Related Interstitial Lung Disease (ILD) or Pneumonitis:** - **Trastuzumab deruxtecan** carried a higher risk of drug-related interstitial lung disease or pneumonitis, occurring in **13.9% of patients**. - Most cases were **low grade**, but this is a notable safety concern. ### **Conclusion** - **Trastuzumab deruxtecan** demonstrated **superior survival benefits** and greater efficacy compared to **ramucirumab plus paclitaxel** in the second-line setting for HER2-positive gastric cancer. - Despite the increased risk of interstitial lung disease or pneumonitis, trastuzumab deruxtecan has been confirmed as an **effective second-line therapeutic option** for this patient population. This study highlights trastuzumab deruxtecan as a promising treatment choice, offering significant improvements in survival and response rates for patients with HER2-positive metastatic gastric cancer.

New Perioperative Strategy in Gastric Cancer

The new perioperative strategy in gastric cancer involves incorporating immunotherapy into the existing chemotherapy regimen to improve outcomes for patients with resectable gastric and gastroesophageal junction cancers. These cancers are highly aggressive, with high recurrence rates even after surgery and chemotherapy. The current standard treatment, known as the FLOT regimen (fluorouracil, leucovorin, oxaliplatin, and docetaxel), has shown survival benefits but remains insufficient to address the high recurrence rates. To address this gap, the phase 3 MATTERHORN clinical trial investigated the addition of durvalumab, an immune checkpoint inhibitor targeting PD-L1 (programmed death-ligand 1), to the FLOT regimen. Durvalumab is designed to enhance the immune system's ability to recognize and attack cancer cells. Early results from the MATTERHORN trial have been promising, showing higher response rates and a potential survival benefit when durvalumab is added to the FLOT chemotherapy regimen. This suggests that immunotherapy, when combined with standard perioperative chemotherapy, could significantly improve outcomes for patients with resectable gastric and gastroesophageal junction cancers. In summary, the new perioperative strategy highlights the potential of integrating immunotherapy (durvalumab) with FLOT chemotherapy to reduce recurrence rates and improve survival in patients with these challenging cancers. This approach represents a significant advancement in the treatment landscape for gastric cancer.

CT Use and Future Cancer Risk

The rising use of CT (computed tomography) scans has sparked concerns about its potential long-term impact on cancer risk, as highlighted by a recent modeling study. Below is a detailed analysis of the findings and their implications: ### Key Findings: 1. **CT Scan Usage in 2023**: - In the U.S., approximately **62 million patients** underwent nearly **93 million CT scans** in 2023 alone. - This marks a significant reliance on CT imaging for diagnostic and medical purposes. 2. **Projected Cancer Cases**: - Researchers estimate that the radiation exposure from this level of CT use could result in about **103,000 future cancer cases**. - These cases could account for up to **5% of all annual cancer diagnoses**, a figure comparable to cancer risks associated with **alcohol consumption** or **excess body weight**. 3. **Age and Type of CT Scans**: - **Adults**: Abdomen and pelvis CT scans contributed the most to the projected cancer cases. - **Children**: Head CT scans were the largest contributor to projected cancers in this group. - **Highest Risk Per Scan**: Children under **1 year of age** face the highest risk per individual scan due to their greater sensitivity to radiation. - **Largest Number of Cases Overall**: Older adults had the highest number of projected cancer cases, primarily because they undergo CT scans more frequently. 4. **Cancer Types Linked to CT Radiation**: - **Adults**: Lung, colon, bladder cancers, and leukemia were the most commonly linked cancers. - **Children**: Thyroid, lung, and breast cancers were the most frequently associated with CT scan radiation. 5. **Lifetime Risk Increase**: - The overall lifetime risk of developing cancer increases slightly due to CT scan radiation exposure — from about **50% to 52.5%**. ### Implications: - **Balancing Risks and Benefits**: - While there is a small increase in lifetime cancer risk, experts emphasize that CT scans are often **essential and life-saving** tools in medical diagnosis and treatment. - The **diagnostic benefits** of CT imaging generally outweigh the **small added cancer risk**, especially in urgent or critical cases. - **Recommendations for Safer Use**: - **Reducing Unnecessary Imaging**: Avoiding CT scans that are not medically necessary can help lower overall radiation exposure. - **Minimizing Radiation Dose**: Using the **lowest radiation dose possible** for effective imaging can reduce long-term risks. - **Special Considerations for Children**: Pediatric patients, especially infants, should be given extra care in minimizing radiation exposure due to their higher sensitivity. ### Conclusion: CT scans are indispensable tools in modern medicine, but their increasing use raises valid concerns about long-term cancer risks. The study underscores the need for judicious use of CT imaging, particularly in vulnerable populations such as children and frequent users like older adults. By optimizing scanning practices and reducing unnecessary exposure, healthcare providers can continue to maximize the diagnostic benefits of CT scans while minimizing potential risks.

Four Key Genes Linked to Worse Gastric Cancer Outcomes

The four key genes linked to worse gastric cancer outcomes, as identified by new research from Brazil, are **BRCA2, CDH1, RHOA, and TP53**. Here’s a detailed breakdown of their significance: ### 1. **BRCA2** - **Role in Cancer**: BRCA2 is well-known for its involvement in breast and ovarian cancers. It plays a critical role in DNA repair, and mutations in this gene can lead to genomic instability, which promotes cancer development. - **Impact on Gastric Cancer**: In the context of gastric cancer, BRCA2 mutations are associated with higher chances of recurrence and death, contributing to worse disease-free and overall survival. ### 2. **CDH1** - **Role in Cancer**: CDH1 is linked to hereditary diffuse gastric cancer and encodes a protein called E-cadherin, which is important for cell adhesion. Mutations in CDH1 disrupt cell-to-cell communication, making it easier for cancer cells to invade and metastasize. - **Impact on Gastric Cancer**: CDH1 mutations are strongly associated with aggressive forms of gastric cancer, leading to poorer prognoses. ### 3. **RHOA** - **Role in Cancer**: RHOA is involved in regulating cell shape, movement, and the cytoskeleton. Alterations in this gene can promote cancer cell migration and invasion. - **Impact on Gastric Cancer**: Mutations in RHOA contribute to cancer progression by enhancing the ability of cancer cells to spread, worsening outcomes for patients. ### 4. **TP53** - **Role in Cancer**: TP53 is one of the most frequently mutated genes in all human cancers. It encodes the p53 protein, which acts as a tumor suppressor by regulating cell cycle arrest, DNA repair, and apoptosis. - **Impact on Gastric Cancer**: Mutations in TP53 disable its tumor-suppressing functions, allowing cancer cells to grow uncontrollably, leading to more aggressive disease and worse survival rates. ### Key Findings from the Research: - **Independent and Combined Effects**: Each of these genes is individually associated with a poorer prognosis in gastric cancer. However, the presence of mutations in multiple genes further increases the risk of recurrence and death. - **Prevalence**: About one-third of the patients in the study carried mutations in at least one of these genes. - **Treatment Implications**: Even with surgery, chemotherapy, and immunotherapy, patients with these mutations had worse disease-free and overall survival compared to those without them. ### Implications for Precision Oncology: - The study suggests that gastric cancer can arise through multiple pathways, and some cases are inherently more aggressive due to these genetic mutations. - **Personalized Treatment**: Identifying these mutations in patients can help guide precision oncology. High-risk patients with these mutations may benefit from more aggressive treatment strategies, while low-risk patients could avoid unnecessary side effects from intensive therapies. This research highlights the importance of genetic testing in gastric cancer to improve prognostic accuracy and tailor treatments to individual patients.

Catching Gastric Cancer early

Catching gastric cancer early is critically important for improving survival outcomes, especially given the poor prognosis associated with late-stage diagnosis. Early detection involves a structured, multidisciplinary approach that includes risk assessment, high-quality endoscopic techniques, and effective surveillance strategies. Below are the key steps and considerations for catching gastric cancer early: --- ### **1. Risk Assessment** - **Identify High-Risk Populations**: Certain groups are at significantly higher risk for gastric cancer. These include: - Individuals of Hispanic and Asian descent. - Immigrants from countries with high gastric cancer incidence (e.g., Japan, Korea, China, and parts of Latin America). - Patients with a family history of gastric cancer or hereditary cancer syndromes (e.g., hereditary diffuse gastric cancer). - Those with Helicobacter pylori infection, which is a major risk factor for gastric cancer development. - Patients with gastric premalignant conditions such as atrophic gastritis, gastric intestinal metaplasia, dysplasia, and epithelial polyps. - **Risk Stratification**: Clinicians should assess risk factors during pre-endoscopy evaluations and prioritize screening for high-risk individuals. --- ### **2. Early Detection Through Screening** - **Programmatic Screening**: Countries in Asia, such as Japan and Korea, have established nationwide gastric cancer screening programs that detect cancer at earlier stages. These programs rely heavily on endoscopy and have significantly improved survival rates. The U.S. does not have similar programs, but targeted screening for high-risk groups could yield similar benefits. - **Endoscopic Surveillance**: Patients with premalignant conditions (e.g., gastric intestinal metaplasia or dysplasia) should undergo regular surveillance with upper endoscopy to monitor for progression to gastric cancer. --- ### **3. High-Quality Endoscopy Techniques** - **Pre-Endoscopy Preparation**: - Use mucosal cleaning agents such as simethicone to enhance visualization. - Ensure adequate CO₂ insufflation for proper distension of the stomach. - **During Endoscopy**: - **Meticulous Technique**: Employ careful inspection of the gastric mucosa to identify subtle abnormalities. - **Photo Documentation**: Capture images of all areas, especially suspicious lesions, to facilitate accurate diagnosis and follow-up. - **Biopsy Protocol**: Use the Sydney biopsy protocol, which involves systematic sampling of the gastric mucosa to detect premalignant changes and early cancer. - **Withdrawal Time**: Ensure a withdrawal time of six to seven minutes, as shorter durations reduce detection rates. This allows for thorough examination of the gastric mucosa. --- ### **4. Post-Endoscopy Follow-Up** - **Pathology Collaboration**: - Work closely with skilled gastrointestinal pathologists to interpret biopsy results accurately. - Utilize validated histologic staging systems such as OLGA (Operative Link on Gastritis Assessment) and OLGIM (Operative Link on Gastric Intestinal Metaplasia) to stage premalignant conditions and guide surveillance intervals. - **Surveillance and Monitoring**: - Patients with premalignant conditions should be enrolled in regular surveillance programs to monitor for progression. - Follow-up intervals should be based on the severity of histologic findings (e.g., more frequent surveillance for high-grade dysplasia). --- ### **5. Addressing Disparities** - **Targeted Outreach**: High-risk populations, such as immigrants and ethnic minorities, often face barriers to care. Clinicians should focus on reducing disparities by increasing access to screening and surveillance programs for these groups. - **Education and Awareness**: Educating patients about the importance of early detection and the role of endoscopy can encourage adherence to recommended screening protocols. --- ### **6. Prevention Strategies** - **Eradication of Helicobacter pylori**: Treating H. pylori infection can significantly reduce the risk of gastric cancer in individuals with chronic gastritis or other risk factors. - **Lifestyle Modifications**: Encourage patients to adopt healthy dietary habits (e.g., reducing salt and processed food intake), avoid smoking, and limit alcohol consumption. --- ### **Impact of Early Detection** When gastric cancer is detected early: - Treatment options are more effective, often involving endoscopic resection or surgery with curative intent. - The 5-year survival rate improves dramatically, sometimes exceeding 90% for early-stage disease. - Patients avoid the challenges of managing advanced, metastatic disease, which has a much poorer prognosis. By adhering to structured guidelines, such as those emphasized by the American College of Gastroenterology (ACG) and the American Society for Gastrointestinal Endoscopy (ASGE), clinicians can improve early detection rates, reduce missed lesions, and ultimately improve survival outcomes for patients with gastric cancer.

ATOMIC Trial – PD-L1 pulse FOLFOX as adjuvant in CRC

The **ATOMIC trial** evaluated the efficacy of combining the PD-L1 inhibitor **atezolizumab** with standard adjuvant chemotherapy (**FOLFOX**) in patients with **stage III colon cancer** that is **mismatch repair-deficient (dMMR)** or **microsatellite instability-high (MSI-high)**. Below is a detailed breakdown of the trial and its findings: --- ### **Key Details of the ATOMIC Trial** #### **Study Design** - **Population:** 712 patients with **stage III colon cancer** that is **dMMR/MSI-high**. - **Intervention Groups:** - **Control arm:** FOLFOX alone for 6 months. - **Experimental arm:** FOLFOX + atezolizumab for 6 months, followed by **atezolizumab alone** for an additional 6 months. - **Primary Endpoint:** **Disease-Free Survival (DFS)** — the time patients remain free of cancer recurrence or progression. --- #### **Results** - **DFS Rates:** - Patients receiving **atezolizumab + FOLFOX** had a **DFS of 86.4%**. - Patients receiving **FOLFOX alone** had a **DFS of 76.6%**. - **Conclusion:** The addition of atezolizumab to FOLFOX significantly improved DFS, demonstrating a **strong survival benefit** for the immunotherapy combination. - **Hazard Ratio (HR):** The trial showed a robust HR favoring the combination therapy, indicating reduced risk of recurrence or progression with atezolizumab. --- ### **Implications** 1. **Potential New Standard of Care:** - The findings suggest that **atezolizumab + FOLFOX** could become the **new adjuvant standard** for patients with **stage III dMMR/MSI-high colon cancer**. - This is particularly relevant because **dMMR/MSI-high colon cancer** represents a subset (~10%) of all colon cancers. 2. **Practice-Changing Potential:** - The trial highlights the importance of **immune checkpoint inhibitors** like atezolizumab in the adjuvant setting for colon cancer patients with dMMR/MSI-high tumors, a group that is highly responsive to immunotherapy due to their immunogenic nature. --- ### **Remaining Questions** While the ATOMIC trial provides compelling evidence for the combination therapy, several questions remain unanswered: 1. **Duration of Chemotherapy:** - Is **6 months** of FOLFOX necessary, or could **3 months** (as increasingly common in practice) suffice? - Shorter chemotherapy durations might reduce toxicity without compromising efficacy. 2. **Role of Atezolizumab Alone:** - Could **atezolizumab alone** (without FOLFOX) be just as effective for these patients, given the strong immunogenicity of dMMR/MSI-high tumors? 3. **Optimal Duration of Atezolizumab:** - Should atezolizumab be administered for **6 months**, **12 months**, or even **24 months**? Longer durations might improve outcomes but raise concerns about toxicity and cost. 4. **Toxicity and Cost:** - What are the long-term side effects and financial implications of adding atezolizumab to standard chemotherapy? --- ### **Significance** Although only ~10% of colon cancers are **dMMR/MSI-high**, this trial has the potential to **change clinical practice** for this subgroup. The combination of immunotherapy with chemotherapy represents a promising strategy to improve outcomes in patients with this specific molecular profile.

Age and Oxaliplatin in CRC chemotherapeutic regime

The use of oxaliplatin in chemotherapy for colorectal cancer (CRC) varies in effectiveness depending on the stage of the disease and the age of the patient. Here's a detailed breakdown based on the findings: ### **Stage II Colorectal Cancer (CRC):** - **Effectiveness of Oxaliplatin:** Adding oxaliplatin to chemotherapy does **not improve survival** for patients with stage II CRC, regardless of age. - **Clinical Implication:** Oxaliplatin is not recommended for stage II CRC patients as it does not provide a survival benefit. ### **Stage III Colorectal Cancer (CRC):** - **Patients 70 Years or Younger:** - **Survival Benefit:** Oxaliplatin significantly improves survival in younger patients with stage III CRC. - **5-Year Survival Rates:** - With oxaliplatin: **85%** - Without oxaliplatin (chemotherapy alone): **78%** - **Clinical Implication:** Oxaliplatin is beneficial and should be considered as part of the chemotherapeutic regime for stage III CRC patients under 70. - **Patients Over 70 Years:** - **Survival Benefit:** Oxaliplatin provides **no clear survival benefit** for older patients with stage III CRC. - **5-Year Survival Rates:** - With oxaliplatin: **71%** - Without oxaliplatin (chemotherapy alone): **68%** - **Treatment Challenges:** Older patients are more likely to stop treatment early (37% vs 24% in younger patients), and early discontinuation is linked to worse survival outcomes. - **Clinical Implication:** Doctors should be cautious about prescribing oxaliplatin to patients over 70, as the benefits are limited and the risk of treatment discontinuation is higher. ### **Key Considerations for Older Patients:** - **Frailty:** The physical condition and resilience of the patient should be assessed before including oxaliplatin. - **Organ Health:** Liver, kidney, and other organ functions should be evaluated, as chemotherapy can be taxing on these systems. - **Support Systems:** The availability of caregivers or a robust support system can influence the patient's ability to complete treatment. - **Individualized Approach:** Age alone should not dictate treatment decisions. Physicians should weigh the risks and benefits based on the patient's overall health and circumstances. ### **Conclusion:** - **Stage II CRC:** Oxaliplatin is not recommended for any age group. - **Stage III CRC:** Oxaliplatin improves survival in patients aged 70 or younger but offers limited benefit for those over 70. Careful consideration of the patient's health status and likelihood of completing treatment is essential for older patients.